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T-acute lymphoblastic leukaemia (T-ALL) is a common childhood cancer. Multiple 
genetic mutations have been identified in T-ALL patients. The most common is the 
mutation of the NOTCH1 oncogene occurring in more than 50% of patients. Poor 
prognosis has often been shown to correlate with the migration and accumulation of 
T-ALL cells in the tissues. Rap and Rho family GTPases play key roles in T cell 
adhesion and migration and are often involved in cancer progression. Most of these 
proteins are post-translationally isoprenylated to facilitate their anchorage to 
membranes, where they function to stimulate signal transduction processes.  
In the first part of these studies, statins were used to reduce prenylation of GTPases, 
and to investigate whether the resulting alteration of GTPase membrane targeting 
affects T-ALL cell migration. Statins inhibited adhesion, chemotaxis and 
transendothelial migration of T-ALL cell lines. A similar effect was observed with 
geranylgeranyl transferase inhibitors and siRNA depletion of Rap1b but not Rap1a, 
RhoA, Rac1, Rac2 and Cdc42. These results suggest that statins and Rap1b depletion 
could be used to reduce tissue invasion in T-ALL. 
In contrast to other Rho family proteins, the atypical Rho GTPases RhoU and RhoV 
are not prenylated but undergo palmitoylation for membrane targeting. They are 
expressed at higher levels in primary T-ALL samples compared to primary T cells, 
and RhoU expression was shown to be unregulated by Notch1.  In the second part of 
these studies downregulation of RhoU and Notch1 by siRNA reduced adhesion and 
migration of T-ALL cell lines. Interestingly, similar functional effects were observed 
upon siRNA depletion of RhoV. RhoU and RhoV partially co-localized and moved 
dynamically between endosomes and the plasma membrane, suggesting they act 
together to regulate membrane trafficking. These results indicate that RhoU and 
RhoV could contribute to T-ALL invasion by regulating T-ALL cell adhesion and 
migration.
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1   
Introduction 
 
1.1 The immune system 
The main function of the immune system is to protect against microorganisms. It 
uses a highly organized array of mechanisms and cell types to distinguish between 
foreign agents and the own body cells and molecules.  
The primary defence of the human body from foreign agents is the anatomic barrier 
provided by epithelial surfaces. If a pathogen is able to pass this barrier, the second 
line of defence is provided by the innate immune system. This includes molecules 
that are either present in biological fluids, such as the complement system, or 
secreted as cells are activated. The cells of the innate immune system include 
monocytes, macrophages, natural killer cells, granulocytes (subdivided into 
neutrophils, eosinophils and basophils) and mast cells (Chaplin, 2006). Other 
important players of the innate immune system are the Toll-like receptors (TLRs). 
Mammals have a repertoire of TLRs through which they recognize a wide range of 
pathogen-associated molecular patterns (PAMPs). PAMPs include peptidoglycan, 
lipopolysaccharide, CpG DNA, and double or single-stranded RNA derived from 
bacterial or viral microorganisms. Interaction of TLRs with PAMPs triggers 
downstream signalling pathways leading to activation of other innate or adaptive 
processes (Kulkarni et al., 2011). A third line of defence against infection is the 
adaptive immune system. This is a specific response that also provides long-term 
protection against re-exposure to the same pathogen.  The main cells of the adaptive 
immune system are B and T lymphocytes.  
In humans, all cells of the immune system originate in the bone marrow or in the 
fetal liver from haematopoietic stem cells in a process known as haemotopoiesis. 
This process occurs in several stages and is mediated by cytokines, including 
interleukins, colony-stimulating factors, interferons, erythropoietin and 






1.1.1 T lymphocytes 
T lymphocytes originate from pluripotent precursors in the bone marrow or fetal 
liver and migrate to the thymus where they undergo differentiation. T cells can 
mature into γδ T cells and αβ T cells which subsequently differentiate into CD4+ T 
cells, CD8+ T cells, natural killer T cells (NKT) and regulatory T cells. Once they 




1.1.1.1 Major histocompatibility complex and antigen recognition 
In the thymus, specific patterns of gene expression lead to T cell proliferation and 
rearrangement of the T cell receptor (TCR). In order for T cells to recognize a 
foreign protein it must be degraded into small antigenic peptides that form physical 
complexes with the major histocompatibility complex receptors (MHC-I or MHC-
II). The TCR can then recognize the antigens presented by MHC molecules on the 
cell surface. MHC molecules play a central role in enabling the immune system to 
distinguish self from non-self. The encounter of a naive T cell with cognate antigen 
on a MHC molecule initiates T cell proliferation and differentiation into memory T 
cells and various T cell effectors (Bjorkman, 1997). The class MHC-I molecules are 
glycoproteins express on the membrane of almost all nucleated cells and they are 
associated with β2- microglobulin. The class MHC-II molecules are heterodimeric 
glycoproteins mainly expressed by antigen presenting cells (APCs). The APCs 
include dendritic cells, macrophages, B cells, and thymic epithelial cells. APCs can 
internalize antigens by either phagocytosis or endocytosis and re-express a part of 
the antigen on the membrane surface with MHC-II molecule (Ryan and Cobb, 2012). 
APCs are able to induce a signal that is necessary for T helper cell activation. CD8+ 
T cells bind to antigens associated with MHC-I and are pre-programmed for 
cytotoxic functions. CD4+ T cells bind to antigens associated with MHC-II and are 






1.1.1.2 T lymphocyte subpopulations 
CD4+ helper T cells (Th) provide regulatory functions of the adaptive immune 
system to respond appropriately to a particular antigen. In particular they promote 
and direct the differentiation and activation of B cells and cytotoxic T cells (Konig 
and Zhou, 2004) 
Th cells include Th1, Th2 and Th17. Although other T-cell subsets, such as Th3 cells 
and Th22 cells, have been described, their lineage-specific transcription factors have 
not been identified (Maddur et al., 2012). After binding peptide on the MHC-II 
complex, Th cells are activated and become effectors secreting growth factors and 
cytokines. For example, Th1 cells secrete interleukin 2 and interferon-γ, and Th2 
cells produce interleukin 4 and 5. Generally, the Th1 subpopulation induces the 
activation of macrophages and synthesis of IgG2b antibody by B cells. The Th2 
subpopulation induces the synthesis of other antibodies including IgE  (see section 
1.1.2).  
Recently the Th17 population has been characterized as a distinct lineage of CD4+ T 
cells. These cells secrete IL-17 and express surface IL-23 receptor and the lineage-
specific transcription factor RORγC. In addition, human Th17 cells specifically 
express the lectin receptor CD161. Th17 cells are important for the clearance of 
extracellular pathogens, however they have been associated with the pathogenesis of 
several autoimmune and inflammatory diseases (Maddur et al., 2012; Park et al., 
2005). 
Treg cells play an important role in the maintenance of immunological self-tolerance 
and immune homeostasis by suppressing pathological immune responses against 
self-antigens. These cells are CD4+ CD25+ and express glucocorticoid-induced 
tumour necrosis factor receptor (GITR), cytotoxic T lymphocyte antigen (CTLA)-4 
and the transcription factor forkhead box P3 (FoxP3). Treg cells can either develop 
in the thymus or be converted in the periphery by TGF-β (Ruffell et al., 2010). Treg 
can be classified in natural Treg (nTreg) and induced Treg (iTreg). iTreg are induced 
in response to antigenic stimulation under tolerogenic conditions and thus contribute 
to the development of an antigen-specific immunosuppressive response. These cells 
can secrete TGF-β and interleukin (IL)-10 that participate in their 






As mentioned above, CD8+T lymphocytes bind MHC-I and are known as cytotoxic 
T cells (Xiong and Bosselut, 2012). Cytokines secreted by Th cells, induce cytotoxic 
T cells to proliferate and differentiate into effectors. These cells do not secrete a lot 
of cytokines but instead scan cells of the body that express their cognate antigen, 
such as virus-infected cells, tumour cells and foreign tissue graft (Chaplin, 2006).  
 
 
1.1.1.3 T cell receptor 
In 95% of T cells the TCR is a heterodimer consisting of an α and β chain linked by 
disulphide bonds. In 5% of T cells the TCR is instead formed of a γ and δ chain.  The 
TCR forms a multisubunit complex with the CD3 complex, which is formed by 
CD3γ, CD3δ, CD3ε and TCRζ subunits. The CD3 subunits contain immunoreceptor 
tyrosine-based activation motifs (ITAMs) (van der Merwe and Dushek, 2011).  
ITAMs in the CD3 complex can be phosphorylated by the Src family tyrosine 
kinases Lck and Fyn. Phosphorylation of ITAMs allows the binding of the ZAP70 
tyrosine kinase, which subsequently phosphorylates LAT and SLP-76 triggering 
activation of signal transduction pathways such as protein kinase C, Ras, Rac and 
phospholipase C (Lin and Weiss, 2001). This is important to initiate T cell responses, 
including proliferation and cytokine synthesis (Sommers et al., 2000).   
T cells can protect from vast number of microbial pathogens as they possess specific 
antigen receptors, encoded a huge array of different TCR. TCR are somatically 
assembled from variable (V), diverse (D) and joining (J) gene elements to generate 
mature VαJα chains and VβDβJβ chains. The assembly of these gene elements is 
mediated by the lymphoid-specific RAG1 and RAG2 proteins that cleave the DNA 
near the V, D and J segments. These elements are then joined by non-lymphoid-
specific DNA repair enzymes, resulting in the V, D, and J gene elements assembling 
in a random process and producing the huge diversity of TCR sequences (Chaplin, 
2010).  
As mentioned above, the TCR receptor complex expressed on the lymphocyte 
surface can recognize an antigen if it is presented in the context of a MHC class I or 
class II molecule. However, to fully activate T cells an interaction also occurs 





cell in a quiescent state via CD3 and CD28 leads to functional activation and entry 
into the cell cycle, leading to cell proliferation and increase in cell size. CD28 co-
activation occurs in part by activation of the transcription factors nuclear factor κB 
(NF-κB) and nuclear factor of activated T cells (NFAT). Apoptosis is suppressed by 
the induction of anti-apoptotic proteins such as BCL-XL and BCL2. The 
phosphatidylinositol 3-kinases (PI3K) pathway is also responsible for activating the 
mammalian target of rapamycin (mTOR) that is required for growth (Acuto and 
Michel, 2003).  
 
1.1.1.4 T lymphocyte development 
In order to develop, early T cell precursors (ETP) from the bone marrow enter 
through the blood vessels into the cortico-medullary junction of the thymus (Figure 
1.1). These precursors migrate and differentiate into double negative (DN) cells 
which do not express CD4 or CD8. DN cells progress through DN1 to DN4 stages 
(Deftos and Bevan, 2000). Development from the ETP to DN3 is coordinated with 
migration through distinct thymic microenvironments. ETPs and DN2 cells have a 
high proliferation rate, and they start to aquire their first T-cell characteristics. At 
DN2 stage cells initiate the rearrangement of the genes encoding the TCRβ, TCRγ 
and TCRδ chains. When they reach the DN3 stage they stop proliferating, and they 
generate the first complete rearranged TCR loci (Rothenberg et al., 2008). DN3 T 
cells with an in-frame TCR gene rearrangement become activated by TCR-
dependent selection. Cells expressing the TCRβ undergo β-selection with the pre-T-
α chain as a pre-TCR. Once a signal is transmitted through the pre-TCR, it 
terminates further β chain rearrengment and cells become double positive (DP), 
expressing CD4 and CD8. DP thymocytes begin to proliferate and form 75-88% of 
thymocytes. The proliferation phase contributes to T-cell diversity by generating a 
clone of cells with a single TCRβ-chain rearrangement. These clones can then 
rearrange the α-chain genes enhancing diversity (Lin and Weiss, 2001). The TCR α-
chain gene rearrangement does not occur until the thymocytes stop proliferating. 
Completing of the TCR gene rearrangement leads to the surface expression of the 
TCRαβ heterodimers, which provides the substrate for the selection into single 





migrate to the thymus periphery and function as mature αβ T cells. T cells that 
rearrange TCR γ and δ-chains are instead selected as γδ T cells (Hayday and 
Pennington, 2007) (Figure1.2). 
About 99% of all thymocyte progeny die during their development in the thymus as 
eliminated by either positive or negative selection. The positive selection selects 
immature thymocytes able to interact with MHC and involves the interaction with 
epithelial cells in the thymic cortex. This process begins in DP thymocytes and takes 
several days to finalize. In the cortex the productive rearrangement of TCR in DP 
thymocytes results in the replacement of the pre-TCR with the clonotypic TCRαβ 
complex. Cells whose receptors can interact with low avidity with self-peptide-MHC 
expressed by cortical stromal cells receive a survival signal. DP thymocytes that fail 
to receive activating signals are 'non-selected' and undergo cell death in the cortex 
without maturing further. Positively selected DP thymocytes that gain the capability 
to survive differentiate into SP expressing CD4 or CD8. These cells are induced to 
express CC-chemokine receptor 7 (CCR7). CCR7-expressing thymocytes are 
attracted to the CCR7 ligands, CC-chemokine ligand 19 (CCL19) and CCL21, which 
are mainly localized and produced in the medulla. In the medulla, newly generated 
SP thymocytes are further selected by the medullary stromal cells, including 
autoimmune regulator (AIRE)-expressing cells, so that the cells that are reactive to 
tissue-specific antigens can be deleted (Ma et al., 2013; Takahama, 2006). This 
negative selection is crucial to eliminate thymocytes that may cause autoimmune 
disease. Positive and negative selections are therefore important to generate mature T 











Figure 1.1 Photomicrograph of the thymus. Image shows the cortex and the 
































Figure 1.2 Schematic representation of T cell development in the thymus. 
Precursors leave the blood vessels in the cortico-medullary junction. The early T cell 
precursors (ETP) migrate to the cortex and differentiate to double negative (DN1). 
DN2 cells migrate more deeply into the cortex. In the subcapsular zone cells undergo 
rearrangements of the TCR β chain. For the later state of development thymocytes 
cross back across the cortex towards the medulla where they change from double 
positive (DP) to single positive (CD4+ or CD8+). Alternatively DN3 thymocytes 
that rearrange γδ chains of the TCR are selected as γδ T cells. 
 
The maturation of SP thymocytes in the medulla includes the production of 
regulatory T cells and the expression of sphingosine-1-phosphate receptor 1 through 
which the cells are attracted back to the circulation that contains a high concentration 
of sphingosine-1-phosphate. During these stages development is coordinated by 
different microenvironments of the thymus epithelium, which provides receptor 
ligands and growth factors. Notch signalling is critical for T cell development and its 







Notch signalling is highly conserved during evolution. Notch signalling serves as a 
mechanism that can regulate gene expression, and depending on the cell type, it can 
regulate proliferation or differentiation (Deftos and Bevan, 2000). The Notch family 
in humans consists of four paralogues (Notch1, Notch2, Notch3 and Notch4). They 
are expressed in a wide variety of tissues and they can interact with at least five 
Notch ligands (Jagged1, Jagged2, Delta-like 1, Delta-like 3 and Delta-like 4) 
(D'Souza et al., 2008).  
Notch proteins are single-pass transmembrane receptors. The extracellular domain is 
composed of a large EGF-like repeat domain and a cysteine-rich region Notch/Lin12 
domain (LN). The extracellular domain is linked to the intracellular domain by the 
heterodimerization domain (HD). Upon proteolytic cleavage, the intracellular 
domain functions as a transcription factor. It includes a RBP-Jκ–associated module 
(RAM), nuclear localization signals (NLS) six tandem copies of ankyrin-like repeats 
(ANK) and a transactivation domain (TAD). The C-terminal proline, glutamic acid, 
serine, threonine-rich (PEST) domain, mediates Notch protein turnover (Deftos and 













Figure 1.3 Domain structure of Notch receptors. The extracellular domain of 
Notch receptors contains EGF-like repeats and a cysteine-rich Notch/Lin12 domain 
(LN). The extracellular domain is linked to the intracellular domain by the 
transmembrane domain (HD). The intracellular domain is formed by the RAM 
domain and 6 ankyrin repeats (ANK), 2 nuclear-localization signals (NLS), followed 
by the transactivation domain (TAD) and a C-terminal proline, glutamic acid, serine, 




Notch1 signalling is activated by the binding of the extracellular domain by ligands 
of the Delta and Serrate/Jagged families. Ligand binding induces the cleavage by the 
ADAM metalloproteinases of a large portion of the ectodomain exposing a site that 
is recognized by the intramembrane γ-secretase (GS) proteolytic complex. Cleavage 
by GS releases the Notch1 intracellular domain (NICD), which enters the nucleus 
and heterodimerizes with the DNA binding transcription factor CSL/RBP-Jκ to 
regulate gene expression. Once bound to CSL, NICD recruits other coactivators, 
including mastermind proteins (MAML1-3), which in turn recruits transcription 
activation complexes to induce expression of downstream target genes (Nwabo 
Kamdje and Krampera, 2011). These genes can either inhibit or promote maturation 
along particular developmental pathways. These genes include DELTEX-1. 





partecipate in T cell anergy as DELTEX-1-deficient mice have attenuated T cell 
activation (Hsiao et al., 2009).  
Another well-known target gene of Notch1 is HES-1. HES-1 is a basic Helix-Loop-
Helix (bHLH) protein that forms homodimers to repress transcription by recruiting 
the transcriptional co-repressor Groucho. HES-1 is required for normal T cell 
development, particularly in the expansion of ETP (Dudley et al., 2009) (Figure 1.4). 
Notch1 was first identified as a gene involved in chromosomal translocations with 
the TRCβ gene in a subset of cases of T cell acute lymphoblastic leukaemia (T-
ALL). The translocations result in the expression of Notch1 receptor which lacks the 
extracellular domain leading to constitutive activation of Notch signalling. The 
identification of Notch1 as a T cell oncogene and the observation that is highly 
expressed in the thymus suggested that it coul be involved in normal T cell 
development. In a mouse model, bone marrow progenitors, in which Notch1 was 
inactivated, enter the thymus and develop into B cells, suggesting that Notch1 can 
regulate a T versus B cell fate (Wilson et al., 2001). Similarly, inactivation of CSL in 
bone marrow progenitors inhibited T cell development which developed instead into 
B cells (Radtke et al., 2004).  These results suggested a specific role of Notch1 in T 
cell commitment and development. In fact T cell commitment occurs following the 
interaction of T-cell precursors with Notch ligands presented by the thymus 
epithelium. The subsequent development of T lineage cells in the thymus requires 
different thresholds of Notch1 signalling. A low threshold is sufficient to suppress B 
cell development by thymus-seeding progenitors, whereas a high threshold is 
required to promote proliferation of early T lineage progenitors and their 
development into CD4+CD8+ thymocytes.  
Notch3 was also described to play a critical role in T cell development (Bellavia et 
al., 2003). More specifically, in the thymus, Notch1 espression is high in the early 
DN thymocytes, low in DP cells and intermediate in CD4+ and CD8+ cells. Instead, 
Notch3 levels are significantly higher compared to Notch1 in DN thymocytes and 
they are down-regulated during the DN to DP transition and are really low levels in 
mature T lymphocytes. The different expression profile of Notch1 and Notch3 
receptors indicates they might play different roles in T cell development. Notch1 has 
been suggested to play a role in the initial T cell lineage commitment of bone 
marrow progenitors and in intrathymic differentiation of T lymphoid cell lineages by 





was shown to be mainly up-regulated in DN immature thymocytes, it has been 
suggested to play a role at the pre-TCR checkpoint (Bellavia et al., 2003; Campese et 
al., 2003). In aggrement with this, in vivo models of active transgenes have shown 
differences between Notch1 and Notch3. In the absence of a functional pre-TCR, 
Notch1 is not able to induce DP thymocyte differentiation. Notch3, instead, is able to 
block the pre-TCR check points forcing DN thymocyte differentiation (Allman et al., 








Figure 1.4 Notch1 signalling. In the thymus Notch1 is recognized by the ligands of 
the Delta and Serrate/Jagged families. Ligand binding induces two sequential 
proteolytic cleavages. ADAM-type metalloproteases cleave a large portion of the 
ectodomain, exposing a site recognised by the intramembrane γ-secretase proteolytic 
complex (GS). Subsequently, cleavage by GS releases the Notch1 intracellular 
domain (NICD), which enters the nucleus and binds to the transcription factor CSL. 
These interactions convert CSL from a transcriptional repressor to an activator by 
displacing co-repressors (CoR) and recruiting coactivators (Co-A). This leads to 







1.1.2 B lymphocytes 
B lymphocytes form 10-20% of circulating lymphocytes and are characterized by 
their production of the immunoglobulin antigen-binding proteins (Ig). Ig molecules 
are formed by two identical heavy chains and two identical k or λ light chains. The 
N-terminal region of the heavy and light chains varies from one antibody molecule 
to another and is known as VH and Vκ or Vλ respectively. The juxtaposition of one VH 
and one Vκ or Vλ domain creates the antigen-binding portion of the Ig molecule. The 
C-terminal portions of the heavy and light chains are constant in each subclass of 
antibody. The heavy chain of the C-terminal portion forms the Fc domain that is 
responsible for the effector functions of the Ig molecule (Chaplin, 2010).  
B lymphocytes originate from haematopoietic stem cells and differentiate in the bone 
marrow to become mature surface IgM- and IgD- expressing cells. During 
differentiation their antigen receptors (surface Ig) are assembled by a RAG1/RAC2-
mediated process similarly to TCRs (Jankovic et al., 2004). In peripheral lymphoid 
tissue, B cells carry on their maturation under the influence of cytokines secreted by 
Th cells to undergo isotype switching and affinity maturation by somatic mutation. 
The isotype switching ensures the production of antibodies of different isotypes with 
distinct biological effector functions but the same antigenic specificity (Chaplin, 
2006). The cytokine IL-10 secreted by Th triggers a switching to IgG1 and IgG3 that 
bind phagocytic cells with high affinity. The cytokines IL-4 and IL-3 cause the 
switching to IgE. IgE binds to Fc receptors on the membranes of basophils and tissue 
mast cells. Localized mast-cell degranulation induced by IgE releases mediators that 
facilitate the recruitment of cells necessary for antiparasitic defence. IgE molecules 
also mediate the hypersensitivity reactions responsible of asthma or hay fever. TGF-
β triggers the switching to IgA which are the main Ig of external secretions such as 
saliva and gut (Baumgarth, 2000). A main difference between the antigen 
recognition by the Ig and by TCRs is that Ig can recognize complex 3 dimensional 
structures, whereas the TCR can only recognize short linear peptide presented by 
MHC-I or II (Chaplin, 2006). 
After antigen stimulation, B cells differentiate into plasma cells that secrete 
immunoglobulins. Each B cell receptor (BCR) expressed on the B cell surface, 
recognizes a specific antigen. The mature BCR form a complex which includes 





complex also includes CD19, CD81 and CD21. The binding of an antigen induces 
the phosphorylation of the cytoplasmic ITAM portion of Igα and Igβ by the Src 
family kinase Lyn. ITAM phosphorylation induces the recruitment of different 
kinases and adaptor proteins depending on the state of cell maturation and antigen 
ligated. These signals include the mitogen-activated protein kinase (MAPK) pathway 
which induces cell proliferation and the Akt pathway which induces cell survival 
(Khan, 2009).  
B cells express CD40, a member of the TNF receptor family that plays a role in the 
interaction of T helper cells and B cells. Activated T-helper cells express a ligand for 




























1.2 T-acute lymphoblastic leukaemia 
T-ALL is a neoplastic disorder that mainly occurs in children with a peak at 2-5 
years of age. It represents 15% of paediatric and 25% of adult acute lymphoblastic 
leukaemia (Mathisen et al., 2013). T-ALL is characterized by clonal proliferation of 
malignant blast cells with an immature T lymphocyte phenotype. T-ALL cells are 
heterogeneous and arrested in a particular stage of maturation that can be correlated 
to their normal counterpart, differentiating T cells. For example the T-ALL cell line 
CCRF-CEM correlates with the pre-T lymphocytes. SUPT1 and Jurkat correlate with 
cortical T-lymphocytes (Burger et al., 1999) (Figure 1.5) 
Commonly T-ALL patients present with fatigue and pallor, spontaneous bleeding 
and lymphadenopathy. Bone and joint pain can be observed, more frequently in 
children causing difficulty to walk. The pathogenesis is also characterized by a high 
white blood count, and infiltration of T-ALL cells into various tissues, particularly 
lymph nodes, spleen and central nervous system (CNS). The migration and 
infiltration of leukaemic cells into tissues often correlates with a poor prognosis for 
patients with T-ALL (Kebriaei et al., 2002). The five years survival rates are 75-80% 
and 35-40% for children and adult respectively. Recently, mortality has decreased 
due to strong chemotherapy and radiotherapy. Because the CNS is the main site of 
relapse, T-ALL patients usually receive cranial irradiation and intrathecal 
chemotherapy. This therapy unfortunately often leads to several side effects 
including growth impairment, neurocognitive deficit and secondary cancers.  It is 
therefore important to develop new targeted therapies with less side effects 
(Demarest et al., 2008). At the stage of diagnosis T-ALL is often associated with 
extramedullary infiltration of leukaemic cells. This is present in 30% to 50% of 
children which have enlargement of the liver or spleen.  
A potential mechanism in the trafficking of leukaemia cells is the interaction of the 
chemokine receptor CXCR4, expressed on T-ALL cells, and its ligand stromal cell-
derived factor-1 (SDF-1/CXCL12) (see section 1.4.3), produced by stromal cells in 
bone marrow and extramedullary organs (Crazzolara et al., 2001). In a study on 11 
paediatric T-ALL patients the overexpression of the chemokine receptor CCR9 and 
the integrin CD103 was identified in one patient. This marker was associated with 
relapse to the gut suggesting that CCR9 or CD103 could contribute to T-ALL 




















Figure 1.5 Correlation of T-ALL cell lines with the normal differentiation 




T-ALL develops as a consequence of oncogenic mutations, in particular 
chromosomal translocations. The chromosomal translocations can occur during T 
cell development as a result of defective TCR recombination leading to aberrant 
proliferation and differentiation. These translocations often involve the juxtaposition 
of a strong promoter from TCR genes on chromosome 7 and 14 with transcriptional 
factor genes, such as TAL1, LMO, LYL1 and HOXA (Graux et al., 2006). Some 
chromosomal translocation can lead to genes encoding to chimeric proteins whit 
oncogenic properties as mixed-lineage leukaemia (MLL)-partner-gene fusions 
(Aifantis et al., 2008). Other common mutations include cryptic deletions that lead to 
the loss of tumour suppressor genes such as INK4 at 9p31 that leads to loss of G1 
control of cell cycle (Graux et al., 2006). 
Nevertheless expression microarrays, quantitative RT-PCR and whole-genome 
sequencing studies have identified different T-cell oncogenes that are dysregulated in 
T-ALL in the absence of chromosomal abnormalities (Ferrando et al., 2004; Sanz-





hs identified different gene expression signatures of leukaemic cells arrested at a 
specific stage of development. LYL1 shares 90% sequence identity with TAL1. 
They are expressed in the developing haematopoietic system but not in the thymus 
(Giroux et al., 2007). For example LYL1 is higly espressed in immature thymocytes 
whereas TAL1 is expressed in late cortical thymocytes (Graux et al., 2006). 
Interestingly, 30% of LYL1 transgenic mice develop T-cell and B-cell leukaemia 
with infiltration in multiple organs. LYL1 is also higly expressed in acute 
myeloblastic leukaemia (AML) and myelodysplastic syndrome (MDS) suggesting 
that it could be involved in the development of these cancers (Meng et al., 2005). 
TAL1 is normally expressed in a subset of haemapoietic cells, endothelial cells and 
cells of the central nervous system. TAL1 gene is located on chromosome 1p32. 
Rearrangements of this locus are present in 25% of T-ALL patients resulting in 
TAL1 activation. TAL1 activation is mainly due to a deletion that replaces the 
regulatory promoter sequence of TAL1 with that of the upstream gene SIL (Brown et 
al., 1990; Janssen et al., 1993).  
Aberrant expression of LMO1 and LMO2 has been found in 45% of T-ALL cases. 
LMO1 was identified in T-ALL patients with chromosomal translocation 
t(11;14)(p15;q11), whereas LMO2 was found in chromosomal translocation 
t(11;14)(p13;q11). Transgenic mice expressing LMO1 or LMO2 develop leukaemia 
with an accumulation of immature DN T cells but the cancer has a long latency. This 
suggests that these genes are necessary but not sufficient to develop leukaemia 
(Aplan et al., 1997). Interestingly, some T-ALL patients have abnormalities of 
LMO2 and TAL1 suggesting they could act synergistically to promote 
tumorigenesis. Moreover, transgenic mice co-expressing LMO2 and TAL1 genes in 
T cells develop T-ALL 3 months earlier than mice with just the LMO2 transgene 
(Larson et al., 1996).  
The homeobox genes normally regulate stages of embryonic development, important 
for morphogenesis and cellular differentiation. These genes encode highly conserved 
master regulators of transcription involved in the early development and regulation 
of haematopoiesis (Aifantis et al., 2008). Among these genes, HOXA (HOXA10 and 
HOXA11) is involved in a translocation associated with T-ALL. The chromosomal 
translocation involves the juxtaposition of TCR regulatory elements near HOXA 





Recently, Notch1 activating mutations have been identified in more than 50% of T-
ALL patients (Weng et al., 2004). Most of the Notch mutations observed in T-ALL 
cell lines and primary T-ALL cells are located in the HD and PEST domains (Figure 
1.3). Mutation of the HD domain leads to ligand-independent Notch1 cleavage and 
constitutive activation of Notch signalling.  The mutations in the PEST domain 
increase the half-life of the intracellular domain (Demarest et al., 2008; Giambra et 
al., 2012). One of the pathways triggered by Notch signalling is PI3K/target of 
rapamycin mTOR pathway.  
mTOR is a serine/threonine kinase that is part of two complexes, mTORC1 and 
mTORC2, with different biochemical structures and substrate specificity (Willems et 
al., 2012). mTORC2 is implicated in proliferation and differentiation of pre-T cells 
mediated by NF-kB and in the expression of the chemokine receptor CCR7 in 
leukaemic cells. CCR7 was shown to mediate leukaemic T-cells infiltration into the 
























1.3 Ras and Rho GTPases as regulators of cell adhesion and 
migration 
Leukocyte migration is tightly regulated and requires adhesion, polarization and 
cytoskeleton reorganization. Key regulators of migration are Rho and Ras GTPases. 
Ras was the first small G-protein to be identified and is mutated in 33% of all human 
cancers (Baines et al., 2011). Mutations in the Ras pathway are common in myeloid 
malignancies. They occur in approximately 20% of adult acute myelogenous 
leukaemia, 40% of chronic myelomonocytic leukaemia, and 30% of juvenile 
myelomonocytic leukaemia cases (Mullally and Ebert, 2010).  
The human Ras superfamily comprises of 154 members divided into five 
families: Ras, Rho, Rab, Arf and Ran families (Wennerberg et al., 2005) (Figure1.6). 
 
 
Figure 1.6  Phylogenetic tree of the mammalian Ras GTPase superfamily. There 
are 20 Rho GTPases classified in 8 subgroups based on sequence similarities (Vega 






Most GTPases cycle between a GDP-bound inactive form and a GTP-bound active 
form that interacts with downstream effector proteins. The GTP-GDP switch is 
regulated by specific classes of proteins: the guanine nucleotide exchange factors 
(GEFs) that promote exchange of bound GDP for GTP, and GTPase activating 








Figure 1.7 Regulation of Rho GTPase activity. Rho GTPases switch between a 
GDP-bound inactive form to a GTP-bound active form. This process is regulated by 
guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). 
Several Rho GTPases are also regulated by the GDP dissociation inhibitors (GDIs) 




1.3.1 Ras and Rho GTPases lipid modification 
Most Ras superfamily GTPases are post-translationally modified by farnesyl or 
geranylgeranyl isoprenoid groups. These modifications facilitate the anchorage of 
these proteins to membranes where they signal to downstream effectors. Isoprenoids 





consensus tetrapeptide motif (cysteine-aliphatic-aliphatic-any). Depending on the X 
of the CAAX motif, GTPases can be either farnesylated or geranylated. If the X of 
the CAAX consensus is a leucine, the GTPase is geranylated, whereas if the X is 















Figure 1.8 GTPase isoprenylation. Depending on the last amino acid, GTPases can 
be either farnesylated or geranygeranylated on the cysteine residue of the CAAX 





Farnesyltransferase or geranylgeranyltransferase catalyse the transfer of the carbon 
isoprenoid chain from farnesylpyrophosphate or geranygeranylpyrophosphate to the 
cysteine residue. Subsequently, an endopeptidase removes the last three amino acids 
from the carboxyl terminus of the protein. The cysteine is then methylated by a 








Figure.1.9 Skeletal formula of farnesylpyrophosphate (A) and 




Several GTPases have a C-terminal polybasic region (PBR) with multiple lysines or 
arginines. This region mediates localization to membranes and interaction with some 
proteins. The PBR can promote the interaction with a nucleocytoplasmic shuttling 
protein SmgGDS. For example the PBR domain of Rac1 was found to enhance the 
nuclear accumulation of a protein complex containing SmgGDS and Rac1 that is too 
large to diffuse through the nuclear pores (Williams, 2003).  
In addition to the polybasic region, some GTPases are C-terminally palmitoylated. 
Palmitoylation is the post-translational covalent addition of the 16-carbon fatty acid 
palmitate (Figure 1.10)  
 






The main difference from isoprenylation is that palmitoylation is a reversible 
process. This allows proteins to associate transiently with membranes, regulating 
their localization or endocytic trafficking (Navarro-Lerida et al., 2012). H-Ras has 
two palmitoylated cysteine residues, Cys181 and Cys184. These sites show distinct 
biological functions. Monopalmitoylation of Cys181 is required for H-Ras targeting 
to the plasma membrane, whereas monopalmitoylation of Cys184 does not permit 
trafficking beyond the Golgi (Roy et al., 2005). Rac1 was also recently demonstrated 
to be palmitoylated at Cys178. Its palmitoylation requires prior prenylation and an 
intact PBR. Lack of Rac1 palmitoylation induces a decrease in cell spreading and 
migration, suggesting palmitoylation is required for Rac1 function in actin 
cytoskeleton remodelling (Navarro-Lerida et al., 2012) (Figure 1.11) 
 
Figure 1.11 GTPase lipid modification. Farnesyl or geranylgeranyl transferase 
catalyse the transfer of isoprenoid groups to a cysteine residue close to the carboxyl 
terminus. Following isoprenylation, an endopeptidase removes the end three amino 
acids from the carboxyl terminus of the GTPases. The new carboxyl terminus is then 
methylated by a methyltransferase. In some GTPases, following transport to the 
plasma membrane palmitoyltransferase catalyses the addition of two palmitoyl long-
chain fatty acid groups to a cysteine residue that is upstream of the isoprenylated 
carboxyterminal cysteine. FPP= farnesyl pyrophosphate. GGPP= geranylgeranyl 
pyrophosphate. F=farnesyl group. G=geranylgeranyl group. Adapted from Donward, 







The Rho GTPases RhoU and RhoV are targeted to membranes by palmitoylation and 
are not prenylated (See 1.3.5.1 and 1.3.5.2). 
Some Rho GTPases are regulated by GDP dissociation inhibitors (Rho GDI). The 
Rho GDIs in humans are GDI α, β, γ. These molecules sequester Rho proteins in the 
cytoplasm by binding the prenyl group at the C-terminus. This prevents the 
dissociation from GDP blocking the Rho protein in an inactive state (Greenwood et 
al., 2006) (Figure 1.7) 
 
 
1.3.2 Statins, geranylgeranyl and farnesyl inhibitors 
Statins are small molecules used to treat hypercholesterolemia and cardiovascular 
disease. They decrease cholesterol synthesis by inhibiting the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase that converts the 3-hydroxy-3-
methyglutaryl-CoA into mevalonic acid, a substrate of the cholesterol pathway 
(Figure 1.12). The synthesis of mevalonate is necessary for the biosynthesis of 
cholesterol but also for other molecules of the mevalonic cascade, such as 
isoprenoids (Greenwood et al., 2006). As described above, Ras/Rho proteins are 
modified by isoprenoids.  Suppression of isoprenoid synthesis has been considered 
responsible for some of the pleiotropic effects of statins.  
Statins are already used to treat hypercholesterolemia, atherosclerosis and 
cerebrovascular disease and have shown beneficial effects in other common diseases 
such as neurodegeneration, osteoporosis and cancer (Fuchs et al., 2008). 
Randomized controlled trials for preventing cardiovascular disease indicated that 
statins had unexpected benefits for reducing colorectal cancer and melanoma. The 
reduction in isoprenylation of the Ras/Rho GTPases, preventing membrane 
localization, might be an important aspect in the cancer prevention properties of 





















Figure 1.12 Statin inhibition of prenylation. Chemical structures of simvastatin 
(A) and lovastatin (B). From Barrett, J Pharm Biomed Anal. 3-Hydroxy-3-
methylglutaryl-CoA reductase catalyzes the synthesis of mevalonic acid, which is 
required for the geranylgeranylpyrophosphate and farnesylpyrophosphate synthesis. 
These groups are covalently added to the Ras/Rho GTPases allowing their anchorage 




The transforming activity of oncogenic Ras requires its prenylation. For this reason 





farnesylation. FTIs inhibit growth and induce tumour regression in Ras-dependent 
tumours in mice and these compounds have been tested in clinical trials in solid and 
haematological malignancies (Karp and Lancet, 2005). Based on initial results, these 
compounds were suggested to be used in combination with chemotherapy, 
radiotherapy or other targeted agents (Mazieres et al., 2004). However, a trial in 
multiple myeloma patients of the FTI inhibitor tipifarnib discouraged the use of this 
drug as only 23 of 36 patients showed disease stabilization (Ocio et al., 2008). The 
lack of success of FTI in inhibiting K and N-Ras is probably due to alternative 
geranygeranylation (Roberts et al., 2008; Whyte et al., 1997). 
Inhibitors of geranylgeranlylation are known as geranylgeranyl transferase inhibitors 
(GGTIs). These compounds have also been developed as potential cancer therapies. 
One reason is that K-Ras, the most commonly mutated Ras isoform becomes 
geranylgeranylated in the presence of FTIs. Moreover, RhoC, Cdc42 and Rac1 are 
all geranylgeranylated and have been shown to have a role in metastasis, in same 
cases downstream of K-Ras. Similar to FTIs, GGTIs inhibit tumour growth in vitro 
and animal models and one GGTI has entered in a clinical trial in patients with 
advanced solid malignancy (Berndt et al., 2011).  
 
 
1.3.3 Rap GTPases  
Rap proteins belong to the Ras superfamily of small G-proteins. Mammals have two 
Rap1 (Rap1a and Rap1b) and three Rap2 (Rap2a, Rap2b and Rap2c) proteins. Rap1 
and Rap2 proteins share 60% sequence homology.  
Rap proteins are involved in several aspects of cell migration, controlling integrin-
mediated adhesion, cell-cell adhesion, cytoskeleton organization, cell polarity and 
intracellular trafficking (Frische and Zwartkruis, 2010). Their effectors contain a Ras 
binding domain (RA)(van Dam et al., 2009). Like other GTPases, Rap proteins cycle 
between a GTP-bound active form and a GDP-inactive form. So far, five distinct 
classes of GEFs have been identified for Rap1: C3G, PDZ-GEF1 and 2, Epac1,2 and 
Repac, CalDAG-GEF1. Rap GAPs include Rap1GAPI and II, Spa1 and 
SIPA1L1/E67P1. Many of these GEFs and GAPs are not specific for Rap1 but can 





Rap1 has been implicated in β1, β2 and β3 integrin activation, a process partialy 
mediated by the effector molecule Rap1-GTP-interacting adaptor molecule (RIAM).  
RIAM belongs to the Mig-10/RIAM/Lamellipodin (MRL) family of adaptor 
proteins. RIAM has an RA domain that mediates the interaction with Rap1. The N-
terminus of RIAM harbours a proline-rich region bracketed by two potential coiled-
coil regions, whereas the C-terminus has a PH domain and a second proline-rich 
region (Boettner and Van Aelst, 2009). Overexpression of RIAM induces cell 
spreading and lamellipodium formation, and also induces activation of β1 and β2 
integrin. RIAM co-immunoprecipitates with talin and expression of RIAM activates 
integrin through talin.  siRNA depletion of RIAM in Jurkat T-cells inhibits adhesion 
to fibronectin. The downregulation of RIAM was also shown to decrease Rap1 
membrane localization (Lafuente et al., 2004).  
Although this process is not fully understood it is likely that RIAM act as scaffolding 
protein binding Rap, which induces talin tethering and integrin activation. Besides 
RIAM, the Rap1 effector RapL is also implicated in integrin activation by regulating 
LFA-1/αLβ2 spatial distribution (Boettner and Van Aelst, 2009). In mouse lymphoid 
tissues stimulated with CXCL12, RapL was found to associate with Rap1. This 
association induced a redistribution with LFA-1 to the leading edge, increasing 
adhesion to ICAM-1(Katagiri et al., 2003). 
Rap1 was demonstrated to be involved in tumorigenesis. Injection of Swiss 3T3 
expressing Rap1 into nude mice resulted in the formation of tumours (Altschuler and 
Ribeiro-Neto, 1998). Rap1 was also shown to be involved in myeloid leukaemic. 
Overexpression of the Rap1 GEF CalDAG-GEF in FDCP1 myeloid cells induced 
growth and transformation. CalDAG-GEF also increased cell adhesion to fibronectin 
through Rap1 (Dupuy et al., 2001). Another example implicating Rap1 in leukaemia 
comes from experiments on SPA-1 deficient mice. SPA-1 is a GAP of Rap1, and 
mice lacking this protein developed a spectrum of myeloid disorders similar to 













Figure 1.13 Effectors, GEFs and GAPs of Rap. Diagram showing the effectors 
(and their functions), GEF and GAPs of Rap. Proteins specific for Rap1 are 
highlighted in orange.  
 
 
Rap1a and Rap1b share 95% sequence identity (Figure 1.14). They differ at just 8 
amino acids located at the C-terminus (Raaijmakers and Bos, 2009). Both proteins 
are post-translationally modified by geranylgeranyl isopreonoids and are expressed 
in a variety of tissues (Wittchen et al., 2011). The distinct roles of Rap1a and Rap1b 
have not been clarified yet. Most studies have only used one isoform. Recently, 
downregulation of Rap1a but not Rap1b was reported to increase endothelial cell 
permeability by destabilizing cell-cell junctions. These data suggest that some 







Figure 1.14 Amino acid sequences of Rap1a and Rap1b. Rap1a and Rap1b share 
95% sequence identity. Differences in amino acid sequence are higlighted in yellow. 




1.3.3.1 Integrins and their ligands  
Chemokines act through G-protein coupled receptors and are important for T cell 
integrin activation. They were first suspected to be responsible for integrin activation 
after the observation that the G-protein signalling inhibitor blocked leukocyte 
adhesion to the endothelium (Bargatze and Butcher, 1993). Chemokines induce 
clustering of specific integrins on the leukocyte surface and more importantly, 
stimulate a conformational change in integrins which increases their affinity for 
ligands expressed on the endothelium (Neeson et al., 2000). 
Integrins are transmembrane adhesion receptors composed of an α and β subunit. In 
humans there are 18 α and β subunits that can assemble into 24 distinct receptors, 
that preferentially bind specific extracellular matrix (ECM) proteins (Arnaout et al., 
2007). Each integrin consists of a large extracellular domain, a transmembrane 
domain and a short cytoplasmic domain. The N-terminus of the α and β subunits 
forms a globular head contain the ligand-binding domain. Integrins can take 3 
conformational states: an inactive state, with low affinity for their ligand, an active 





For leukocyte adhesion to the endothelium, the integrins LFA-1 (αLβ2) and VLA-4 
(α4β1) play a major role. Their main ligands on the endothelium are the intercellular 
adhesion molecule (ICAM-1) for LFA-1 and the vascular cell adhesion molecule 
(VCAM-1) for VLA-4. LFA-1 also binds junctional adhesion molecule-A (JAM-A), 
contributing to T cell and neutrophil transendothelial migration (TEM) and LFA-1-
mediated arrest of T cells (Ostermann et al., 2002). ICAM-1 and VCAM-1 are 
basally expressed in resting endothelial cells, and ICAM-1 and VCAM-1 expression 
is induced by stimulation with proinflammatory cytokines such as IL-1 and TNF-α 
(Barreiro et al., 2002). VCAM-1 and ICAM-1 appear to play different roles during 
adhesion and TEM. Adhesion of T cells to activated endothelial cells was markedly 
inhibited by blocking antibodies to VCAM-1, but not by blocking antibodies to 
ICAM-1. ICAM-1 instead had a predominant role in TEM even when T cell 
adhesion to the endothelium was not mediated by ICAM-1 (Oppenheimer-Marks et 
al., 1991).  
Leukocytes and platelets express various types of integrins and defects in integrin 
expression or activation in immune cells result in immunodeficiency or autoimmune 
diseases. An α4 integrin antagonist has been used for treatment of multiple sclerosis 
as it reduces the adhesion and migration of lymphocytes and monocytes into the 
parenchyma reducing brain lesions (Gottlieb et al., 2004; Miller et al., 2003). 
In resting T lymphocytes, integrins are evenly distributed on the cell surface in an 
inactive state but they can be rapidly activated by diverse cellular agonists. The 
activation of integrins induces a conformational change in the extracellular domains 
leading to an increase in affinity for ligand binding (Stewart and Hogg, 1996). 
Integrin-ligand interactions are dependent of divalent cations, that can enhance or 
suppress the ligand binding activity. The α subunit I domain contains a unique metal 
binding site specific for Mg2+ and Mn2+, and the conserved I-like domain of the β 
subunit contains a similar cation binding motif. Mg2+ and Mn2+ can induce 
conformational changes in many integrins that correlate with an increase in the 
affinity state. The stimulation of integrin with Mg2+ requires chelation of the divalent 
cation Ca2+ (Leitinger et al., 2000).  
Chemokine or TCR stimulate inside-out signalling to activate integrins. As 
mentioned above, in the inactive state the ligand-binding site is bent and close to the 





the tail of the β subunit can generate a conformational change outside with an 
intermediate ligand affinity. Once the cytoplasmic α and β tails are sufficiently 
separated and the extracellular parts stand up the high-affinity conformation is 
reached (Zhang and Wang, 2012). The change in integrin conformation is important 
to arrest rolling leukocytes on blood vessels, as integrins can then bind the 
endothelial ligands, undergoing an additional allosteric rearraengment of the ligand-
binding domain to induce the anchorage of integrins to the actin cytoskeleton. This 
process might be mediated by the actin binding sites of talin (Alon and Shulman, 
2011). There are two talins, talin1 and talin2. Suppression of talin1 by RNAi inhibits 
VLA-4 and LFA-1 mediated arrest of lymphocytes on endothelial ligands (Manevich 
et al., 2007; Shamri et al., 2005). The binding of talin to the β subunit of integrins 
can be enhanced by phosphatidylinositol (4,5)-bisphosphate. The association of talin 
is not always enough to anchor integrins to the actin cytoskeleton. The β subunit 
needs a second co-activating signal by kindlin proteins (Figure1.15). In murine 
leukocytes binding of β1 and β2 integrin requires the presence of both talin1 and the 






Figure 1.15 Integrin activation. Talin and kindlin bind the cytoplasmic tail of β 
integrin leading to changes in the conformation from an inactive state to active state. 






Several Rho GTPases have been reported to be involved in integrin activation, 
including RhoA, Rac1 and Rap1. RhoA activation stimulated β1 and β2 integrin-
mediated adhesion in murine thymocytes. In vivo RhoA depletion was found to 
impair adhesion to VCAM-1, but this process was suggested to be downstream of 
Rap1 and Rac1 (Vielkind et al., 2005). A constitutively active Rac mutant induced 
spreading of Jurkat cells and their adhesion to fibronectin in an integin-dependent 
manner. Cell adhesion mediated by active Rac was not due to changes in the 
expression or affinity state of integrins but to cell spreading (D'Souza-Schorey et al., 
1998). Rap1 has been well characterized as a protein involved in inside-out integrin 
activation, although the different contribution of the two isoforms Rap1a and Rap1b 
is not yet well understood. Rap1 regulates all integrins connected to the actin 
cytoskeleton (β1, β2 and β3) and was shown to control both integrin activation and 
integrin clustering depending on the integrin and the cell type (Bos, 2005). 
 
 
1.3.4 Rho GTPases  
There are 20 Rho GTPases in humans (Figure 1.6). Rho GTPases are implicated in 
the regulation of several cellular process and functions including cytoskeleton 
rearrangements, cell movement, vesicles trafficking and cell cycle progression. Most 
Rho GTPases are 20-28 kDa. Rho GTPase expression varies across tissues and is 
regulated by multiple stimuli. They exert their function by interaction with 
downstream targets such as protein kinases, phospholipases and actin nucleators 
(Heasman and Ridley, 2008).  
To date 83 RhoGEFs have been identified (Sanz-Moreno et al., 2008). Different 
GEFs can activate one or more Rho GTPases coordinating the Rho GTPases with 
different downstream effectors (Garcia-Mata and Burridge, 2007). GEFs are 
classified into two families: the Dbl family and the DOCK family. The Dbl proteins 
contain a Dbl-homology (DH) domain, which is responsible for the catalytic activity, 
and an adjacent PH domain. Some PH domains mediate GEF membrane localization 
as they can bind phospholipids promoting their localization to the plasma membrane 
(Rossman et al., 2005). The DOCK family lacks the DH domain and contains two 
DOCK homology regions (DHR1 and 2) that promote guanine nucleotide exchange 





important for localization or for the formation of protein complexes. Extracellular 
signals regulate GEFs and GAPs by inducing postranslational modifications which 
affect activity and localization allowing protein complex formation. There are more 
than 70 RhoGAPs in humans (Bos et al., 2007).  
The atypical members of the Rho GTPase family do not act as molecular switches 
and do not cycle between a GTP-bound and a GDP-bound form. Rnd, RhoH and 
RhoBTB proteins lack GTPase activity, hence they are constitutively bound to GTP 
(Aspenstrom et al., 2007). The atypical Rho GTPases RhoU and RhoV have a high 
intrinsic GDP/GTP exchange rate and are therefore mainly in an active form (Shutes 
et al., 2004).  
 
 
1.3.4.1 RhoU  
RhoU belongs to the Cdc42 subfamily which also includes RhoV, RhoQ and RhoJ 
(Ellenbroek and Collard, 2007). RhoU shares 57% of the amino acid sequence 
identity with Cdc42. 
RhoU is also known as Wrch1, and its gene is located on the human chromosome 
1q42. RhoU was first isolated and cloned as a Wnt-inducible gene (Tao et al., 2001). 
Wnt-1 signalling is important for the development of organisms from nematodes to 
mammals (Cadigan and Nusse, 1997), but Wnt-1 was also identified as an oncogene 
implicated in tumorigenesis (Peifer and Polakis, 2000). The role of Wnt-1 signalling 
in development and tumorigenesis is mediated by its target genes. Wnt-1 through 
RhoU is able to induce transformation of mouse mammary epithelial cells (Tao et 
al., 2001).  
RhoU possesses a unique N-terminal 46 amino acid sequence extension containing 
several PxxP SH3-binding motifs (Figure 1.16).  
RhoU has a CAAX motif at the C terminus (CCFV). Despite this, RhoU does not 
undergo isoprenylation but is modified by palmitate (see section 1.3.1). Its 
localization is not affected by inhibitors of protein prenylation but by inhibitors of 
protein palmitoylation (Berzat et al., 2005). In fibroblasts, RhoU localizes to plasma 
membrane and endosomes (Tao et al., 2001).  
RhoU has not so far been studied in T cells. RhoU overexpression was shown to 





fibroblasts. Like Cdc42, RhoU induces filopodium formation and stress fibre 
dissolution in NIH3T3 fibroblasts (Tao et al., 2001). In HeLa cells, RhoU strongly 
localized to focal adhesions, and RhoU downregulation incresead focal adhesions 
formation and inhibited cell migration (Chuang et al., 2007).  
RhoU is able to activate p21 serine/threonine kinase (PAK), one of the most studied 
effectors of Rho GTPases (Tao et al., 2001). N-terminal deletion of RhoU enhances 
its ability to bind PAK1 (Shutes et al., 2004). NCK2 was also identified as a binding 
partner of RhoU. The PxxP-rich domain at the N-terminus of RhoU binds the second 
and third SH3 domains of NCK2 (Saras et al., 2004). The N-terminus of RhoU also 
associates with the adaptor protein Grb2, which increases RhoU activity (Shutes et 
al., 2004). Interestingly, after epidermal growth factor (EGF) stimulation, RhoU 
colocalizes with the EGF receptor on endosomes in a Grb2-dependent manner in 
pancreatic cancer cells (Zhang et al., 2011).  
RhoU also binds the nonreceptor tyrosine kinase Pyk2. The interaction requires 
RhoU to be in a GTP-bound form and also required the N-terminal proline-rich 
extension. The interaction requires the presence and activity of Src and has a role in 
filopodium formation in fibroblasts (Ruusala and Aspenstrom, 2008). In H1299 non-
small cell lung cancer cells RhoU relocates to the plasma membrane upon serum 
stimulation. Serum stimulation induces Src-mediated tyrosine phosphorylation of 
RhoU at Tyr254 residue. This phosphorylation decreases GTPase activity and the 
ability of RhoU to interact with downstream effectors (Alan et al., 2010). 
RhoU was also shown to bind to Par6 in epithelial cells. Par6 is a scaffolding protein 
important in establishing epithelial cell polarity and in regulating tight junction (TJ) 
formation. Their interaction was shown to affect epithelial cell TJ assembly and actin 
organization (Brady et al., 2009). 
Recently, ARHGAP30 has been identified to interact with RhoU. ARHGAP30 is 
closely related to the Cdc42-specific RhoGAP CdGAP. RhoU was found to bind 
ARHGAP30 and CdGAP in co-immunoprecipitation assays in fibroblasts. 
Overexpression of ARHGAP30 phenocopied RhoU in inducing filopodium 
formation and stress fibre disassembly, suggesting a role downstream of RhoU (Naji 






The RhoV gene is located on the human chromosome 15q15 which is a fragile site in 
the human genome. RhoV shares 55.4% of total amino acid identity with RhoU and 
43.5% with Cdc42. RhoV is higly expressed in gastric, pancreatic and cervical 
cancer (Katoh, 2002). RhoV is also moderately overxpressed in pro-myelocytic 
leukaemia, Burkitt's lymphoma and colorectal cancer (Katoh, 2002). Like RhoU, 
RhoV is able to activate PAKs and contains a unique N and C-terminal extension 
(Aronheim et al., 1998; Weisz Hubsman et al., 2007) (Figure 1.16). Overexpression 
of RhoV induces the induction of lamellipodia possibly through interaction with 
Pak2 (Aronheim et al., 1998). 
RhoV lacks a CAAX motif, and undergoes palmitoylation for membrane targeting. 
Immunofluorescence analysis of NIH3T3 fibroblasts overexpressing GFP-RhoV 
showed that RhoV localizes to the plasma membrane and endosomes. Moreover 
NIH3T3 cells overexpressing RhoV showed transforming activity which requires an 
intact C-terminus. Deletion of the N-terminal extension enhanced its transforming 
activity, suggesting a negative regulatory role of this domain (Chenette et al., 2006). 
In PC12 cells, RhoV expression induces apoptosis and activation of JNK signalling 
via both death receptor-mediated and mitochondrial apoptotic pathways as 
determined by caspase-8 and caspase-9 activation. This suggests a possible role of 
RhoV in regulating PC12 apoptotic activity in a JNK-dependent manner (Shepelev et 








Figure 1.16 Amino acid sequences of Cdc42, RhoV and RhoU. The amino acid 
sequence of Cdc42 was aligned with those of RhoU and RhoV. The proline residues 
in the N-terminal domain of RhoU are underlined. Amino acids required for RhoU 
and RhoV membrane targeting are denoted by orange boxes. The yellow box 
indicates RhoU phosphorylation site. The red boxes indicates palmitoylation site of 























Figure 1.17 Domain structure of RhoU and RhoV. RhoU and RhoV consist of 
258 and 236 amino acids respectively. The C- terminus of both proteins is 
palmitoylated. The phosphorylation site at the C-terminus of RhoU is indicated. The 
N-terminal domain of RhoU is proline-rich. Downstream partners of RhoU and 
















1.4 Rap and Rho GTPases and T lymphocyte migration 
Mature T lymphocytes circulate in the blood stream as non-adherent cells. It has 
been estimated that under normal conditions T lymphocytes spend less then 30 
minutes in the blood circulation, repeatedly visiting secondary lymphoid organs. 
This traffic is fundamental for a good immune surveillance. To reach secondary 
lymphoid organs, T lymphocytes need to cross the vascular endothelium. Once in the 
lymph nodes, T cells scan the area searching for APCs. The immunological synapse 
between the T lymphocytes and APCs triggers a signalling cascade that eventually 
induces the activation and proliferation of the T lymphocytes. After activation T 
lymphocytes enter in the blood stream and transmigrate through the blood vessels to 
reach the inflamed or infected area (Rougerie and Delon, 2012). Rho GTPases 
mediate this process by controlling each step of transendothelial migration: adhesion 




1.4.1 Rap and Rho GTPases in adhesion 
In resting T cells, integrins are in an inactive conformation. This conformation is 
maintained by the atypical Rho GTPase RhoH. Downregulation of RhoH in Jurkat 
and primary human T cells causes an increase of αLβ2/LFA1-dependent adhesion 
onto ICAM-1 (Cherry et al., 2004). Recently Cdc42 was also described as a negative 
regulator of LFA-1 activation (Bolomini-Vittori et al., 2009). Rap1 is a major and 
well established regulator of integrin activation as described above.  
Rac1 also plays a role in integrin activation during chemotaxis. Rac1 was shown to 
increase spreading of Jurkat cells in a β1-dependent manner (D'Souza-Schorey et al., 
1998). In addition stimulation with the chemokine CXCL12 promotes α4β1-
dependent integrin activation through Rac1 in human T cells (Garcia-Bernal et al., 
2005). Interestingly, Rac1 and Rac2 deficient T cells have a defect in adhesion to 
ICAM-1, suggesting that Rac1 and Rac2 participate in β2 as well as β1-mediated 
adhesion. Moreover, only depletion of both Rac1and Rac2 induces this striking 
defect, suggesting a possible redundant function of these two GTPases (Faroudi et 





macrophages Rac1 and Rac2 were showed to have distinct roles. Macrophages 
lacking Rac2 had a reduction in podosomes while lack of Rac1 altered cell shape and 
reduced membrane ruffling (Zhang et al., 2012).  
RhoA has important functions in T cell development in the thymus (Corre et al., 
2001). RhoA activation is sufficient to promote β1 and β2 integrin-mediated 
adhesion in murine thymocyte. Loss of RhoA function impaired thymocytes to 
adhere and to migrate on VCAM-1 and prevented integrin activation induced by the 
GTPases Rac-1 and Rap1a in vivo. This suggests a role of RhoA in regulating cell 
adhesion and migration during T cell development (Vielkind et al., 2005).  
 
 
1.4.2 Rho GTPases and cell migration 
Chemokine stimulation is important for T cell polarization and this is a fundamental 
step for T cell migration. During polarization, T cells acquire a motile morphology 
with a broad leading edge at the front called the lamellipodium, where the 
chemokine receptor and activated αLβ2 integrin (LFA-1) are localized, and a uropod 
at the back where ezrin-radixin-moesin proteins (ERM), ICAM-1/3 and CD44 are 
distributed (Gerard et al., 2007).  
T cell polarization and migration require the re-organization of the actin 
cytoskeleton, a process regulated mainly by the classical Rho GTPases Rac, Rho and 
Cdc42. The cytoskeleton undergoes dynamic changes depending on what is required 
in a particular situation. Monomeric G-actin can polymerize into filaments (F-actin). 
G-actin binds ATP in a complex with Mg2+. ATP binding stabilizes the actin 
monomer promoting polymerization (Le Clainche and Carlier, 2008). The new actin 
filaments initiate from an actin nucleus that can accept actin monomers. During actin 
polymerisation, actin monomers are added either free or in complex with the actin 
binding protein profilin to the barbed ends of pre-existing filaments. The 
polymerization is terminated by capping proteins such as Gelsolin or Eps8 (Mathisen 
et al., 2013). The spontaneous assembly of monomers into actin filaments is a slow 
and an unfavourable process. It is enhanced by actin nucleators such as the Arp2/3 
complex or proteins of the formin family. The Arp2/3 complex comprises of Arp2 
and Arp3 proteins and together with 5 actin-related proteins (ARPC). The Arp2/3 





promoting factors (NPFs) such as WAVE and WASP (Park et al., 2007). The formin 
family is divided in different subclasses: Diaphanous (mDia), formin-related proteins 
in leukocytes (FRLs), dishevelled-associated activators of morphogenesis (DAAMs), 
formin homology domain proteins (FHODs), formins (FMNs), delphilin and inverted 
formins (INFs). Formins nucleate non-branching actin filaments and remain bound 
inhibiting the apability of capping proteins to block polymerisation.  Formins 
nucleate linear actin filaments and they have been proposed to mediate filopodium 
formation (Campellone and Welch, 2010; Faix and Grosse, 2006). Depolymerisation 
of F-actin is mediated by ADF/Cofilin proteins that bind preferentially to ADP-actin, 
promoting the release of actin monomers. Profilin promotes the exchange of ADP 
for TP on G-actin monomers, to start a new cycle of polymerisation (Kiuchi et al., 
2007).  
The lamellipodium contains a branching network of actin filaments. The main 
regulators of lamellipodium formation are Rac1 and Rac2 (Ridley et al., 1992). Rac 
GTPases regulates actin polymerization through the WAVE complex, consisting of 
WAVE, PIR121/Sra-1, Nap125, HSPC300 and Abl interactor (Abi). Rac binds to 
PIR121/Sra-1. In response to stimuli, WAVE can signal to the Arp2/3 complex 
inducing actin polymerization (Rougerie and Delon, 2012).  
Several GEFs play a role in T cell migration by activating Rac1. Among these, 
DOCK2 is particularly important in T cells. Knockout of DOCK2 blocks Rac 
activation and consequently cell migration (Garcia-Bernal et al., 2006). Rac is not 
the only Rho GTPase to induce actin polymerization. Cdc42 can also activate WASP 
and N-WASP leading to actin nucleation by the Arp2/3 complex (Harris and Tepass, 
2010). Cdc42 is also able to induce filopodium formation via mDia formins, which is 
not important to generate force but is instead important for chemotaxis in T cells 
(Rougerie and Delon, 2012). 
RhoA has recently been shown to play a role at the leading edge of crawling and 
transmigrating T cells. Active RhoA was found at the front of CCRF-CEM cells 
during TEM and its activity correlates with both retraction and protrusion (Heasman 
et al., 2010). 
The accumulation of F-actin at the front of cells is, together with the contraction of 
the uropod, important to generate the force to move forward. The uropod generates a 
contractile force through myosin II interaction with actin bundles (Rougerie and 





on myosin II activity. Rho isoforms induce myosin light chain (MLC) 
phosphorylation and inhibit MLC phosphatase via their downstream targets ROCK1 
and ROCK2 (Kaibuchi et al., 1999; Takesono et al., 2010). 
The RhoA/ROCK/myosinII axis was also shown to be important in the maintenance 
of migratory polarity by controlling actomyosin contractility and microtubule 
stability (Heasman et al., 2010). In polarized T cells the microtubule organizing 
centre (MTOC) localizes at the back of the cell, behind the nucleus, along with 
ROCK. Treatment of T cells with nocodazole depolymerizes microtubules, 
increasing RhoA activity and inducing loss of migratory polarity (Takesono et al., 
2010). Moreover, RhoA depletion in CCRF-CEM T-ALL cells leads to loss of 
migratory polarity (Heasman et al., 2010). Active RhoA localizes at the back of T 
cells where it is associated with ROCK-mediated contraction (Heasman et al., 2010) 






















Figure 1.18 Signalling in T cell migration. In polarized T cells the microtubule 
organizing centre localizes behind the nucleus.  Rac1 activates the WAVE complex, 
leading to Arp2/3-mediated actin polymerisation at the lamellipodium. Cdc42 
induces filopodia via the formin mDia2. RhoA activation at the rear of the cell 
controls uropod contractility through ROCK inhibtion of MLC phosphatase and 
subsequent MLC phosphorylation. Cdc42 contributes to membrane extension via 
WASP which activate the Arp2/3 complex. RhoA  is also proposed to be active at 
the front of the cell to induce actin polymerization  through  mDia and membrane 





Polarity proteins mediate migratory polarity in T cells. These proteins are conserved 
during evolution and they induce the polarized distribution of multiprotein 





Scribble modules. During migratory polarization these complexes can cooperate to 
induce polarity or antagonize each other to achieve cell asymmetry.   
The Crumbs complex was identified in Drosophila melanoganster and consists of 
Crumbs, Protein associated with Lin seven 1 (Pals1) and Pals1-associated tight 
junction protein (PATJ). The Scribble complex consists of Scibble, Discs large (Dlg) 
and Lethal giant larvae (Lgl) (Ellenbroek et al., 2012). Components of the Par, 
Scribble and Crumbs complexes localize asymmetrically in migrating polarized T 
cells. The scribble protein complex localizes in the uropod and downregulation of 
Scribble impairs T cell polarization (Iden and Collard, 2008). Immunological 
synapses between T-cells and APC involves a polarized and adhesive contact 
between the T cell and APC. Dlg and Scribble proteins are important during 
immunological synapse formation as they redistribute from the uropod to the 
immunological synapse to colocalize with Par3 and the TCR (Ludford-Menting et 
al., 2005). Cdc42 not surprisingly has a role in T cell polarization. It was found to 
prevent the formation of a lamellipodium in the uropod avoiding “two headed” cells, 
hence preserving polarity (Ratner et al., 2003). The Par polarity complex is formed 
by Cdc42, Par3, Par6 and the atypical PKCs (aPKCι and aPKCζ). The activation of 
the complex at the front of the cell leads to the binding of adenomatous polyposis 
coli protein, a tubulin binding protein at the plus-ends of microtubules. The binding 
of adenomatous polyposis coli protein to the plus ends of microtubules together with 
the association of Dlg helps to establish polarity (Jaffe and Hall, 2005). The Par 
complex controls T cell migratory polarity. Active Cdc42 at the leading edge binds 
the Par6/Par3/aPKC complex inducing binding to the T lymphoma invasion and 
metastasis 1 (Tiam1). Tiam1 is a GEF that activates Rac via Par3. Tiam1 is a 
downstream effector of active Rap1a and acts as a scaffolding protein bringing Par3 
complex close to Rap1a and Rac1 by simultaneous binding to Par3 and Rap1a-GTP. 
This suggests that Rap1a recruts Tiam1 and the Par complex to the site of activation. 
Tiam1 can therefore couple Rap1a/Cdc42/Par-complex leading  to the activation of 








The selective recruitment of different leukocyte populations into tissues is 
determined by the presence of chemokines on a tissue and the respective receptors 
on leukocytes. Chemokine and chemokine receptor expression varies on different 
leukocyte subtypes and across the vasculature. For example, CCR7 and CXCR5 are 
differentially expressed on lymphocytes and dendritic cells allowing these cells to 
change their homing capacity and traffic routes (Lipp and Muller, 2003; Mackay, 
2001).  
So far about 40 chemokines are known, and they are classified according to the 
configuration of cysteine residues at the N-terminus into four families: CC, CXC, C 
and CX3C. They are small (8-14 kDa) molecules that regulate trafficking and host 
defence of leukocytes. They signal through the G protein-coupled receptors (GPCR) 
superfamily (Zlotnik and Yoshie, 2000). CXCL12 (also known as SDF-1) is 
produced by the bone marrow stromal and endothelial cells and is the ligand of the 
GPCR CXCR4. CXCLl2 has been shown to activate several signalling pathways in 
T cells, including PI3Ks, mitogen-activated protein kinase and protein kinase C. 
CXCL12 was also shown to induce Rac1 and Cdc42 activation and its effectors 
(Haddad et al., 2001). 
Several studies indicate the important role of CXCR4 in leukaemic cell homing into 
the bone marrow. Treatment of primary human leukaemic cells with CXCR4 
blocking antibodies decreased their homing into the bone marrow of mice which fail 
to develop mature T and B cells and consequently are immunodeficient 
(NOD/SCID). Administration of anti-human CXCR4 monoclonal antibodies to mice 
previously engrafted with primary human AML or ALL cells leads to a decrease in 
the levels of leukaemic cells (Tavor and Petit, 2010). Since the expression of a 
specific chemokine directs the homing of hematopoietic cells, chemokine receptor 
expression can be used to predict the possible metastatic site of a tumour. For 
example, at diagnosis, a 4-year old T-ALL patient had marked overexpression of the 
gut homing molecules chemokine receptor 9 (CCR9) and CD103. The relapse of 
leukaemia was subsequently confined to the gut. This suggests a role of chemokines 
in determining the location of relapse (Annels et al., 2004). 
To reach a site of inflammation, leukocytes have to move significant distances where 





molecules and to respond by directional migration is known as chemotaxis. Cells are 
also able to detect small changes in chemoattractant concentrations. During 
chemotaxis, T cells acquire a motile morphology as described above with a 
lamellipodium where the chemokine receptor and activated αLβ2 integrin (LFA-1) 
are localized, and a uropod at the back where ERM, ICAM-1/3 and CD44 are 
distributed (Gerard et al., 2007). The movement of leukocytes is controlled by 
internal and external signals, which activate signalling pathways resulting in 
cytoskeleton remodelling and cell movement.  
One of the main signalling proteins activated upon chemotactic stimulus is the PI3K 
pathway (Welch et al., 2003). There are 3 classes of PI3K: type I (which is divided 
in two subclasses IA and IB), type II and type III. The type I PI3KA (PI3Kα, β and 
δ) are activated by tyrosine kinase receptors while PI3KB (PI3Kγ) is activated by G 
protein-coupled receptors. Their activation leads to the accumulation of 
phosphatidylinositol 3,4,5-trisphosphate on the plasma membrane recruiting 
phosphatidylinositol 3,4,5-trisphosphate-binding proteins that drive further signals. 
The type II and III differ from the type I structurally and are involved respectively in 
clathrin and endosomal regulation (Giambra et al., 2012).  
The migration speed is affected by PI3K inhibitors, emphasizing a role of PI3Ks in 
chemotaxis (Stephens et al., 2002). PI3Ks have been shown to stabilize protrusion of 
the leading edge, facilitating accumulation of downstream effectors in this region 
(Stephens et al., 2008). Receptor activation of heterotrimeric G proteins is important 
for chemotaxis. In particular, Gβγ components of G proteins have been shown to be 
essential for chemotaxis signalling (Firtel and Chung, 2000). The dissociation of 
heterotrimeric G proteins activates PI3Kγ (Stephens et al., 2002). 
Phosphatidylinositol (3,4,5)-triphosphate can activate Rac. Rac can also stimulate 
PI3K activation, creating a positive-feedback loop at the front of the cells (Welch et 
al., 2003). PI3K was also shown to activate Cdc42, which is not involved in 
feedback loop but constrains the leading edge where phosphatidylinositol (3,4,5)-
triphosphate accumulates, thereby maintaining a persistent direction during 







1.4.4 Leukocyte transendothelial migration 
TEM and localization of leukocytes is an essential requirement for the immune 
system to clear pathogens. This process is active and tightly regulated and involves 





Figure 1.20 Schematic rappresentation of leukocyte transendothelial migration. 
Rolling is the first step of transendothelial migration. It is mediated by selectins and 
PSGL-1. Subsequently the leukocyte firmly adheres to the endothelium by binding 
of active β1 and β2 integrins to VCAM-1 and ICAM-1 expressed on the endothelium 
surface.  Leukocytes can then transmigrate either through endothelial junctions 





1.4.4.1 Endothelium: the blood vessel wall  
The endothelium consists of a monolayer of cells that acts as a barrier for the 
passage of cells and macromolecules from the blood to tissues. On the other hand the 
endothelium needs to function as an entry point for the lymphocytes and leukocytes 
to reach the targeted tissue or organ. In the endothelium, cell-cell junctions are 
classified into adherens junctions (AJ) and TJ. AJ are important for the initiation of 





of endothelial cell growth and angiogenesis. TJ have a major role in permeability 
controlling the passage of solutes and ions (Bazzoni and Dejana, 2004). Different 
molecules characterize these two types of junctions, forming homophilic 
interactions. Adhesion molecules are anchored to the actin cytoskeleton by adaptor 
molecules. These adaptor molecules also transmit signals to the cell interior to 
modulate gene expression and cell behaviour (Matter and Balda, 2003) 
The main transmembrane protein of endothelial AJ is vascular endothelial cadherin 
(VE-cadherin). Optimal cell-cell adhesion by VE-cadherin requires the binding of 
the C-terminal intracellular domain to catenins. The intracellular portion of VE-
cadherin binds p120, β and γ-catenin (Vestweber, 2008). The nectin-afadin complex 
colocalizes with cadherins at AJ. Nectin is an immunoglobulin-like adhesion 
molecule linked to the actin cytoskeleton via the afadin protein. The nectin-afadin 
complex seems to be important for TJ formation as well as it associates with TJ 
proteins (Takahashi et al., 1999). The major trans-membrane components of TJs are 
claudins and occludins. Among these, claudin-5 was shown to be an endothelial cell-
specific TJ protein (Morita et al., 1999). Occludin also contributes to TJ stabilization 
and optimal barrier function. For example downregulation of occludin induces an 
increase in endothelial permeability (Cummins, 2012). The transmembrane 
junctional adhesion molecule (JAM) proteins are associated with TJs and regulate 
tight junction assembly and endothelial permeability (Ebnet et al., 2004). The 
cytoplasmic TJ components zona occludens-1 and 2 (ZO-1 and ZO-2) act as 
scaffolding proteins between transmembrane and cytoplasmic proteins and ZO-1 has 














Figure 1.19 Endothelial cell-cell adhesion. Cell-cell adhesion is regulated by tight 
and adherens junctions. The transmembrane proteins of the adherens junctions are 




1.4.4.2 Rolling and adhesion 
It is well established that leukocyte TEM involves sequential events, starting with 
the rolling of the leukocyte on blood vessel walls (Cernuda-Morollon and Ridley, 
2006). This process is mediated by transmembrane glycoproteins known as selectins. 
The selectins are L-selectins, expressed on leukocytes, and E- and P-selectins 
expressed on endothelial cells which interact with P-selectin glycoprotein ligand1 
(PSGL1) and other glycosylated ligands. They regulate the capture and rolling of the 
leukocyte on the endothelium (Laubli and Borsig, 2010).  
One of the key events for the initiation of this process is the activation of the 
endothelium by proinflammatory cytokines such as tumour necrosis factorα (TNFα), 
thrombin, and IL-1. TNFα stimulation induces the expression of E-selectin on the 
endothelium (Puri et al., 2005). P-selectin is stored in granules that fuse with the 
plasma membrane when platelets and endothelial cells are activated (Zarbock et al., 
2011). The extracellular domain of all selectins is a C-type lectin domain followed 
by an epidermal growth factor-like domain. The cytoplasmic tail of L-selectin is 
composed of 17 amino acids in humans and has been reported to bind α-actinin, 
calmodulin and members of the ERM family (Ivetic and Ridley, 2004). Most L-





affinity binding, L-selectin often contains sulphated sugar moieties or sulphated 
tyrosyl residues that are important for leukocyte homing. Leukocyte activation leads 
to the cleavage of the membrane-proximal region of L-selectin resulting in the 
shedding of the extracellular domain (Wedepohl et al., 2012). 
PSGL-1 is expressed on almost all leukocytes and on certain endothelial cells and it 
is functional only when it is glycosytated. One role of PSGL-1 is to promote 
leukocyte-leukocyte interaction facilitating the recruitment of other leukocytes to the 
site of inflammation including those that do not express ligands for E or P-selectin. 
E-selectin also can bind glycosylated CD44 and the E-selectin ligand 1 (ESL1). 
Leukocyte rolling requires rapid formation and breaking of selectin binding to their 
ligands, and this process occurs under blood flow conditions. It has been 
demonstrated that rolling cells detach from the endothelium when the flow is 
stopped. This is a characteristic of selectins, as L and P-selectin require shear stress 
to act (Ley et al., 2007). 
Leukocyte rolling can also be mediated by integrins. T cell lines, T cells and 
neutrophils, have been shown to roll on vascular cell-adhesion molecule 1 (VCAM1) 
by engaging of VLA4/α4β1 on their surface. VLA4 was also shown to mediate 
lymphocyte rolling in venules of the central nervous system (Alon et al., 1995). β2 
integrins were suggested to mediate rolling of mouse neutrophils on ICAM-1, and 
human lymphocytes were shown to enhance rolling when ICAM-1 was co-expressed 
with L-selectin ligands on endothelial cells (Kadono et al., 2002; Singbartl et al., 
2001).  
The rolling of leukocytes on the blood wall allows the cells to slow down and to 
detect chemokines on the endothelium surface. Chemokines activate leukocyte 
integrins receptor promoting adhesion to ICAM-1 and VCAM-1 expressed on the 
endothelium surface (see sections 1.3.3.1 and 1.4.1) (Huo et al., 2003). 
 
 
1.4.4.4 Transendothelial migration 
The transmigration of leukocytes through the endothelium can occur through a 
paracellular or transcellular route. In the paracellular route the leukocyte migrates 





through an endothelial cell (Cernuda-Morollon et al., 2010; Johnson-Leger et al., 
2000). 
 
1.4.4.4.1 Paracellular TEM 
This mechanism can be very rapid and involves the transient opening of the 
endothelial junctions allowing the leukocyte passage. The binding of leukocytes to 
the endothelium induces cytoskeleton rearrangements in the endothelial cells via 
ROCK and MLC phosphorylation. The clustering of ICAM-1 or VCAM-1 induced 
by leukocyte binding induces an increase in RhoA activity and in stress fibres. This 
leads to an increase in cell contractility and endothelial permeability. RhoA might be 
activated via the ERM family. ERM could bind RhoGDI facilitating RhoA activation 
(Millan and Ridley, 2005). 
Reactive oxygen species (ROS) production upon Rac1 activation in endothelial cells 
has also been reported to be important for TEM, as preteatment with oxygen-radical 
scavengers inhibits TEM (van Wetering et al., 2002). Moreover ICAM-1 mediated 
signalling during neutrophil adhesion activates ROS production in endothelial cells, 
leading to cytoskeletal remodeling important for TEM (Wang and Doerschuk, 2000).  
Several molecules expressed at the endothelium junction facilitate TEM. These 
molecules include PECAM-1, VE-cadherin, CD99 and JAMs and ESAM. PECAM-1 
and JAM proteins are members of the Ig superfamily. VE-cadherin, as previously 
described, is a member of the cadherin family, and CD99 is a unique molecule 
(Muller, 2003). During extravasation VE-cadherin transiently disperses from the 
junctions to allow the passage of the leukocyte (Shaw et al., 2001). PECAM-1 is 
expressed on both leukocytes and on endothelial cells. In endothelial cells, it 
localizes to cell-cell junctions and on structures know as the lateral border recycling 
compartment (LBCR). The homophilic interaction between the N-terminal domain 
of PECAM-1 expressed on endothelium and leukocytes is important for 
transmigration. During transmigration, PECAM recycles from the LBCR and 
concentrates around the migrating leukocyte (Mamdouh et al., 2008; Mamdouh et 
al., 2003). Although PECAM-1 is required for transmigration, blocking antibody 
against PECAM-1 is not able to inhibit leukocyte migration completely, suggesting 
that other players are important for this process. PECAM-1 knockout mice have no 





between the endothelium and the basement membrane (Bogen et al., 1994; Muller et 
al., 1993). CD99 is expressed on the leukocyte surface and at endothelial cell-cell 
adhesions and like PECAM-1, facilitates leukocyte TEM in a homophilic manner. 
Blocking of CD99 on the leukocyte or endothelium inhibits monocyte TEM, and 
blocking both CD99 and PECAM-1 gives an additive effect abolishing TEM almost 
completely (Schenkel et al., 2002). JAMs have been reported to be involved in 
inflammation and to facilitate TEM of leukocytes. JAM-A was shown to bind the 
leukocyte integrin LFA-1 in a heterophilic manner involving the membrane proximal 
domain of JAM-A. JAM-A also mediates homophilic binding between leukocytes 
and endothelial cells (Ostermann et al., 2002). JAM-B has not been demonstrated to 
be involved in TEM. JAM-C is highly expressed on endothelial venules and 
HUVECs. Antibodies against JAM-C block migration of polymorphonuclear 
leukocytes across HUVECs in response to CXCL12 in vitro (Johnson-Leger et al., 
2002). ESAM is JAM-related protein expressed on endothelial cells and on activated 
platelets (Petri and Bixel, 2006). It was shown to mediate migration of neutrophils 
through the vessel wall by influencing endothelial cell contacts. Extravasation is 
reduced in ESAM knockout mice (Wegmann et al., 2006).  
In summary, several endothelial cell surface and adhesion molecules localize at 
endothelial cell contacts. These molecules have been found to participate in 
leukocyte TEM. 
 
1.4.4.4.2 Transcellular TEM 
The paracellular route is not the only mechanism by which leukocytes can cross the 
endothelial barrier. In the early 1960s, morphological studies of leukocyte TEM 
revealed that some leukocytes could extravasate without disrupting endothelial 
junctions. Leukocytes can in fact pass through a membrane pore of an endothelial 
cell and this was observed in vitro and in vivo (Carman and Springer, 2004; 
Phillipson et al., 2008).  
The mechanism of transcellular migration involves subcellular membranous 
structures such as caveolae, fenestrae and vesiculo-vacuolar organelles that promote 
the passage of liquid and macromolecules through the endothelial cells (Wittchen, 
2009). Fenestrae are specialized plasma membrane microdomains where the apical 





frequent in specialized vascular beds that require high permeability such as 
endocrine organs. Tumours can also have a fenestrated endothelium (Roberts and 
Palade, 1997). Caveolar localization is determined by F-actin and caveolin-1 
distribution. ICAM-1 was shown to translocate to F-actin and caveolin-1-rich 
regions where it was transcytosed to the basal plasma membrane via caveolae. T-
lymphocytes were shown to extend pseudopodia into endothelial cells in caveolin 
and F-actin-rich regions, inducing the translocation of ICAM-1 and caveolin-1 the 
endothelial basal membrane, membrane fusion and transcellular passage of the T-
lymphocyte (Millan et al., 2006). 
Lymphocytes use “invasive podosomes” to explore the endothelial surface and form 
transcellular pores in a process mediated by Src kinase and WASP. Treatment of 
lymphocyes with Src inhibitors reduced podosome formation. The inhibition of 
podosomes selectively blockes transcelluar migration (Carman et al., 2007).  
Interstingly, another group showed that Mac-1 (CD11b/CD18) deficient leukocytes, 
which are not able to crawl on the endothelium surface preferentially, use the 























1.5 Aims of the project 
The migration and infiltration of T-ALL cells into tissues is correlated with a poor 
prognosis (Aifantis et al., 2008). Leukaemic cells need to adhere and transmigrate 
from the blood vessels in order to infiltrate and accumulate into tissues. Rap and Rho 
GTPase are masters of T lymphocyte migration, and they are known to contribute to 
cancer progression by regulating cancer cell proliferation and invasion, but their role 
in T-ALL is far from being elucidated.  
1. The first aim of my project was to investigate whether the lack of GTPase 
prenylation caused by the compund statin could affect T-ALL cell adhesion 
and migration. The main objective was to identify which GTPases are 
involved in the adhesion and migration of T-ALL cells. 
2. Several Rho GTPase genes were found to be dysregulated in T-ALL patient 
samples. These genes include the atypical GTPase RhoU. The dysregulation 
of RhoU was found to be correlated with aberrant Notch1 signalling. RhoU 
was identified as a target gene of Notch1. The second aim of my project was 
to characterize the function of RhoU and Notch1 in T-ALL cell adhesion and 
migration. This was achieved by using different Notch1- mutated T-ALL cell 
lines. 
3. The third aim of my project was to further characterize the function of RhoU 
in T-ALL cell transendothelial migration, in parallel with its close relative 
RhoV. Interestingly, RhoV was also found to be upregulated in T-ALL 
patients. Using an overexpression approach, the localization and distribution 
of RhoU and RhoV was also investigated in T-ALL cells. Furthermore the 
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Statins are known to inhibit signaling of Ras superfamily GTPases and reduce T-cell 
adhesion to ICAM-1. Here we address the hypothesis that statins affect T-cell 
adhesion and migration by modulating the function of specific GTPases. Statins 
inhibit the synthesis of mevalonic acid, which is required for farnesyl and 
geranylgeranyl isoprenoid synthesis. Ras superfamily GTPases are post-
translationally isoprenylated to facilitate their anchorage to membranes, where they 
function to stimulate signal transduction processes. We demonstrate that 1 µM statin 
inhibits the adhesion, migration, and chemotaxis of the T-acute lymphoblastic 
leukemia (T-ALL) cell line CCRF-CEM, and transendothelial migration of CCRF-
CEM and PEER T-ALL cells, but higher statin concentrations are needed to inhibit 
adhesion of primary T cells. Similar effects are observed following treatment with a 
geranylgeranyl transferase inhibitor (GGTI-298) or RNAi-mediated knockdown of 
Rap1b but not Rap1a, Rac1, Rac2, RhoA or Cdc42. Statins also alter Rap1 activity 
and Rap1b localization. Rap1 levels are higher in primary T cells than T-ALL cells, 
which could explain their reduced sensitivity to statins. These results demonstrate for 
the first time that the closely related Rap1a and Rap1b isoforms have different 
functions, and suggest that statins or Rap1b depletion could be used to reduce tissue 




















Statins are widely used to lower cholesterol levels in patients, thereby reducing risk 
of cardiovascular disease. In particular in patients with heart failure statins are 
beneficial due to their effects on inflammation, oxidative stress and vascular tone 
(Tang and Francis, 2010; Zeiser et al., 2009). These drugs have been reported to 
have anti-inflammatory properties (Dinarello, 2010; Liao and Laufs, 2005) and their 
possible role in cancer prevention has also attracted attention (Gauthaman et al., 
2009; Kuoppala et al., 2008). 
Statins acts by competitive inhibition of 3-hydroxy-3 methylglutaryl coenzyme A 
(HMG-CoA) reductase, resulting in a decrease in mevalonic acid synthesis. 
Mevalonic acid is an upstream substrate in the formation of cholesterol and also of 
the farnesyl and geranylgeranyl isoprenoids. These isoprenoids are post-
translationally added to a carboxy terminal cysteine of CAAX motifs on proteins 
such as small Ras-superfamily GTPases, and facilitate anchorage of these proteins in 
membranes, where they signal to downstream effectors  (Greenwood et al., 2006). 
By inhibiting synthesis of isoprenoids, statins therefore reduce the localization of 
Ras-superfamily proteins to membranes. A beneficial effect of statins has been 
reported in colorectal and melanoma cancer prevention, and the inhibition of 
Ras/Rho GTPase prenylation, leading to their mislocalization, could contribute to the 
cancer prevention property of statins (Demierre et al., 2005).  
Ras and Rho family GTPases are signal transduction proteins involved in cell 
proliferation, cell survival, cytoskeletal reorganization, membrane trafficking and 
motility. These proteins are normally activated by guanine nucleotide exchange 
factors (GEFs) that promote the switching from an inactive GDP to an active GTP 
state, and inactivated by GTPase activating proteins (GAPs) which enhance the 
intrinsic GTPase activity of the proteins. Some Rho GTPases are also regulated by 
GDP dissociation inhibitors (GDIs) that bind to prenyl groups and thereby inhibit 
membrane localization (Schmidt and Hall, 2002). Statins have been shown to 
increase the level of RhoA-GTP yet inhibit its signaling to downstream targets such 
as ROCKs (Cordle et al., 2005; Rattan, 2010; Wang et al., 2008).  
T-ALL is a hemotological cancer of T lymphocytes (Real and Ferrando, 2009), for 
which poor prognosis has often been shown to correlate with the migration and 





transmigrate from the blood to tissues, leukocytes interact with and adhere to the 
endothelial cells lining the blood vessels. This involves the activation of integrins 
such as LFA-1, which is expressed on the leukocyte surface and binds to endothelial 
cell adhesion molecule ICAM-1 (Liu et al., 2004). Chemokines and cytokines can 
activate the Ras GTPase Rap1 which induces integrin activation through inside-out 
signaling (Wittchen et al., 2005).  
Here we demonstrate that low concentrations of statins inhibit LFA-1 activation on 
T-ALL cells and consequently reduce adhesion to ICAM-1 and transendothelial 
migration of T-ALL cells, but do not affect migration of primary T cells. 
Downregulation of Rap1b but not Rap1a induces similar effects on T-ALL cells, 
implying that the response to statins is primarily due to inhibition of Rap1b-mediated 


























2.3 Materials and Methods 
2.3.1 Cell culture and drug treatment  
CCRF-CEM (ATCC, LGL Promochem, Middlesex, UK), PEER, Jurkat and SUPT1 
(kind gift of Prof. Asim Khwaja) cells were maintained in RPMI-1640 containing 2 
mM glutamine and supplemented with 10% fetal calf serum, 1 mM sodium pyruvate, 
10 mM Hepes, penicillin (100 U/ml) and streptomycin (100 µg/ml). Cells were used 
between passage 1 and 10. T-lymphoblasts were derived from human peripheral 
blood mononuclear cells. Cells were cultured in RPMI-1640 supplemented with 10% 
human AB serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) and 
stimulated with 8 µg/ml phytohaemagglutinin for 48 h. Cells were subsequently 
maintained in medium containing 10 U/ml of interleukin-2 (Roche, Mannheim, 
Germany), and used between passage 4 and 10. Where indicated, T-ALL cells and T-
lymphoblasts were treated for 16 h with 1 µM simvastatin or lovastatin (Calbiochem, 
Nottingham, UK), 250 µM mevalonolactone (mevalonic acid; Sigma-Aldrich, 
Dorset, UK), 10 µM FFI (Enzo, Exeter, UK) or GGTI-298 (Calbiochem). Cell 
viability was determined with 0.4% Trypan blue solution. Human umbilical vein 
endothelial cells (HUVECs) (Biowhittaker, Wokingham, UK) were cultured in flasks 
coated with 10 µg/ml fibronectin (FN; Sigma-Aldrich) in EBM-2 medium 
supplemented with 2% fetal calf serum and endothelial cell growth supplements 
(Lonza Biologics, Slough, UK). Cells were used between passage 1 and 4. 
2.3.2 Transfection  
CCRF-CEM cells (5 x 105) were transfected by nucleofection (Amaxa Biosystems 
Nucleofection System, Lonza Biologics) with 20 µg plasmid DNA (see 4.2.2.6, 
4.2.2.7 and 4.2.2.8) or 1.2 µM siRNA (Dharmacon, Colorado, USA) in 100 µl of 
Nucleofection reagent (kit C, Lonza Biologics). siRNA sequences were Rap1b-1: 
GAACAACUGUGCAUUCUUA; Rap1b-2: CAAUGAUUCUUGUUGGUAA; 
Rap1a-1: CAAUAAAUGUGACCUGGAA; Rap1a-2: 
GCGAGUAGUUGGCAAAGAG; Rac1-1: AGACGGAGCUGUAGGUAAA; Rac1-
2: UAAGGAGAUUGGUGCUGUA; Rac2-1: CAGCCAAUGUGAUGGUGGA; 
Rac2-2: ACAAGGACACCAUCGGAGAA; Cdc42-1: 
GAUUACGACCGCUGAGUUA; Cdc42-2: GAUGACCCCUCUACUAUUG; 





CGACAGCCCUGAUAGUUUA. siControl was from Thermo Fisher Scientific (D-
001810-02-20, Lafayette, USA). Cells were used for experiments 48-72 h after 
siRNA transfection or 24 h after DNA plasmid transfection. pMT2-HA-Rap1b was a 
kind gift of Prof Johannes Bos.  
2.3.3 Adhesion assays 
Ninety-six-well plates were coated overnight with 5 µg/ml ICAM-1 (R&D Systems, 
Abingdon, UK) or 10 µg/ml FN, then blocked in 1% BSA in PBS for 30 min. 
Treated cells were centrifuged at 240 g for 4 min and resuspended in PBS at 106 
cells/ml. Cells were then incubated at 37°C for 15 min with 2 µM Cell Tracker 
CMFDA (Invitrogen, Paisley, UK). Samples were resuspended in warm media and 
105 cells/well (each sample in triplicate) were incubated at 37°C for 30 min. After 
washing with PBS, the plate was read on a Fusion-αFP plate reader (PerkinElmer, 
Cambridge, UK) at 485 nm excitation and 525-535 nm emission. Alternatively, 
images of CMFDA-labeled cells were acquired using Metamorph software (MDS 
Analytical Technologies, Wokingham, UK), on a Nikon Eclipse TE2000 microscope 
with a 4x objective. Cell numbers were determined using Volocity software 
(PerkinElmer, Cambridge, UK). 
2.3.4 Chemotaxis assay and transendothelial migration 
Transwell filters (Costar) were coated with 5 µg/ml ICAM-1. 2x105 T cells were 
added in the top chamber and 600 µl of medium containing 30 ng/ml CXCL12 
(R&D Systems) was added to the bottom chamber. Cells in the lower chamber were 
counted after 1 using a Casy Counter (Roche Innovatis, Bielefeld, Germany). 
HUVECs were grown to confluency on FN-coated 5-µm transwell filters and then 
stimulated with 10 ng/ml TNF-α (R&D Systems, Abingdon, UK) for 16 h. After 
washing, 2x105 T cells were added onto the HUVECs in the top chamber and 600 µl 
of medium containing 30 ng/ml CXCL12 was added to the bottom chamber. Cells in 
the lower chamber were counted after 1h or 2 h using a Casy Counter. 
2.3.5 Timelapse microscopy 
HUVECs were grown to confluency on FN-coated coverslips and stimulated with 
TNF-α for 16 h. Cells were incubated for 8 min with 30 ng/ml CXCL12 then washed 





were added to the HUVECs and time lapse images were acquired every minute for 1 
h using Metamorph software on a Nikon Eclipse TE2000 microscope with a 20x 
objective. Cells were tracked and migration speed (µm/min) determined using 
ImageJ analysis software. 
2.3.6 Flow cytometry 
To measure total surface LFA-1, CCRF-CEM cells (2x105) were incubated for 30 
min at 4°C with 1:100 CD11a antibody (BD Bioscience, Oxford, UK) or 1:50 IgG2a 
as an isotype control (Serotec, Kidlington, UK). To measure surface levels of active 
LFA-1, cells were incubated for 15 min at 37°C with 200 µM MnCl2 (Hogg et al., 
2002), then for 30 min at 37°C with 1:100 mAb24 (kind gift of Prof Nancy Hogg). 
Cells were incubated with Alexa Fluor 488-labelled anti-mouse antibody 
(Invitrogen) then analysed on a Becton Dickinson FACS Calibur machine using the 
FlowJo program. 
2.3.7 Immunofluorescence 
CCRF-CEM cells (5x105) were transfected with 20 µg pMT2-HA-Rap1b (see 
4.2.2.6, 4.2.2.7 and 4.2.2.8). After 24 h, cells were treated with 1 µM simvastatin for 
16 h and cytospun onto coverslips by centrifugation at 300g for 5 min. HUVECs 
(1.5x105) were seeded onto FN-coated coverslips and treated for 16 h with 1 µM 
simvastatin. Samples were fixed with 4% paraformaldehyde, permeabilized with 
0.1% Triton-X100, then incubated for 1 h with 1:200 mouse anti-HA antibody (Santa 
Cruz, California, USA) or 1:200 anti-mouse VE-cadherin  antibody (BD 
Biosciences, Oxford, UK) followed by 1:500 Alexa Fluor 488 anti-mouse antibody  
(Invitrogen). Coverslips were mounted onto slides using anti-fade mounting medium 
(Dako, Ely, UK).  
2.3.8 GTPase activity assays 
GST-RalGDS-RBD, GST-PAK-PBD and GST-Rhotekin-RBD were transformed in 
BL21 E.coli and plated on a LB agar plate containing 100 µg/ml ampicillin. A 
colony was inoculated in 100 ml of LB/ampicillin and grown overnight at 37°C. The 
following day the cultures were diluted 1:20 into fresh medium and grown to an 





expression and the bacteria were incubated for 2 h at 30°C. Bacterial pellets were 
collected by centrifugation for 15 min at 1500 g and the pellets stored at -40°C. 
Bacterial pellets were resuspended in STE buffer (10 mM Tris pH 8.0, 150 mM 
NaCl, 1 mM EDTA) and lysed by the addition of 100 µg/ml lysozyme for 20 min on 
ice. After, 5 mM DTT, 1% Tween-20 and 0.03% SDS were added, the lysates were 
mixed and then centrifuged at 14000 g for 20 min and the supernatant collected. The 
supernatants were then incubated with the glutatione sepharose beads (GE 
Healthcare) at 4°C for 2 h, and the bead-bound proteins washed three times and used 
in the pull-down assays. CCRF-CEM cells (106/pulldown) were lysed in 400 µl of 
pull-down buffer (25 mM Hepes pH7.5, 150 mM NaCl, 1% NP-40, 10 mM MgCl2, 1 
mM EDTA, 25 mM NaF, 1 mM Na3VaO4, 10 µg/ml aprotinin, 100 µM PMSF and 
10% glycerol). 40 µl of the lysate was retained to determine total GTPase levels. The 
remaining lysate was incubated with the protein-bound beads on a rotor for 1 h at 
4°C. The beads were washed 3 times in pull-down buffer, boiled in Laemmli sample 
buffer and used for western blotting.  
2.3.9 Western blot analysis 
Cells were lysed in 1% SDS followed by addition of 1% Triton X-100, 25 mM NaF, 
1 mM Na3VO4 and 10 mg/ml aprotinin, then incubated for 10 min on ice and 
clarified by centrifugation. Cleared lysates were boiled for 5 min in 4X sample 
buffer (0.25 M Tris-HCl pH 6.8, 8% SDS (w/v), 40% glycerol (w/v), 10% β–
mercaptoethanol (w/v), 0.2% Bromophenol blue (w/v)). Lysates were separated on 
4-12% Bis-Tris polyacrylamide gels (Invitrogen) or on a 12.5% poly-acrilamide gel 
then transferred to nitrocellulose membrane (Millipore, Watford, UK). Membranes 
were incubated in blocking buffer (5% non-fat dried milk in TBS containing 0.1% 
Tween-20) for 1 h at room temperature and then incubated for 1 h with 1:1000 
dilutions of the following antibodies diluted in blocking buffer: Rap1b (36E1), 
Rap1a/Rap1b (26B4), RhoA (67B9), or Cdc42 (11A11) (Cell Signaling Technology, 
Massachusetts, USA), Rap1a (C-17) (Santa Cruz), Rac1 (23A8) or Rac2 07-604 
(Millipore). Membranes were then incubated with horseradish-peroxidase-
conjugated anti-mouse, anti-rabbit or anti-goat antibodies (GE Healthcare, Chalfont 
St Giles, UK). Antibodies were visualized using the ECL detection system (GE 






2.4.1 Statins inhibit adhesion and chemotaxis of T-ALL cell lines but not of 
primary T-lymphoblasts 
To investigate the effect of statin treatment on T-ALL cell adhesion, we first 
performed an adhesion assay on ICAM-1. ICAM-1 is expressed on the endothelial 
cell surface and is fundamental in mediating adhesion between the endothelium and 
leukocytes (Vestweber, 2007). We observed a 50% reduction in the binding of 
CCRF-CEM cells to ICAM-1 following treatment with 1 µM simvastatin or 
lovastatin (Figure 2.1A). Addition of 250 µM mevalonic acid rescued the statin-
induced inhibition of adhesion (Figure 2.1A).  This indicates that statins are acting 
by inhibiting HMG-CoA reductase, rather than binding directly to the β2 integrin 
(LFA-1) L-site and thereby inhibiting adhesion to ICAM-1 (Kallen et al., 1999; 
Weitz-Schmidt et al., 2001). We also observed a significant decrease in Jurkat cell 
adhesion to FN that was rescued by mevalonic acid (Figure 2.1B). As T cells bind 
FN mostly through the β1 integrin (Hauzenberger et al., 1994), this effect cannot be 
attributed to statin binding to β2 integrin. The effect of statins on adhesion was not 
due to changes in T-ALL cell viability (Supplementary Figures 2.1A and B).  
Surprisingly, 1 µM simvastatin or lovastatin did not reduce the adhesion of primary 
T-lymphoblasts, but some inhibition was observed at 10 µM statins (Figure 2.1C).  
This was not due to a difference in adhesion to ICAM-1 between primary T-
lymphoblasts and CCRF-CEM cells (supplementary Figure 2.1C).  
Similarly, 1 µM statin treatment did not affect T-lymphoblast chemotaxis towards 
CXCL12 (SDF-1), whereas it inhibited chemotaxis of CCRF-CEM cells (Figures 
2.1D and E).  The reduction in CCRF-CEM cell chemotaxis was also rescued by 
mevalonic acid (Figure 2.1E), while mevalonic acid by itself had no effect on 
chemotaxis (supplementary Figure 2.1D).  Together, these results indicate that 
statins inhibit adhesion and migration of T cells and that T-lymphoblasts are less 














Figure 2.1. Statins inhibit adhesion and chemotaxis of T-ALL cell lines but not 
of primary T-lymphoblasts. CCRF-CEM (A) and Jurkat (B) cells were treated for 
16 h with 1 µM simvastatin or lovastatin alone or in combination with 250 µM 
mevalonate. The cells were then labeled with Cell Tracker CMFDA, added to wells 
coated with ICAM-1 (A) or FN (B) and adhesion determined after 30 min. Primary 
T-lymphoblasts (C) were treated with 1, 5, or 10 µM simvastatin or lovastatin. Cells 
were labeled with Cell Tracker CMFDA and adhesion to ICAM-1-coated wells 
determined after 30 min. (D,E) T-lymphoblasts (D) or CCRF-CEM cells (E) were 
treated for 16 h with 1 µM simvastatin and 250 µM mevalonic acid where indicated. 
Cells were then added to ICAM-1-coated transwells containing 30 ng/ml SDF-1 in 
the lower chamber. Cells in the lower chamber were counted after 1 h. Data shown 
are the mean of 3 independent experiments ± SEM. * p<0.05, **p<0.01; 2-way-





2.4.2 Statins dysregulate Rap1, Rac1 and RhoA activity in CCRF-CEM cells 
Given the effect of statin treatment on CCRF-CEM and Jurkat cell adhesion and the 
known effect of statins in inhibiting protein prenylation, we investigated whether 
they altered the activity of GTPases. In particular, we focused on Rap1, Rac1 and 
RhoA as these GTPases have been implicated in integrin-mediated adhesion (Hattori 
and Minato, 2003; Takaishi et al., 1997; Vielkind et al., 2005). 
Incubation of CCRF-CEM cells for 16 h with simvastatin increased the level of 
GTP-bound Rap1 (Figure 2.2A and B). This was prevented by co-treatment with 
mevalonic acid (Figure 2.2A). Statin treatment induced a shift in the mobility of 
Rap1 on SDS-PAGE, reflecting the reduced prenylation (Supplementary Figure 
2.2A). Statins have been reported to increase levels of RhoA-GTP and Rac1-GTP in 
THP-1 cells (Cordle et al., 2005), and we also observed an increase in active Rac1 
and RhoA in CCRF-CEM cells (Figure 2.2A, B and C). This increase in GTP-
loading could be due to mislocalization of unprenylated proteins, for example 
leading to reduced interaction with GAPs. This hypothesis is supported by the 
observation that treatment with the geranylgeranyl transferase inhibitor (GGTI) 
GGTI-298, which prevents prenylation of Rap1, Rac1 and RhoA (Roberts et al., 
2008; Wennerberg et al., 2005), also resulted in higher levels of GTP-bound Rap1, 
Rac1 and RhoA (Figure 2.2E-H). Rap1, Rac1 and RhoA are post-translationally 
geranylgeranylated at the C-terminus, whereas some other Rho and Ras family 
proteins are farnesylated (Roberts et al., 2008; Wennerberg et al., 2005). Consistent 
with this, no changes in GTP-loading of Rap1 was observed following incubation 
















Figure 2.2. Statins and GGTI increase Rap1, Rac1 and RhoA activity in CCRF-
CEM cells. CCRF-CEM cells were treated for 16 h with 1 µM lovastatin or 
simvastatin alone or in combination with 250 µM mevalonic acid (A-D), or with 10 
µM GGI-298 (E-H) or FFI (I). Cell lysates was incubated with GST-RalGDS 
(Rap1), GST-PAK-PBD (Rac1) or GST-Rhotekin-RBD (RhoA) beads then analysed 





(B, F, I), Rac1 (C and G) and RhoA (D and H) were quantified using ImageJ. Data 
shown are the mean of 3 independent experiments ± SEM. *p<0.05, **p<0.01; 2-
way-paired t-test. Experiments performed by Elvira Infante. 
 
 
2.4.3 Low concentrations of statins do not dysregulate Rap1 activity in primary 
T-lymphoblasts 
As we had observed that statins at 1 µM did not affect the adhesion or chemotaxis of 
primary T-lymphoblasts (Figure 2.1C, D), we next investigated the effect of statins 
on Rap1 activity in these cells. Treatment of T-lymphoblasts with 1 µM simvastatin 
did not affect Rap1 activity (Figure 2.3A). However, 10 µM simvastatin did increase 
Rap1 activity significantly in T-lymphoblasts, and induced a further increase in Rap1 
activity in CCRF-CEM cells above that induced by 1 µM simvastatin (Figure 2.3B-
D).   This analysis also showed that the total level of Rap1 was much lower in 
CCRF-CEM cells than in T-lymphoblasts. Similarly, Rap1 levels were lower in a 
panel of T-ALL cell lines compared to primary T-lymphoblasts (Figure 2.3E).  These 
results suggest that the higher expression level of Rap1 protein in T-lymphoblasts 




















Figure 2.3. Primary T-lymphoblasts are less sensitive to statins and have higher 
Rap1 levels than T-ALL cells . Primary T-lymphoblasts (A-C) and CCRF-CEM 
cells (B, C) were treated for 16 h with the indicated concentrations of simvastatin. 
Cell lysates were incubated with GST-RalGDS beads then analysed by western 
blotting with Rap1 antibody. Relative levels of active Rap1 were quantified using 
ImageJ (A, C, D). (E)Total Rap1 expression in primary-T-lymphoblasts and T-ALL 
cell lines CCRF-CEM, Jurkat, SUPT-1 and PEER was analyzed by western blotting 
and relative levels quantified using ImageJ. Data shown are the mean of 3 
independent experiments ± SEM. * p<0.05, **p<0.01; 2-way-paired t-test. 














2.4.4 Rap1b is required for T-ALL cell adhesion and migration  
To investigate the importance of prenylation for adhesion, we treated CCRF-CEM 
cells with 10 µM GGTI-298 or FFI. There was a significant reduction of adhesion to 
ICAM-1 when cells are treated with GGTI-298 compared to untreated or FFI-treated 
samples (Figures 2.4A and B). To determine whether GTPases implicated in 
integrin-mediated adhesion affected T-ALL cell adhesion to ICAM-1, we used 
siRNA to knockdown the expression of the two Rap1 isoforms (Rap1a and Rap1b) 
(Figure 2.4C), RhoA, Rac1, Rac2 and Cdc42 in CCRF-CEM cells (Figure 2.4H). 
Rap1b but not Rap1a depletion strongly reduced adhesion to ICAM-1 (Figures 2.4D 
and E). Interestingly, knockdown of Rap1a led to reduced adhesion to FN suggesting 
that this isoform is involved in β1 but not ß2/LFA-1 activation (Figure 2.4F). 
Knockdown of Rac1, Rac2, Cdc42 and RhoA did not affect adhesion (Figure 2.4G). 
Interestingly, Rap1a and Rap1b levels were higher in T-lymphoblasts than in CCRF-
CEM and Jurkat cells (Supplementary Figure 2.1C), indicating that both Rap1a and 
Rap1b contribute to the increase in total Rap1 observed (Figure 2.3E). 
As statins can affect the localization of GTPases through inhibiting prenylation, we 
examined the effect of simvastatin on Rap1b localization in CCRF-CEM cells. Rap1 
has previously been shown to be activated by the chemokine CXCL12 (Wittchen et 
al., 2005). Simvastatin treatment altered the localization of Rap1b and induced its 
accumulation on multiple punctate structures in the cytoplasm in CXCL12-
stimulated cells (Figure 2.4I). These might be endosomes, similar to the localization 
of Rap1a prior to translocation and activation at the plasma membrane (Bivona et al., 





















Figure 2.4. Rap1b depletion leads to reduced adhesion of CCRF-CEM clls. 
CCRF-CEM cells were treated for 16 h with 10 µM GGI-298 (A) or FFI (B). Cells 
were then labeled with Cell Tracker CMFDA, plated on ICAM-1 and adhesion 
measured after 30 min. CCRF-CEM cells were transfected with siRNAs targeting 
Rap1b, Rap1a (C-F), Rac1, Rac2, Cdc42 or RhoA (G, H). (C, H) Levels of each 
protein were analysed by western blotting. GAPDH was used as a loading control. 
Blots shown are representative of 3 independent experiments. (D-G) Adhesion 
assays were performed on ICAM-1 or fibronectin as indicated. *p<0.05, **p<0.01; 
2-way-paired t-test. (I) CCRF-CEM cells were transfected with a plasmid encoding 
pMT2-HA-Rap1b. After 24 h, cells were treated for 16 h with 1 µM simvastatin then 
incubated with 1 ng/ml CXCL12 for 30 min. Subsequently, samples were cytospun 
for 5 min at 300g onto coverslips. After fixation and permeabilization, samples were 
stained with an anti-HA antibody and with DAPI to stain nuclei and imaged by 





2.4.5 Statins and Rap1b regulate integrin activity  
We next investigated if statins, GGTI or Rap1b depletion affected adhesion by 
inducing changes in the surface expression and/or activation of integrins. LFA-1 is 
normally expressed on the leukocyte surface in an inactive form but it can be 
activated by addition of Mn2+ (Hogg et al., 2002). No significant changes were 
observed in the cell surface expression of LFA-1 subunit CD11a (αL) following 
statin or GGTI treatment (Figure 2.5A) or knockdown of Rap1a or Rap1b (Figure 
2.5B). To investigate LFA-1 activation, we used the mAb24 antibody which 
recognizes the active form of LFA-1 (Dransfield and Hogg, 1989; Lu et al., 2001). 
Both statins and GGTI-298 but not FFI inhibited LFA-1 activation (Figures 2.5C and 
D). Similarly, knockdown of Rap1b but not Rap1a reduced LFA-1 activation (Figure 
2.5E). These results indicate that the statin-induced inhibition of adhesion to ICAM-
1 is due at least in part to reduced Rap1b prenylation and hence, decreased activation 













Figure 2.5. Statins, GGTI and Rap1b regulate LFA-1 integrin activity. CCRF-
CEM cells were treated for 16 h with 1 µM simvastatin (A and C) or 10 µM GGTI-
298 (A and D), or transfected with siRNAs targeting Rap1b or Rap1a (B and E). 
Cells were then stained for αL integrin (CD11a) (A and B), or were incubated for 15 
min with 200 µM MnCl2 (Mn2+) then stained for active LFA-1 with mab24 (C-E). 
Cells were analysed by flow cytometry. Data show the mean of 3 experiments ± 













2.4.6 Statin treatment and Rap1b downregulation inhibits transendothelial 
migration of T-ALL cells  
Transendothelial migration (TEM) of leukocytes is a crucial step during 
inflammation and immune responses, and requires LFA-1 adhesion to endothelial 
ICAM-1 (Newton et al., 2009).  We found that statin treatment significantly 
decreased the TEM of CCRF-CEM and PEER T-ALL cells, but not primary T-
lymphoblasts (Figure 2.6A). Consistent with a specific involvement of Rap1b in 
LFA-1 activation, Rap1b but not Rap1a depletion reduced TEM of CCRF-CEM cells 
(Figures 2.6B and C). Treatment of endothelial cells for 16 h with1 µM simvastatin 
did not disrupt endothelial cell-cell junctions or the endothelial monolayer 
(Supplementary Figure 2.2E), indicating that at this concentration statins are unlikely 
to alter endothelial integrity. 
Time-lapse movies were performed in order to visualize the effect of statins on T-
ALL cell morphology and migration on endothelial cells. Most control CCRF-CEM 
cells had a polarized migratory morphology, with a lamellipodium at the front and 
uropod at the back (Sanchez-Madrid and Serrador, 2009), and migrated across the 
endothelial monolayer (Figure 2.6D, top panels). Cells treated with 1 µM simvastatin 
had a more rounded phenotype and were not polarized (Figure 2.6D, middle panels). 
Some statin-treated cells transiently extended protrusions in different directions but 
without forming a stable lamellipodium or uropod (Figures 2.6D and E). These 
effects were reversed by co-incubation with mevalonic acid (Figure 2.6D, lower 
panels). Tracking of statin-treated cells showed that they had a reduced migration 
speed on the endothelial surface compared to controls (Figure 2.6F). These data 
indicate that statins reduce TEM both by reducing adhesion of T-ALL cells to 
















Figure 2.6. Statin treatment and Rap1b downregulation reduce transendothelial 
migration of T-ALL cells. Primary T-lymphoblasts, CCRF-CEM cells and PEER 
cells were treated for 16 h with 1 µM simvastatin (A) or transfected with siRNAs 
targeting Rap1a or Rap1b (B and C) then added to confluent HUVECs on transwell 
filters. After 1 h (primary-T-lymphoblasts) or 2 h (CCRF-CEM and PEER), cells that 
had transmigrated through the HUVECs towards SDF-1 in the lower chamber were 





**p<0.01; 2-way-paired t-test.  (D) CCRF-CEM cells treated with 1 µM simvastatin 
with or without 250 µM mevalonic acid for 16 h were added to HUVECs and 
imaged by timelapse microscopy. Images show cells at 0, 10, 20 and 30 min; 
asterisks (top panels) indicate examples of CCRF-CEM cells undergoing 
transendothelial migration. Bar, 50 µm. (E) Zoom of a representative cell treated 
with 1 µM simvastatin (boxed region in D), showing extension of protrusions in 
different directions. (F) Relative velocity of CCRF-CEM cells on HUVECs, 
compared to control. Data are from 3 independent experiments ± SEM. *p<0.05; 2-

































A critical step in T-ALL progression is the accumulation of leukaemic cells in the 
tissues, which requires adhesion to and transmigration through the endothelium.  
Here we demonstrate that both statins and a geranylgeranyl transferase inhibitor 
reduce of T-ALL cell adhesion, LFA-1 integrin activation, migration and TEM, 
indicating that the effects of statins are due to reduced protein prenylation rather than 
cholesterol depletion.  Our results suggest these responses are predominantly due to 
inhibition of Rap1b, since depletion of Rap1b but not its closely related isoform 
Rap1a has similar effects to statins on T-ALL cell adhesion and migration.  
The relative contributions of the two Rap1 isoforms, Rap1a and Rap1b, to integrin 
activation have not been investigated previously. Studies with Rap1a- and Rap1b-
null mice indicate that each isoform affects integrin-mediated leukocyte adhesion, 
although the two isoforms have not been compared directly. For example, primary 
hematopoietic cells isolated from Rap1a-null mice have reduced adhesion to FN but 
just a slight decrease of adhesion to ICAM-1 (Duchniewicz et al., 2006), while B 
cells from Rap1b-null mice have reduced ICAM-1 adhesion and chemotaxis (Chu et 
al., 2008).  
Rap1 stimulates integrin activation through its target Riam, which in turn regulates 
talin interaction with integrins (Banno and Ginsberg, 2008; Frische and Zwartkruis, 
2010). In addition, in T cells the Rap1 target RAPL interacts with and regulates the 
spatial distribution of LFA-1 (Katagiri et al., 2003; Mor et al., 2007). Rap1a and 
Rap1b differ by only 8 amino acids, most of which are close to the C-terminus (Lee 
et al., 2009; Raaijmakers and Bos, 2009). Our results indicate that Rap1b is 
specifically required for T-ALL cell adhesion to ICAM-1 whereas both isoforms 
contribute to adhesion to FN. This suggests that the interacting partners and/or 
localization of Rap1a and Rap1b could be different.  
It is interesting that Rac1, Rac2 and RhoA were not required for T-ALL adhesion to 
ICAM-1, since there is evidence that they and/or specific RhoGEFs regulate ICAM-
1 adhesion in response to chemokines or B/T cell receptor engagement (Tybulewicz 
and Henderson, 2009). The signal transduction pathways leading from Rac and Rho 
to integrin activation are not clear, in contrast to the well-characterized mechanisms 
linking Rap1 to integrins.  It is thus possible that Rho GTPase involvement in 





depletion of Rac and Rho proteins clearly affects T-cell behavior: we have recently 
shown that RhoA and Rac2 are required in CCRF-CEM cells for transendothelial 
migration, and that RhoA depletion dramatically alters T-cell morphology and 
reduces migration on endothelial cells (Heasman et al., 2010). 
The increase in GTP-bound Rap1 and Rho GTPases in statin- and GGTI-treated cells 
is presumably due to altered localization of the unprenylated proteins. Since GTP 
levels are higher than GDP levels in cells, we predict that GTPase proteins are 
initially loaded with GTP when they are synthesized. If GTPases are unable to be 
prenylated and hence are mislocalized then it is unlikely they will encounter GAPs 
and thus they will remain GTP-loaded (Spilker and Kreutz, 2010).  However, they 
also will not interact efficiently with their downstream targets when unprenylated 
and thus their downstream signaling will be inhibited, despite being GTP-loaded 
(Satoh et al., 2001; Wang et al., 2008). 
Simvastatin and lovastatin are often used at 10 µM or higher concentrations in 
experiments in vitro (Schiefelbein et al., 2008; Zhang et al., 2008), although they can 
increase RhoA-GTP levels at 1 µM (Cordle et al., 2005). Plasma levels of lovastatin 
were reported to be between 200-250 nM, 6 h after administration of 160 or 200 mg 
of lovastatin to human acute myeloid leukaemia (AML) patients (Lewis et al., 2005). 
Thus statin levels of 1 µM could be present at earlier timepoints, but 10 µM is likely 
to be much higher than most leukaemia cells in the blood would be exposed to for 
any significant time in vivo. Statins at 10 µM have been reported to reduce AML cell 
viability in vitro (Sassano et al., 2007), but in our experiments 1 µM statin did not 
affect the viability of primary T-lymphoblasts or T-ALL cells. Furthermore, 1 µM 
statin did not affect T-lymphoblast adhesion to ICAM-1 or migration but did inhibit 
T-ALL responses, suggesting that it may be possible to inhibit T-ALL recruitment to 
tissues selectively without affecting primary T cells.  Interestingly, we found that the 
active form of Rap1 and the levels of Rap1a and Rap1b protein are higher in primary 
T-lymphoblasts than CCRF-CEM and Jurkat cells, and that Rap1 was only activated 
by 10 µM statin but not 1 µM statin in T-lymphoblasts. This might explain why 
statins are less effective at inhibiting primary T-lymphoblast adhesion to ICAM-1. 
In conclusion, our data indicate that Rap1b is the main Rap1 isoform required for 
adhesion to ICAM-1, chemotaxis and TEM of T-ALL cell lines. Our results suggest 
that statins, GGTIs or other inhibitors of Rap1b signalling could be potential 





2.6 Supplementary materials  
 
Supplementary Figure 1.1. CCRF-CEM cells (A) or primary-T-lymphobasts (B) 
were treated for 16 h with the indicated concentrations of simvastatin or lovastatin. 
Cell viability was determined with Trypan blue. (C) CCRF-CEM cells and primary 
T-lymphoblasts were labeled with Cell Tracker CMFDA and added to ICAM-1-
coated wells for 30 min. Adherent cells were counted from images acquired by 
epifluorescence microscopy. Bars, 100 µm. (D) CCRF-CEM cells were treated with 
250 µM mevalonic acid for 16 h. Cells were then added to ICAM-1-coated 
transwells containing 30 ng/ml SDF-1 in the lower chamber. Cells in the lower 





























Supplementary Figure 1.2. (A) CCRF-CEM cells were treated for 16 h with 1 µM 
simvastatin. Cell lysates were separated on a 12.5% polyacrylamide gel and analysed 
by western blotting using Rap1 antibody. (B) CCRF-CEM cells were transfected 
with the indicated siRNAs.  After 72 h, cell lysates were prepared and western 
blotted with antibodies to Rap1a, Rap1b or total Rap1 (lower panel: antibody 
recognizes Rap1a and Rap1b). (C) Rap1a and Rap1b expression in T-lymphoblasts, 
CCRF-CEM and Jurkat cell lysates was analysed by western blotting. GAPDH was 
used as a loading control. Blots shown are representative of 3 independent 
experiments. (D) HUVECs were treated for 16 h with 1 µM simvastatin. Cells were 
stained with anti-VE-cadherin antibody and DAPI to stain nuclei and analysed by 
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NOTCH1 is frequently mutated in T-cell acute lymphoblastic leukaemia (T-ALL), 
and can stimulate T-ALL cell survival and proliferation.  Here we explore the 
hypothesis that Notch1 also alters T-ALL cell migration.  Rho GTPases are well-
known to regulate cell adhesion and migration. We have analysed the expression 
levels of Rho GTPases in primary T-ALL samples compared to normal T cells by 
quantitative PCR. We found that 5 of the 20 human Rho genes are highly and 
consistently upregulated in T-ALL, and 3 further Rho genes are expressed in T-ALL 
but not detectably in normal T cells. Of these, RHOU expression is highly correlated 
with the expression of the Notch1 target DELTEX-1. Inhibition of Notch1 signalling 
with a γ-secretase inhibitor (GSI) or Notch1 RNAi reduces RhoU expression in T-
ALL cells, whereas constitutively active Notch1 increased RhoU expression. In 
addition, Notch1 or RhoU depletion, or GSI treatment, inhibits T-ALL cell adhesion, 
migration and chemotaxis. These results indicate that NOTCH1 mutation stimulates 
T-ALL cell migration through RhoU upregulation which could contribute to the 























T-cell acute lymphoblastic leukaemia (T-ALL) is a common cancer in children. T-
ALL patients usually present with large numbers of leukaemic blasts with an 
immature T-cell phenotype in the bone marrow and peripheral blood. Although 
current ALL treatment protocols have success rate of around 70 to 80% five-year 
event-free survival in children, T-ALL is associated with a poorer prognosis than B-
ALL (Pieters and Carroll, 2010). Leukaemic blasts can infiltrate numerous tissues, 
with the central nervous system (CNS) being a frequent site of metastasis (Aifantis et 
al., 2008; Crazzolara et al., 2001). CNS relapse in T-ALL requires more aggressive 
treatment regimens that can lead to secondary malignancies or neurocognitive 
disorders(Bhojwani et al., 2009). A better understanding of the genes involved in the 
pathogenesis of T-ALL could allow the development of T-ALL therapies that have 
fewer negative effects on long-term patient health. 
Among the genetic alterations that are associated with the development of T-ALL, 
mutation of the NOTCH1 oncogene is one of the most common, being present in 
over 50% of cases (van Grotel et al., 2008; Weng et al., 2004). Notch1 is required for 
T lineage commitment and regulates T cell maturation in the thymus (Hayday and 
Pennington, 2007; Vicente et al., 2010). Notch1 recognises ligands of the Delta and 
Serrate/Jagged families expressed in the thymic stroma. Ligand binding induces two 
sequential proteolytic cleavage events. The first cleaves a large portion of the 
ectodomain, exposing a site recognised by the intramembrane γ-secretase proteolytic 
complex (GS). Cleavage by GS releases the Notch1 intracellular domain (NICD), 
which enters the nucleus where it associates with the DNA-binding protein CSL 
(CBF1/Su(H)/Lag1) and other proteins to regulate transcription of a wide range of 
genes, including DELTEX-1 and HES1 (Aster et al., 2011). NOTCH1 mutations 
found in T-ALL commonly lead to constitutive Notch1 signalling via ligand-
independent NICD production, or enhanced NICD half-life (Ferrando, 2009). 
Constitutive Notch1 signalling promotes leukaemic cell survival and proliferation. 
Notch1 also regulates expression of the chemokine receptor CCR7, which 
contributes to CNS metastasis in T-ALL (Buonamici et al., 2009), but whether 






Rho family GTPases control haematopoietic cell morphology, migration and 
adhesion as well as cell proliferation and differentiation (Tybulewicz and Henderson, 
2009; Van Hennik and Hordijk, 2005). Most Rho GTPases are active when bound to 
GTP, and inactivated when the bound GTP is hydrolysed to GDP. Signalling through 
Rho GTPases is therefore controlled by regulatory proteins that modulate GTP 
binding and hydrolysis, including guanine nucleotide exchange factors (GEFs) and 
GTPase-activating proteins (GAPs). Twenty Rho family members have been 
identified in humans, several of which have atypical properties (Boureux et al., 
2007). Rnd1, Rnd2, Rnd3 and RhoH have amino acid substitutions that prevent 
GTPase catalytic activity, and therefore only exist in a GTP-bound state. RhoBTB1 
and RhoBTB2 are much larger than other Rho GTPases, and appear not to bind or 
hydrolyse GTP (Aspenstrom et al., 2007; Chang et al., 2006).  RhoU and RhoV are 
also considered atypical because they have high intrinsic GDP/GTP exchange rates 
and therefore are likely to be predominantly in the GTP-bound state (Aspenstrom et 
al., 2007). Rho proteins act through their downstream effectors to regulate 
cytoskeletal and adhesion dynamics, and thereby contribute to cell migration. 
Altered expression of Rho genes or activation of Rho proteins has been reported in a 
variety of cancer types, and the RhoH gene is mutated in some lymphomas 
(Ellenbroek and Collard, 2007; Vega and Ridley, 2008). Rho proteins contribute to 
the enhanced migration and invasion of cancer cells (Parri and Chiarugi, 2010; 
Symons and Segall, 2009; Vega and Ridley, 2008). 
In this study, we have investigated the hypothesis that the pathogenesis of T-ALL 
involves the altered expression of Rho family genes. We have investigated the 
mRNA expression of human Rho genes in primary T-ALL leukaemic blast samples 
and compared it to the expression in normal peripheral blood T cells. We have found 
that several Rho genes have significantly increased expression in T-ALL, and in 










3.3 Materials & Methods 
3.3.1 T-ALL patient samples and normal T-lymphocyte isolation 
The primary childhood leukaemia samples used in this study were provided by the 
Leukaemia and Lymphoma Research Childhood Leukaemia Cell Bank (UK), in 
accordance with the requirements of the Childhood Cancer and Leukaemia Group 
(CCLG) and the Cell Bank Steering Committee. Frozen samples (mononuclear bone 
marrow cells or peripheral blood) obtained from 30 T-ALL patients at diagnosis 
were used. T-ALL samples are generally accepted to be more than 90% leukaemic 
blasts.  T-lymphocytes were isolated from buffy coats of 5 healthy blood donors. 
Mononuclear cells were separated by density gradient according to the 
manufacturer’s protocol (Lymphoprep, Axis-Shield). Cells were then treated with 
0.5% phytohaemagglutinin (Sigma-Aldrich, Dorset, UK) in RPMI medium 
(Invitrogen, Paisley, UK) containing 10% foetal calf serum for 48 h, followed by 
culture for 10 days in 10 U/ml human IL-2 (Roche Diagnostics, Burgess Hill, UK). 
The T-lymphocyte populations obtained were >90% pure, defined by CD4+ or 
CD8+ single positive populations measured by flow cytometry with anti-CD4 and 
anti-CD8 antibodies (BD Bioscences, Oxford, UK). 
 
 
3.3.2 Cell culture and GSI treatment 
CCRF-CEM cells were purchased from ATCC (LGL Promochem, Middlesex, UK). 
PEER, SUPT1, MOLT16 and LOUCY T-ALL cell lines (see Figure 1.5) were from 
the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany). Cell lines were cultured in Dulbeco’s RPMI containing 2 mM glutamine 
and supplemented with 10% fetal calf serum, 1 mM sodium pyruvate, 10 mM Hepes, 
penicillin (100 U/ml) and streptomycin (100 µg/ml). COS7 cells were grown in 
DMEM containing 10% fetal calf serum, penicillin (100 U/ml) and streptomycin 
(100 µg/ml). GSI (Compound E, Calbiochem, Nottingham, UK) was solubilised in 
dimethylsulphoxide (DMSO). Cell lines were resuspended in medium containing 
100 nM GSI or an equal volume of DMSO and cultured for the indicated times. For 
7 day treatments, cells were re-treated at a lower cell density in fresh GSI-containing 





3.3.3 Transfection  
CCRF-CEM cells (5 x 105) were transfected by nucleofection (Amaxa Biosystems 
Nucleofection System) with 1.2 µM siRNA (Sigma-Aldrich) in 100 µl of 
Nucleofection reagent (kit C, Lonza Biologics, Slough, UK). siRNA sequences were 
RhoU-1: CAGAGAAGAUGUCAAAGUC; RhoU-2: 
AAGCAGGACUCCAGAUAAAUU; Notch1-1: GAACGGGGCUAACAAAGAU; 
Notch1-2: GCAAGGACCACUUCAGCGA. siControl was from Thermo Fisher 
Scientific (D-001810-02-20, Lafayette, USA). Cells were used for experiments 48 to 
72 h after siRNA transfection. 
pcDNA3 encoding HIS-tagged Notch1 intracellular domain (NICD) or vector alone 
(see 4.2.2.6, 4.2.2.7 and 4.2.2.8) was transfected into COS7 cells by electroporation. 
Cells were detached from the plate and washed twice in electroporation buffer (10 
mM KCl, 10 mM K2PO4/KHPO4 pH 7.6, 25 mM Hepes pH 7.6, 2 mM MgCl2, 0.5% 
Ficoll 400). After resuspending in 250 µl  of electroporation buffer cells were mixed 
with 5 µg DNA in a 0.4 cm electroporation cuvette and left on ice for 10 min. 
Samples were then electroporated at 250 V, 975 µF and left again on ice for 5 min 
and at room temperature for other 5 min. Cells were finally plated in 10 cm dish and 
incubated for 24 h at 37°C.  After 48 h, cells were solubilised in protein sample 
buffer, and protein expression was analysed by immunoblotting.  
 
 
3.3.4 Sample preparation and real-time SYBR-Green PCR 
RNA from T-ALL samples and control T-lymphocytes was extracted by the Trizol 
method (Invitrogen), and treated with DNase (RNase-free, Ambion) to remove 
genomic DNA. RNA concentration was determined, and purity was checked by 
measuring the A260/A280 ratio. cDNA was prepared from identical amounts of 
RNA template with Superscript VILO cDNA synthesis kit (Invitrogen).  
Relative mRNA expression of Rho genes was determined by real-time polymerase 
chain reaction (RT-PCR) assays, using SYBR-Green detection chemistry (PCR 
mastermix from Primer Design, Southampton, UK) and the ABI Prism 7000 
Sequence Detection System (Applied Biosystems). Primers used for each gene are 





across different exons or across exon-exon boundaries to avoid detection of genomic 
sequences. Each gene assay was validated for amplification efficiency between 90 
and 110% by serial template dilutions, and for specificity by melting curve analysis 
and agarose gel electrophoresis. The expression analysis for each gene was carried 
out in a 96 well format, comparing all 5 control samples to batches of 6 or 7 T-ALL 
samples, and for each sample assaying a Rho gene in parallel with GAPDH as a 
reference. CT values of controls could therefore be used to correct for plate-to-plate 
variations (see 4.2.2.10, 4.2.2.11 and 4.2.2.12). 
 
 
3.3.5 Statistical analyses 
For T-ALL-associated expression changes, mean CT values for each sample were 
first normalised to GAPDH CT values (expressed as dCT). Differential gene 
expression between control and T-ALL samples was determined by the Mann-
Whitney U test for medians of dCT values. For clustering analyses, the comparative 
CT method (Schmittgen and Livak, 2008) (using the average CT of the controls) was 
used to determine relative fold expression changes for Rho genes in each T-ALL 
sample. Cluster analysis software (Cluster 3.0) (de Hoon et al., 2004) and Java 
Treeview (Saldanha, 2004) were used to generate a heat-map of the fold changes as 
well as carry out unsupervised hierarchical clustering of genes and T-ALL samples. 
Complete linkage clustering algorithm was applied, using Pearson correlation as the 
similarity metric. Characteristics of grouped or clustered T-ALL patients were 
compared by Mann-Whitney U test for medians or the Fisher’s Exact test for 
associations, in two-tailed tests and considered significant if P < 0.05. Statistical tests 




Cells were lysed directly in 4X sample buffer (see 2.3.9) and immediately heated to 
at least 90°C for 10 min. Proteins were resolved by polyacrylamide gel 
electrophoresis, transferred to PVDF membrane, and detected by immunoblotting. 





Cell Signaling, Hitchin, UK), RhoU (Wrch1 ab80315, Abcam, Cambridge, UK), ß-




Glass coverslips were coated with 10 µg/ml fibronectin at 4°C overnight and blocked 
in 2.5% BSA in phosphate-buffered saline (PBS) for 1 h. 2x105 cells were added to 
each coverslip and incubated at 37°C with 1ng/ml of CXCL12 (R&D Systems, 
Abingdon, UK) for 30 min. Subsequently, samples were fixed with 4% 
paraformaldehyde and permeabilized in 0.1% Triton-X-100. Following 2 washes in 
PBS cells were incubated with Alexa Fluor 546 phalloidin (A22283, Invitrogen) and 
FITC-labeled anti-α-­‐tubulin antibody (Sigma) for 1 h. Coverslips were mounted onto 
glass slides using Dako (Ely, UK) anti-­‐fade mounting medium. Images were 
acquired using a Zeiss LSM500 confocal microscope (Zeiss). F-actin content was 
measured using ImageJ software. Each experimental condition was done with 
triplicate coverslips, counting 100 cells on each. Data was pooled from three 
independent experiments.  Polarized cells were defined as having F-actin localized to 
one side of the cell, defined as the leading edge, and the microtubule organizing 
center (MTOC) localized at the other side of the nucleus with respect to the leading 
edge.  Elongated tails on cells were defined as a narrow protrusion at the opposite 
side to the leading edge, at least the length of the cell body. 
 
 
3.3.8 Time-lapse microscopy 
The siRNA-transfected or DMSO/GSI-treated CCRF-CEM cells were counted 
(Innovatis CASY cell counter, Roche Applied Bioscience, Burgess Hill, UK), and 
2×105 were added to each well of a fibronectin-coated 8-well culture slides (BD 
Falcon, Oxford, UK). After 30 min, wells were washed three times with complete 
culture medium to remove loosely attached and non-viable cells, and then stimulated 
with 1 ng/ml of CXCL12. Bright field phase-contrast images were collected every 





device camera (ORCA, Hamamatsu Photonics, Welwyn Garden City, UK) using 
Metamorph software (Cairn Research, Faversham, UK). Cells were tracked, and 
velocities and distance migrated calculated using ImageJ. 
 
 
3.3.9 Adhesion assay 
The 96-well plates were coated overnight at 4°C with 10 µg/ml fibronectin. Cells 
were resuspended in PBS at 106 cells per ml and incubated at 37 °C for 15 min 
with 2 µM CellTracker Green CMFDA (Invitrogen). Cells were then resuspended in 
warm media and 105 cells per well (each sample in triplicate) were incubated at 
37°C for 30 min. After washes with PBS, the plate was read on a Fusion-αFP plate 




3.3.10 Flow cytometry 
T-ALL cells (2 × 105) were centrifuged and washed with PBS. Cells were fixed at 
room temperature for 10 min with 4% paraformaldehyde and permeabilized with 
0.1% Triton X-100. Samples were then incubated with 0.2 µg/ml Alexa 488-
labelled phalloidin and analysed on a Becton Dickinson FACS Calibur machine 
















3.4.1 Atypical Rho genes are upregulated in T-ALL  
To study Rho GTPase involvement in the pathogenesis of T-ALL we investigated 
Rho gene expression in 30 primary T-ALL blast samples compared to mature T cells 
from 5 healthy blood donors. Expression of each Rho gene mRNA was determined 
by quantitative PCR, using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
a reference gene (Suppl Fig. 3.1). Rho mRNA expression for each T-ALL sample 
was quantified relative to the mean of the control samples (Fig. 3.1A, Table 1). To 
determine which of the genes were differentially expressed to a statistically 
significant degree, a Mann-Whitney test was applied (Table 1), considering the 
median to be the best representation of the data, which in many cases were skewed 
and not normally distributed (Fig. 3.1A). Five Rho genes were significantly 
upregulated in the T-ALL samples: RHOH, RHOBTB1, RHOA, RHOB and RHOU. 
RHOA and RHOH were very consistently increased in nearly all the T-ALL samples 
although the median fold upregulation was quite small. The magnitude of 
RHOBTB1, RHOB and RHOU upregulation was much higher, but with more 
variation across the T-ALL samples (Fig. 3.1A, Table 1). Three genes were not 
detectable in normal T cell samples but were detected in more than 30% of T-ALL 
samples: RHOV, RND2 and RND3. We therefore could not determine the fold 
expression differences relative to normal T cells for these genes, however the 
variation in expression with T-ALL samples was analysed (Fig. 3.1B). RHOD was 
not expressed in normal T-cell or T-ALL samples, and preliminary analysis indicated 
that RHOJ is also not expressed (data not shown), in agreement with our published 
data on normal T cells and the CCRF-CEM T-ALL cell line (Heasman et al., 2010). 
Interestingly, 5 of the 8 differentially expressed Rho genes (RHOBTB1, RHOU, 
RHOV, RND2 and RND3) belonged to the atypical sub-class (Aspenstrom et al., 
































Figure 3.1 Rho mRNA expression in T-ALL. (A) RNA was extracted from 30 T-
ALL blast samples and normal T lymphocytes from 5 peripheral blood samples of 
healthy donors. mRNA expression of each Rho gene was measured by quantitative 
PCR, using GAPDH expression as a reference. Rho gene expression in each T-ALL 
sample was determined relative to the mean expression of the normal control 
samples using the comparative Ct method. Data are expressed as fold expression 
relative to control on a logarithmic scale. (B) mRNA expression of Rho genes not 
detected in normal T lymphocytes. The T-ALL sample with the lowest detected 
mRNA expression was assigned a relative expression level of 2. Other values are 
shown relative to this sample. Values above each column indicate the percentage of 































Table 1. Rho mRNA expression in T-ALL relative to healthy controls. RNA was 
extracted from 30 T-ALL blast samples and normal T lymphoblasts from 5 
peripheral blood samples of healthy donors. mRNA expression of each Rho gene 
was measured by quantitative PCR (qPCR) using glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as a reference gene. GAPDH-normalized Rho expression 
values (dCT) were used to compare expression levels between normal and T-ALL 
populations using a two-tailed Mann–Whitney U-test of medians. *P<0.05, 










3.4.2 Rho gene expression patterns cluster T-ALL patients in two groups  
T-ALL samples were grouped according to similarity of Rho expression (fold 
expression relative to controls) using clustering algorithms. The expression values 
were visualized in a heat-map, with a dendrogram showing the resulting clusters of 
T-ALL samples (Fig. 3.2). This analysis resulted in the resolution of two major 
clusters of T-ALL patients (denoted clusters A and B). The upregulation of RHOH, 
RHOBTB1, RHOA, RHOB and RHOU was similar in both clusters, as expected due 
to the consistency of the changes in these 5 genes across all samples. The distinction 
between the two groups reflected the expression of genes that showed variable 
expression across the T-ALL samples. Cluster A was enriched in samples where the 
expression of several Rho genes was lower than normal controls, including RAC1, 
RHOC, CDC42 and RHOQ, whereas cluster B had a greater incidence of higher-
than-normal expression of these genes. The two Rho expression profile clusters 
might reflect different patient characteristics.  They did not show a significant 
association with available patient information on age at diagnosis, white blood cell 
count (WBC), CNS disease and relapse incidence, but it is likely that a higher 
number of T-ALL samples would be required for this analysis.  
In addition to the cluster analysis, the expression of each Rho gene was 
independently tested for association with patient information. Interestingly, the 
expression of RHOQ, RND1 and RHOB was significantly correlated with WBC 
count (Table 2). As described above, RHOB is highly upregulated in the T-ALL 
samples. Although RHOQ and RND1 expression in T-ALL was not different overall 
from normal controls (Fig. 3.1), this suggests that RHOQ and RND1 expression are 
increased in a subset of patients with higher WBC. The WBC count could correlate 


































Figure 3.2 Association of Rho expression and T-ALL disease characteristics. 
Relative expression data for T-ALL samples were log2 transformed and an 
unsupervised hierarchical clustering algorithm applied (see Materials and methods). 
The legend indicates the magnitude and direction of expression changes relative to 






























Table 2. Association between relative Rho expression in T-ALL and WBC.  
The fold expression values for each Rho gene were tested for correlation with WBC 
at diagnosis, using Pearson's correlation statistic, r. The r values can range from 1, 
indicating perfect correlation, to −1, indicating perfect inverse correlation. *P<0.05, 














3.4.3 RHOU expression correlates with Notch1 signalling in T-ALL  
The NOTCH1 gene is mutated in over 50% of T-ALL cases, leading to dysregulated 
Notch1 signalling (Aster et al., 2011).  Mutations in other genes such as FBXW7, a 
ubiquitin ligase involved in Notch1 turnover, also contribute to constitutive Notch1 
signalling in T-ALL (O'Neil et al., 2007). We therefore investigated whether the Rho 
gene alterations we observed in the T-ALL samples were linked to aberrant Notch1 
signalling. 
We used the mRNA expression levels of the Notch1 target gene DELTEX1 as a read-
out of constitutive Notch1 signalling and screened the T-ALL samples using 




































Figure 3.3 Association of RhoU expression with Notch1 signalling in T-ALL 
patients and cell lines. (A) DELTEX-1 mRNA expression in T-ALL and control 
samples was analysed by quantitative PCR using GAPDH expression as a reference. 
DELTEX-1 mRNA expression in each T-ALL sample was determined relative to the 
mean expression of the normal control samples using the comparative Ct method. 
Data are expressed as fold expression relative to controls on a logarithmic scale. (B) 
Scatter plot of RHOU and DELTEX-1 expression in T-ALL samples. (C) Cells from 
a panel of T-ALL-derived cell lines in growth phase were lysed and then analysed 
for RhoU protein expression and cleaved Notch1 intracellular domain levels by 
immunoblotting. A representative blot from three independent experiments is shown 
Experiments in A and B were performed by Dr Parag Bhavsar. Experiments in C 










DELTEX1 transcript levels were at least two-fold higher than control T cells in 68% 
of samples, indicating increased Notch1 signalling. This could be due to NOTCH1 
mutations or other mutations that affect Notch1 signalling. 
We determined whether the relative expression levels of any of the Rho genes 
correlated with the expression of DELTEX1 using a Spearman Rank test (Table 3). 
RHOU (Fig. 3.3B) and RAC2 mRNA levels were found to be significantly associated 
with DELTEX1 in T-ALL samples. Since we had identified RHOU as upregulated in 
T-ALL, we decided to investigate the relationship between RHOU and Notch1 
signalling further.  
A number of T-lymphoblastic cell lines have been derived from T-ALL patients. 
Several have mutations that lead to constitutive Notch1 signalling, whereas others 
have normal ligand-dependent Notch signaling (O'Neil et al., 2007). We used a panel 
of T-ALL cell lines to investigate whether there was an association between Notch1 
signalling status and RhoU protein expression. In accordance with published data, 
we detected cleaved Notch1 in PEER, SUPT1, CCRF-CEM, DND41 and Jurkat lines 
but not in LOUCY and MOLT16 lines, which do not have Notch1 mutations (Fig. 
3.3C) (O'Neil et al., 2007). The different sizes of NICD detected in the cell lines 
reflect different sites of mutation in Notch1 and/or FBW7, a ubiquitin ligase 
involved in Notch1 degradation (O'Neil et al., 2007). RhoU protein was expressed in 
all the cell lines, indicating that RhoU expression is not strictly dependent on 
oncogenic Notch1 activation.  However, it was highest in SUPT1, DND41 and 




































Table 3. Association between relative Rho gene expression and DELTEX-1 
levels in T-ALL. DELTEX-1 mRNA expression was analysed by quantitative PCR, 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)-normalized dCT values 
were used to test for correlation between Rho gene and DELTEX-1 expression using 















3.4.4 RhoU expression is regulated by Notch1 signalling 
To determine if RhoU expression is influenced by Notch1 signalling, we first 
utilized the γ-secretase inhibitor (GSI) compound E to block the generation of NICD 
(Palomero et al., 2006; Palomero et al., 2007). T-ALL cell lines with activating 
Notch1 mutations (CCRF-CEM, SUPT1 and PEER) and lines with wild-type Notch1 
(LOUCY and MOLT16) were treated with GSI or DMSO (vehicle control) for three 
and seven days to allow time for gene expression changes to occur. RHOU mRNA 
levels in response to the treatment were determined by qPCR (Fig. 3.4A). DELTEX1 
mRNA levels were quantified to confirm Notch1 signalling inhibition, and CDC42 
mRNA was used as an additional control since its expression was not correlated with 
DELTEX1 (Table 3). As expected, GSI treatment led to a dramatic reduction in the 
levels of DELTEX1 mRNA in all three NOTCH1 mutant lines. GSI treatment 
resulted in a reduction of RHOU mRNA in these T-ALL lines, whereas CDC42 was 
unaffected (Fig. 3.4A). In contrast, in the NOTCH1 wild-type lines, RHOU 
expression was unaffected by GSI treatment. We could not detect DELTEX1 mRNA 
well enough for quantification in LOUCY and MOLT16 lines, consistent with the 
absence of constitutive Notch1 signalling (Fig. 3.4A). 
We next analyzed the dependence of RhoU protein expression on Notch1 signalling. 
GSI treatment resulted in a reduction of NICD levels at three and seven days of 
treatment in the three NOTCH1 mutant lines, showing that the GSI treatment was 
inhibiting Notch1 cleavage. There was a progressive reduction in RhoU protein with 
GSI treatment in these lines (Fig. 3.4B), whereas Rac2 levels were not affected 
(Suppl Fig. 3.2A). In contrast, RhoU protein levels in the lines with wild-type 
NOTCH1 (LOUCY, MOLT16) were unaffected by GSI treatment. As expected, 
NICD was not detected in these lines (Fig. 3.4B). 
γ-secretase cleaves a number of proteins in addition to Notch1 (Wolfe, 2009), and 
thus we tested whether the effects of GSI on RhoU were also observed with direct 
Notch1 inhibition. Two different Notch1 siRNAs strongly reduced RhoU protein 
levels in CCRF-CEM cells (Fig. 3.4C).  To determine whether Notch1 signalling 
alone could induce RhoU expression, the NICD was expressed in COS7 cells. NICD 
expression led to an increase in RhoU protein levels (Fig. 3.4D). Together, these data 








Figure 3.4 Notch1 regulates RhoU expression. (A) T-ALL cell lines were treated 





analysed by quantitative PCR to determine relative mRNA expression levels of 
DELTEX-1, RHOU and CD CDC42, with GAPDH as a reference. Fold expression 
changes were determined relative to expression in DMSO-treated cells using the 
comparative Ct method. (B) Cells treated as in (A) were lysed and protein levels of 
the cleaved NICD and RhoU were determined by immunoblotting. Blots were 
probed for GAPDH or β-tubulin as loading controls. Representative data from three 
independent experiments are shown. (C) CCRF-CEM cells were transfected with 
control siRNA or two different siRNAs (1, 2) targeting Notch1. Cells were lysed 
after 72 h and analysed by immunoblotting for levels of NICD, RhoU, and GADPH 
as a loading control. (D) A construct encoding His-tagged NICD was transfected into 
Cos7 cells. After 48 h, cells were solubilized in protein sample buffer and His-tag 
and RhoU were detected by immunoblotting. GADPH was used as a loading control. 
A representative blot from three independent experiments is shown. Experiments in 
A, B were performed by Dr Parag Bhavsar (CCRF-CEM) and Elvira Infante (SUPT-





3.4.5 RhoU regulates T-ALL cell polarization, migration and adhesion 
Since Rho GTPases are well known to regulate cell migration (Heasman and Ridley, 
2008), we investigated whether RhoU affected the migration of T-ALL cells.  We 
chose CCRF-CEM cells since they have mutated NOTCH1, and are well 
characterized for their migration behaviour (Heasman et al., 2010; Infante et al., 
2011; Takesono et al., 2010). RhoU expression was downregulated in CCRF-CEM 
cells by transfection with two different siRNAs (Suppl Fig. 3.2B). RhoU-depleted 
cells had a rounder morphology and migrated more slowly on fibronectin than 
control siRNA-transfected cells (Fig. 3.5A, B).   Similarly, GSI-treated cells and 
Notch1-depleted cells were more rounded and migrated more slowly than control 
cells (Fig. 3.5A, B).  RhoU- and Notch1-depleted cells and GSI-treated cells also 
showed reduced total migration distance over 1 h (Fig. 3.5C) and RhoU and GSI 








Figure 3.5 RhoU regulates T-ALL cell morphology and migration. CCRF-CEM 
cells were transfected with control siRNA, two different siRNAs (1, 2) targeting 





Cells were added onto fibronectin-coated wells and stimulated with 1 ng/ml 
CXCL12 for 30 min. Phase-contrast time-lapse images were collected every 1 min 
for 1 h. Images shown are at 0 min. Scale bar, 50 µm. Representative of three 
independent experiments. Relative velocity (B) and accumulated distance (C) was 
determined by tracking 60 cells in each of three independent experiments. (D) Cells 
were added to fibronectin-coated transwells containing 30 ng/ml CXC12 in the 
lower chamber. Cells that had migrated into the bottom of the well were counted 
after 1 h using a Casy Counter. Data shown are mean of three independent 
experiments±s.e.m. *P<0.05, **P<0.01; two-tailed paired t-test. Experiments 































The rounded phenotype of RhoU-depleted and Notch1-inhibited cells suggested they 
might have an adhesion defect. Indeed, depletion of RhoU or Notch1 or treatment 
with GSI reduced adhesion CCRF-CEM cells to fibronectin (Fig. 3.6, Suppl Fig. 
3.2C).  
Similarly, RhoU depletion reduced adhesion of two other T-ALL cell lines, 
JURKAT and PEER (Fig. 3.6A, Suppl Fig. 3.2B), indicating that the effect of RhoU 









Figure 3.6 RhoU and Notch1 regulate T-ALL cell adhesion. CCRF-CEM, 
JURKAT or PEER cells were transfected with control siRNA or two different 
siRNAs (1, 2) targeting RhoU or Notch1, as indicated. After 72 h, cells were 
labelled with CellTracker dye CMFDA and incubated on fibronectin-coated wells. 
Adhesion was determined after 30 min. Data shown are the mean of three 
independent experiments±s.e.m. *P<0.05, **P<0.01; two-tailed paired t-test. 









Next we investigated whether RhoU depletion or Notch1 inhibition altered migratory 
polarity by staining for F-actin and microtubules (Takesono et al., 2010).  RhoU or 
Notch1-depleted cells and GSI-treated cells still had a single F-actin-rich 
lamellipodium at the front and the microtubule-organising center was behind the 
nucleus, but there was a strong reduction in the number of cells with tails compared 
to control cells (Fig. 3.7A-D). Interestingly, the total level of F-actin in RhoU-
depleted or GSI-treated cells was increased (Fig. 3.7E), and the level of F-actin in 
lamellipodia also increased (Fig. 3.7F). RhoU depletion therefore affects T-ALL cell 
morphology and migration, and these effects can be reproduced by GSI-mediated 















Figure 3.7 RhoU regulates polarity. CCRF-CEM cells were transfected with 
control siRNA, two different siRNAs targeting RhoU or Notch1 (1, 2) or treated for 
7 days with 100 nM GSI or DMSO (vehicle). (A, B) Cells were plated onto 





were then fixed and stained for F-actin and α-tubulin and imaged by confocal 
microscopy. Arrow indicates microtubule-organizing centre (MTOC); * indicates 
high F-actin staining in the lamellipodium. Scale bar, 10 µm. (C, D) The percent of 
polarized cells and cells with tails was quantified as described in the Materials and 
methods, by counting 100 cells in each of 3 independent experiments. (E) Cells were 
fixed, permeabilized and incubated with Alexa Fluor 488-labelled phalloidin and 
analysed by flow cytometry. (F) F-actin level at the leading edge was quantified 
using ImageJ software. Data shown are the mean of three independent 
experiments±s.e.m. *P<0.05, **P<0.01; two-tailed paired t-test. Experiments 

































The pathophysiology of T-ALL suggests a significant deregulation of cell migration 
and tissue infiltration. Large numbers of T-ALL cells accumulate in the peripheral 
blood and tissues, with frequent metastasis to the CNS. We show that 8 of the 20 
human Rho GTPases are upregulated in T-ALL compared to normal T cells. We find 
that expression of the atypical Rho family member RHOU is regulated by Notch1 
and demonstrate that RhoU is required for optimal adhesion, migration and 
transendothelial migration of T-ALL cells.  This indicates that RhoU could 
contribute to T-ALL progression in NOTCH1 mutant T-ALL patients.   
RhoU and RhoV form a subfamily of Rho GTPases that have a high intrinsic 
guanine nucleotide exchange activity and are thus believed to be predominantly 
GTP-bound (Aspenstrom et al., 2007). RhoU (also known as Wrch1) and RhoV (also 
known as Chp) have been implicated in migration in several cell types but have not 
previously been studied in leukocytes. For example, they have been shown to 
stimulate lamellipodial or filopodial extension and/or an increase in integrin-based 
focal adhesions (Aronheim et al., 1998; Aspenstrom et al., 2004; Chuang et al., 
2007). In osteoclasts, RhoU is found in podosomes and influences integrin signaling 
(Brazier et al., 2009), and RhoU is required for neural crest cell migration in vivo 
(Fort et al., 2011). Our data also indicate that RhoU is involved in regulating T-ALL 
cell adhesion.  RhoU-depleted T-ALL cells had a more rounded phenotype and 
lacked uropods/tails. RhoU depletion also resulted in reduced migration and 
CXCL12-stimulated chemotaxis. Loss of the uropod and reduced migration are 
consistent with a decrease in cell adhesion. So far it is not clear how RhoU or RhoV 
affect cell adhesion, although RhoV was shown to bind to and cause the degradation 
of the Rac/Cdc42 effector PAK1, which is implicated in focal adhesion turnover 
(Arias-Romero and Chernoff, 2008; Weisz Hubsman et al., 2007). The increased 
expression of RhoU and RhoV in T-ALL samples compared to normal T cells could 
therefore affect their attachment in the bone marrow and thymus, as well as entry 
into and out of the peripheral circulation and tissues.  
The increased expression of Rho GTPases that we observe in T-ALL samples is 
likely to reflect gene expression changes due to T-ALL genetic alterations (Aifantis 
et al., 2008; Ferrando et al., 2002). Indeed, we show that RHOU expression is 





T-ALL cell lines treated with SAHM1, a new type of Notch inhibitor that prevents 
formation of the active NICD/CSL transcription factor complex (Downward, 2003).  
Importantly, similar morphological and migratory phenotypes were induced in T-
ALL cells by RhoU depletion and by inhibiting Notch1 activation with GSI 
treatment, indicating that RHOU is the predominant target of Notch1 involved in 
regulating cell migration. Interestingly, RHOU was initially identified as a Wnt-
regulated gene (Tao et al., 2001), and Wnt signaling plays an important role in T cell 
development (Weerkamp et al., 2006). In the future it will be important to test 
whether other T-ALL-associated transcription factors affect the expression of Rho 
GTPases upregulated in T-ALL. 
In addition to RHOU and RHOV, we found that 4 other atypical Rho GTPases are 
upregulated in T-ALL: RHOH, RHOBTB1, RND2 and RND3.  RHOH is mutated 
through chromosomal translocations or somatic hypermutation in a number of B-
cell-derived leukaemias and lymphomas, but has not previously been implicated in 
T-cell-derived leukemias (Fueller and Kubatzky, 2008). However, it does regulate T-
cell receptor signaling and T-cell migration (Tybulewicz and Henderson, 2009; 
Wang et al., 2010), and could thereby affect T-ALL progression. So far little is 
known about RhoBTB1 in cancer.  It has been proposed as a candidate tumour 
suppressor in head and neck cancer, but the mechanistic basis for this function is 
unknown (Berthold et al., 2008a). There is no evidence as yet that RhoBTB1 is 
involved in cytoskeletal regulation (Aspenstrom et al., 2004); instead, the RhoBTB 
proteins have been implicated in cullin3-based ubiquitination as well as transcription 
regulation via BTB domain-dependent interactions (Aspenstrom et al., 2004; 
Berthold et al., 2008b). It will therefore be important to determine how RhoBTB1 
contributes to T-ALL. In contrast to RhoBTB1, Rnd2 and Rnd3 affect the actin 
cytoskeleton and affect cell migration in a variety of cultured cell lines (Aspenstrom 
et al., 2004; Riou et al., 2010), although their function has not so far been studied in 
lymphocytes.   
RHOB was consistently highly upregulated in T-ALL, whereas the fold-increase in 
RHOA expression was less.  RHOA overexpression has been reported in a variety of 
tumor types, including colon, breast, testicular germ cell and head and neck 
squamous cell carcinomas (Gomez del Pulgar et al., 2005). On the other hand, RhoB, 
which is involved in actin organization and membrane receptor trafficking (Ridley, 





analysis in solid tumors, although how it acts is not completely understood (Huang 
and Prendergast, 2006; Vega and Ridley, 2008). RHOB expression is rapidly induced 
in response to a variety of stimuli including growth factor stimulation and genotoxic 
stress (Huang and Prendergast, 2006), and thus it is possible that a specific stimulus 
in T-ALL cells induces high RHOB levels.  
In addition to our results on Rho GTPases, some T-ALL-related gene expression 
analysis studies have identified other potential regulators of cell migration. For 
example, the tetraspanin TALLA-1 (tetraspanin-7) is a target of the transcription 
factor TAL1 (Ono et al., 1997), which is frequently overexpressed in T-ALL (Graux 
et al., 2006). Several tetraspanins affect integrin-mediated processes such as 
adhesion, migration and invasion, but the function of TALLA-1 is not known 
(Yanez-Mo et al., 2009). TAL1 target genes identified by chromatin 
immunoprecipitation included some regulators of the cytoskeleton (Palomero et al., 
2006). Overexpression of NICD altered the expression of chemokines, cell adhesion 
molecules and metalloproteases (Buonamici et al., 2009).  In particular, the 
chemokine receptor CCR7 was upregulated and caused targeting of leukaemic blast 
cells to the brain endothelium. Together with our data, these results indicate that 
genes regulating cell adhesion, migration and invasion are modulated in T-ALL and 
















































Supplementary Figure 3.1. Range of Rho GTPase expression in control T cells 
and T-ALL samples. RNA was extracted from 30 T-ALL blast samples and normal 
T-lymphocytes from 5 peripheral blood samples of healthy donors. mRNA 
expression of each Rho gene was measured by quantitative PCR, using GAPDH 
expression as a reference. The CT value for each Rho gene is shown relative to the 












Supplementary Figure 3.2. RhoU depletion in T-ALL and effects of γ-secretase 
inhibition on protein expression and cell adhesion. (A) CCRF-CEM, SUPT1 and 
PEER cells were treated with 100 nM GSI or DMSO (vehicle) for 7 days. Cleaved 
Notch1 intracellular domain and Rac2 were detected by western blotting.  (B) 
CCRF-CEM, JURKAT and PEER cells were transfected with control siRNA and 
two different siRNAs (1, 2) targeting RhoU. The level of RhoU was determined 3 
days after transfection by immunoblotting. GADPH was used as a loading control. 
(C) CCRF-CEM cells were treated with 100 nM GSI or DMSO for 7 days. Cells 
were then labelled with cell tracker dye CMFDA and incubated on fibronectin-
coated wells. Adhesion was determined after 30 min. Data shown are the mean of 3 
independent experiments ± SEM. *p <0.05, **p <0.01; two-tailed paired t-test. 










RhoU and RhoV belong to the Cdc42 subfamily. They are atypical GTPases with 
high intrinsic guanine nucleotide exchange, and are therefore likely to be 
constitutively GTP-bound in cells (Chenette et al., 2005; Saras et al., 2004). In 
contrast to most Rho GTPases, both RhoU and RhoV have an N-terminal and C-
terminal extension that distinguishes them from the classical Rho GTPases. In 
particular the N-terminal extension is proline-rich and is likely to bind SH3 domain 
containing proteins. RhoU has been demonstrated to bind via its proline-rich domain 
to NCK2 (Saras et al., 2004). They do not have a functional CAAX box and instead 
are targeted to membranes by palmitoylation (Aronheim et al., 1998; Saras et al., 
2004). RhoU and RhoV protein sequences share 55% identity. They have both been 
reported to be involved in the formation of filopodia and migration of several cell 
types (Aronheim et al., 1998; Fort et al., 2011). Like Cdc42, RhoU and RhoV were 
shown to activate PAK (Weisz Hubsman et al., 2007) (Saras et al., 2004; Tao et al., 
2001). Interestingly, RhoV is not expressed in normal T cells but is overexpressed in 
a subset of T-ALL patients samples (Bhavsar et al., 2012).  
In the previous chapter, RhoU was shown to regulate T-ALL cell migration. 
Knockdown of RhoU by siRNA transfection affected the morphology of CCRF-
CEM cells, inducing a round phenotype and a decrease in tail formation. RhoU 
depletion also inhibited the adhesion of several T-ALL cell lines to fibronectin. 
These results suggested RhoU might contribute to tissue infiltration in T-ALL by 
affecting adhesion. The role of RhoV in T-ALL cells has never been investigated 
before. In this chapter the roles of RhoU and RhoV in T-ALL cells were investigated 
in parallel using Jurkat cells, as this cell line was shown to express both RhoU and 
RhoV. The localization, distribution and interaction of these proteins was also 





4.2 Materials and Methods 
Chemicals were all purchased from Sigma-Aldrich (Dorset, UK) unless otherwise 
stated.  
4.2.1 Cell biology 
4.2.1.1 Cell culture 
T-ALL cell lines (CCRF-CEM, PEER, SUPT-1 and Jurkat) were maintained in 
RPMI-1640 (containing 2 mM glutamine) (Invitrogen, Paisley, UK) supplemented 
with 10% fetal calf serum (FCS) (Biosera, East Sussex UK), 1 mM sodium pyruvate, 
10 mM Hepes, Penicillin (100 U/ml) and Streptomycin (10 µg/ml) (Invitrogen). 
Once cells reached a density of 2 x 106 cells/ml, they were diluted to a concentration 
between 2 and 5 x 105 cells/ml. 
Human umbilical vein endothelial cells (HUVECs) were grown in EBM-2 medium 
with growth factors (EGM-2) containing 2% FCS (Lonza, Slough, UK). Prior to 
seeding the cells, flasks were coated 10 µg/ml fibronectin (FN) (Sigma-Aldrich) for 
1 hour at 37°C. For passaging, cells were washed with PBS (without Ca2+/Mg2+) 
(Invitrogen) and incubated with 1 ml trypsin-EDTA (Invitrogen) at 37°C until all 
cells detached. The cells were then diluted in fresh culture medium. Cells were used 
until passage five.  
COS7 cells were grown in DMEM medium (Invitrogen) containing 10% FCS, 
Penicillin (100 U/ml) and Streptomycin (10 µg/ml). For passaging, cells were 
washed with PBS (without Ca2+/Mg2+) and incubated with 1 ml trypsin-EDTA at 
37°C until all cells detached. Cells were then diluted in fresh culture medium. 
 
4.2.1.2 Transfection of siRNAs 
Jurkat cells were diluted to a density of 5 x 105 cells/ml. After 24 h, cells were mixed 
with 1.2 µM siRNA in 100 µl Nucleofection reagent kit C (Lonza) and transferred to 
an electroporation cuvette. Cells were then nucleofected with an Amaxa 
Nucleofector apparatus, using programme X-001 according to the manufacturer’s 
instructions (Lonza). siRNA sequences were RhoV-1: 
GAGGGACGAUGUCAACGUA; RhoV-2 GAAGAAACUGAAUGCCAAA; 





GCUCAGCCUUGACGCAGAA. siControl was from Thermo Fisher Scientific (D-
001810-02-20, Lafayette, USA). After transfection cells were transferred to 5 ml of 
warm medium and incubated for 48-72 h at 37°C.  
 
4.2.1.3 Transfection of plasmids 
Jurkat cells (107) were mixed with 30 µg plasmid in 250 µl of Opti-MEM (Gibco), 
transferred to a 0.4 cm electroporation cuvette and left at room temperature for 10 
min. Samples were electroporated using a GenepulserII (Bio-Rad, Hertfordshire, 
UK) at 250 V, 975 µF and left again at room temperature for 10 min. Cells were then 
plated in 5 ml warm medium and incubated for 8-16 h at 37°C. 
COS7 cells were detached from the plate and washed twice with electroporation 
buffer (10 mM KCl, 10 mM K2PO4/KHPO4, pH 7.6, 25 mM Hepes, 2 mM MgCl2 
and 0.5% Ficoll 400). After resuspending in 250 µl of electroporation buffer, cells 
were mixed with 5 µg DNA in a 0.4 cm electroporation cuvette, left on ice for 5 min, 
then at room temperature for 5 min. Cells were finally plated in a 10 cm dish and 
incubated for 24 h at 37°C.  
 
4.2.1.4 Adhesion assay on endothelial cells (manual counting) 
Glass coverslips were incubated for 16 h with 10 µg/ml FN at 37°C. HUVECs were 
grown to confluency on coverslips and stimulated for 16 h with 10 ng/ml TNF-α 
(R&D systems, Abingdon, UK). Jurkat cells were then incubated at 37°C for 15 min 
with 2 µM Cell Tracker CMFDA (Invitrogen, Paisley, UK). Samples were 
resuspended in warm media, and 2 x 105 cells/well were seeded onto the HUVEC 
monolayer and incubated at 37°C for 15 min. After two washes to remove un-bound 
cells, samples were fixed with 4% paraformaldehyde for 10 min. Following two 
washes in PBS, cells were incubated with Alexa Fluor 546 phalloidin (Invitrogen) 
for 1 h to visualize F-actin. Coverslips were mounted onto glass slides using Dako 
anti-fade mounting medium (Dako, Ely, UK). Images were acquired using a Zeiss 
LSM510 confocal microscope using a Plan Fluor 20x objective and Zen software 
was used to analyse the data. Five random fields for each condition were acquired 





4.2.1.5 Adhesion assay on endothelial (plate reader)  
Black 96 well plates (Costar, Corning, NY, USA) were coated for 1 h with 10 µg/ml 
FN at 37°C. HUVECs were grown to confluency in the wells and stimulated for 16 h 
with 10 ng/ml TNF-α. Jurkat cells were then incubated at 37°C for 15 min with 2 
µM Cell Tracker CMFDA. Samples were resuspended in warm medium and 2 x 105 
cells/well (each sample in triplicate) seeded onto the HUVECs monolayer. Cells 
were incubated at 37°C for 15 min. After 3 washes to remove un-bound cells, 
adhered cells were measured by detection of fluorescence using a plate reader 
(PerkinElmer, Cambridge, UK) at 485 nm excitation and 523-535 nm emission.  
 
4.2.1.6 Transwell based transendothelial migration assay  
HUVECs were grown to confluency on FN-coated (10 µg/ml) 5 µm pore transwell 
filters (Costar) and then stimulated with 10 ng/ml TNF-α for 16 h. After washing, 
2.5 x 105 Jurkat cells in 200 µl medium were added onto the HUVECs monolayer in 
the top chamber, and 600 µl medium containing 30 ng/ml of CXCL-12 (R&D 
systems) was added to the bottom of the wells. After 3 h of incubation at 37°C, the 
cells that had transmigrated into the lower chamber were counted using a Casy cell 
counter.  
 
4.2.1.7 Live imaging microscopy 
Glass bottom dishes (MatTek, Ashland, MA, USA) were coated with 10 µg/ml FN at 
4°C overnight and blocked with 2.5% bovine serum albumin in PBS for 1 h. Jurkat 
cells (106) were added to the dishes, and incubated at 37°C for 30 min. After two 
washes cells were stimulated with 1 ng/ml of CXCL12 in 1 ml of phenol red-free 
RPMI and images acquired every 10 sec for 10 min using a LSM510 confocal 
microscope with a Plan-Apochromat 63x/1.40 NAOil DIC M27 objective. Zen 
software was used to analyse the movies.  






4.2.1.8 Immunofluorescence microscopy 
Glass coverslips were coated with 10 µg/ml FN at 4°C overnight and blocked with 
2.5% bovine serum albumin in PBS for 1 h. Jurkat cells (2.5 x 105) were added to 
each coverslip and incubated at 37°C with 1 ng/ml CXCL12 for 30 min. 
Subsequently, samples were fixed with 4% paraformaldehyde for 10 min and 
permeabilized in 0.1% Triton-X-100 for 4 min. Cells were then incubated with 1:200 
dilution of anti-myc-epitope (sc-40, Santa Cruz Biotechnology, SA, USA) primary 
antibody for 1 h at room temperature, followed by incubation with Alexa Fluor-488, 
546 or 647 anti-mouse IgG secondary antibody (Invitrogen) for 1 h at room 
temperature. Samples were, when indicated, incubated for 1 h at room temperature 
with Alexa Fluor-546 phalloidin to visualize F-actin. Coverslips were mounted onto 
glass slides using Dako anti-fade mounting medium and visualized under a LSM510 
confocal microscope with a Plan-Apochromat 63x/1.40 NAOil DIC M27 objective 
and Zen software was used to analyse the data.  
Protein co-localization was quantified using Zen software, which calculates an 
overlap coefficient. Overlap values range from 0 to 1. An overlap of 1 indicates 
perfect pixel co-localization (Hoebe et al., 2007).  
 
4.2.1.9 Analysis of filopodia and cell spreading 
Jurkat cells transfected with plasmids encoding pRK5-myc-RhoU or RhoV (kind gift 
of Pontus Aspenström (Saras et al., 2004)) were seeded onto FN-coated coverslips. 
Cells were then fixed and stained with anti-myc epitope antibody and Alexa Fluor-
546 phalloidin. Filopodia and spread cells were quantified by scoring myc-RhoU or 

























Figure 4.1 Example of filopodia and a spread cell.  Jurkat cells were seeded onto 
FN-coated coverslips for 30 min. Cells were fixed and stained with Alexa Fluor-546 
phalloidin. Left image shows a well spread cell. Star indicates filopodia protrusions. 
Right image shows a round and not spread cell (scale bar 10 µm).  
 
 
4.2.2 Molecular Biology 
4.2.2.1 Generation of GFP-RhoU, GFP-RhoV and Cherry-RhoU vector 
RhoU and RhoV cDNAs were subcloned from a pRK5 to pEGFP-C1 vector 
(Clontech, Saint-Germain-en-Laye France).  pEGFP-C1 was digested using BamHI 
and DraI, while pRK5-myc-RhoU or pRK5-myc-RhoV were digested using BamHI 
and PsiI. After purification on agarose gels, RhoU and RhoV were ligated into 
pEGFP-C1. E. coli were transformed with 5 µl of ligation and clones were verified 
by plasmid digestion using EcoRI (Figure 4.2).  
RhoU from pEGFP-RhoU was subsequently subcloned in pmCherry-C1 (kind gift 
Dr Maddy Parsons). pEGFP-RhoU and pmCherry-C1 were digested with EcoRI. To 
avoid self-ligation, pmCherry-C1 was incubated with calf intestinal alkaline 
phosphate (CIP). Since this enzyme catalyzes the removal of 5’ phosphate groups 
required by ligases, the plasmid DNA cannot self-ligate. After agarose gel 
purification, RhoU was ligated into pmCherry-C1 and E. coli transformed with 5 µl 










Figure 4.2 Schematic diagram of RhoU and RhoV subcloning into pEGFP-C1. 
pRK5-RhoU or RhoV were digested with BamHI and PsiI while pEGFP-C1 was 
digested with BamHI and DraI restriction enzymes. RhoU and RhoV cDNAs were 







Figure 4.3 Schematic diagram of RhoU subcloning into a pmCherry-C1. 
pEGFP-RhoU and pmCherry-C1 were digested with EcoRI restriction enzyme. 









4.2.2.2 Restriction enzyme digestion of DNA 
Plasmid DNA (1µg) was digested with 10 units of the appropriate restriction enzyme 
(DraI, PsiI, BamHI and EcoRI) in the buffers recommended by the manufacturer 
(New England Biolabs, Hertfordshire, UK) for up to 2 h. To avoid self-ligation, 
destination vectors were incubated with 10 units of CIP (New England Biolabs) for 
30 min at 37°C.  
 
4.2.2.3 Agarose gel elctrophoresis 
1% (w/v) agarose was dissolved in TAE buffer (40 mM Tris acetate, 1 mM EDTA  
and 11.4% (v/v) glacial acetic acid)  using a microwave oven. Ethidium bromide (0.5 
µg/µl) was added to the gel and, after complete polymerization, DNA samples 
separated by electrophoresis at 100 V in TAE buffer. DNA fragments were 
visualized on a UV-transilluminator. 
 
4.2.2.4 Extraction of DNA from agarose gels 
The DNA fragments of interest were excised under a UV-transilluminator using a 
sterile scalpel and weighed. DNA was then isolated using the QIAquick gel 
extraction kit (QIAGEN, West Sussex, UK) according to the manufacturer’s 
instructions. Fragments were mixed with 3 volumes of buffer QG (composition not 
provided) per mg of gel and incubated at 50°C until the gel was completely 
dissolved. After addition of 1 volume of isopropanol, the sample was applied to a 
QIAquick spin column and centrifuged at 14000 g for 1 minute. The column was 
washed twice with PE (composition not provided) at 14000 g for 1 min and DNA 
eluted in 50 µl ddH20 by centrifugation at 14000 g for 2 min. 
 
4.2.2.5 DNA ligation 
DNA fragments were ligated into the appropriate destination vector using 200 units 
T4 DNA ligase (New England Biology) in the supplied ligation buffer at 16°C for 16 
h. A 3-fold excess volume of insert over destination vector was used. 5 µl of ligation 






4.2.2.6 Transformation of competent bacteria  
Plasmid DNA (10 ng) or 5 µl of ligation were mixed with 100 µl of competent DH5α 
cells and incubated on ice for 30 min. The bacterial suspension was heat-pulsed for 
45 sec at 42°C and placed again on ice for 2 min. 900 µl LB (without antibiotics) 
was then added to the bacteria and incubated at 37°C for 1 hour. Finally, 100 µl of 
the cells were plated onto a Luria broth (LB) agar plates containing 100 µg/ml 
ampicillin or 50 µg/ml kanamycin, as appropriate.  
 
4.2.2.7 Purification of plasmid DNA from bacteria 
For small-scale production of plasmid DNA, QIAprep Miniprep Kits were used. LB 
medium (2 ml) containing 100 µg/ml ampicillin or 50 µg/ml kanamycin was 
inoculated with a single colony from an agar plate and incubated overnight at 37°C. 
Bacteria were centrifuged at 3000 g for 15 min and the pellet resuspended in 250 µl 
Buffer A (50 mM glucose, 25 mM Tris-HCl, pH 8.0, 10 mM EDTA, 10 µg/ml 
RNase A). After mixing with 250 µl lysis buffer (200 mM NaOH, 1% SDS), 350 µl 
neutralization buffer (3 M potassium acetate and 2 M acetic acid) were added to the 
sample and cell debris and proteins removed by centrifugation at 14000 g for 10 min. 
The supernatant was then applied to a QIAprep spin column and centrifuged at 
14000 g for 1 min. Columns was washed twice with 750 µl wash buffer (750 mM 
NaCl, 50 mM MOPS pH 7.0, 15% isopropanol (v/v)) and DNA eluted with 50 µl 
ddH20 by centrifugation for 1 min at 14000 g.  
For larger scale plasmid DNA purification, Qiagen EndoFree Maxiprep Kits were 
used. 100 ml of bacterial culture was pelleted at 3000 g for 15 min and resuspended, 
lysed and neutralized in 10 ml of buffers described for the miniprep protocol. 
Lysates were clarified using filter-syringes provided with the kit. Endotoxin removal 
buffer (1.5 ml) was added to the sample and incubated on ice for 30 min.  In the 
meantime a column provided by the kit was equilibrated with the equilibration buffer 
(50 mM NaCl, 50 mM MOPS pH 7.0, 15% isopropanol (v/v), 15% Triton-X-100). 
The sample was then applied to the column and washed twice with wash buffer (1 M 
NaCl, 50 mM MOPS pH 7.0, 15% isopropanol (v/v)). The DNA was eluted with 15 
ml of higher salt buffer (1.25 M NaCl, 50 mM Tris/HCl pH 8.5, 15% isopropanol 





8000 g for 45 min. Pellets were washed with 5 ml 70% ethanol and resuspended in 
200 µl ddH20.  
 
4.2.2.8 Determination of DNA and RNA concentration 
DNA or RNA concentration was determined using a Nano-Drop spectrophotometer 
system (Thermo scientific, Hampshire, UK) at an optical density (OD) of 260 nm 
and 280 nm. The DNA concentration (ng/µl) was automatically calculated using the 
formula concDNA= OD260 x 50 µg/ml. The RNA concentration (ng/µl) was 
automatically calculated using the formula concRNA= OD260 x 40 µg/ml. 
 
4.2.2.9 DNA sequencing 
Purified plasmid DNA (1 µg) was sent to MWG (www.eurofinsdna.com) for DNA 
sequencing.  
 
4.2.2.10 RNA isolation using Trizol 
Suspension cells (5 x 106) were pelleted in a microcentrifuge tube and incubated for 
5 min with 1 ml Trizol (Invitrogen) at room temperature. Chloroform (0.2 ml) was 
added to the sample and the tube was vigorously inverted 10 times. Samples were 
left at room temperature for 3 min and subsequently centrifugated at 14000 g for 15 
min at 4°C. After centrifugation the upper phase of the samples was transferred into 
a new tube, mixed with 0.25 ml of isopropanol to precipitate the RNA and incubated 
on ice for 10 min. RNA was pelletted by centrifugation at 14000 g for 15 min at 4°C 
and the pellet air-dried for 10 min. Pellets were resuspended in 10 µl of RNase free 
H2O (Ambion, Invitrogen, Paisley, UK).  
In order to remove DNA contamination, the purified RNA was incubated with 
DNase1 buffer and 1 µl DNase enzyme (Ambion) for 30 min at 37°C. The DNase 
was inactivated following the addition of 5 µl DNase inactivation buffer beads for 2 
min at 37°C. Samples were then centrifuged at 10000 g for 2 min and supernatants 







4.2.2.11 cDNA synthesis 
Reverse transcription was performed using SuperScript-Vilo cDNA Synthesis Kit 
(Invitrogen). RNA (1 µg) was mixed with the VILO reaction mix and SuperScript 
Enzyme Mix according to the manufacturer’s instructions. Samples were first 
incubated for 10 min at room temperature and subsequently incubated for 1 hour at 
42°C. The reaction was terminated by 5 min at 85°C. 
 
4.2.2.12 Real-time SYBR-green PCR  
The relative mRNA level of RhoV was determined by qPCR using SYBR green 
detection chemistry (PCR mastermix from Primer Design, Southampton, UK). 
SYBR green is a fluorescent dye that binds double stranded DNA. Therefore, during 
the qPCR reaction the fluorescence increase proportionally with the amount of 
amplified DNA. The reaction was performed in an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems). Primers for RhoV and GAPDH (for 
normalization) were designed and validated by Dr Parag Bhavsar as described in 
chapter 3. cDNA obtained from 1 µg RNA was diluted 1/65, and of this 3 µl were 
mixed with 3 µl of primers and 6 µl 2X SYBR green mix  in a total reaction volume 
of 12 µl. The reaction was carried out with an initial 10 min denaturation at 95°C 
followed by 40 cycles of 10 sec at 95°C (denaturation) and 30 sec at 60°C (annealing 
and extension). To verify that just one product was amplified a dissociation step was 
added at the end of the reaction (one denaturation cycle at 95°C for 15 sec followed 
by 20 sec of amplification at 60°C). The data were analysed using the ABI7000 




2-∆∆CT = [(CT gene of interest – CT internal control) sampleA- (CT gene of 









The CT values indicate the number of cycles after which the SYBR green 
fluorescent signal crosses a threshold level. In this calculation the fold difference of 





For immunoprecipitation of myc-epitope-tagged proteins, transfected COS7 cells 
were lysed into lysis buffer containing 1% Triton-X-100, 50 mM Tris HCl, 150 mM 
NaCl, 1 mM DTT, 25 mM NaF and complete EDTA-free protease inhibitor (Roche 
Applied Science, Burgess Hill, UK). Samples were centrifuged for 10 min at 14000 
g. 40 µl of clarified samples was kept to determine total protein level, while the 
remaining lysate was incubated with 20 µl of anti-myc-agarose beads (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) at 4°C for 2 h on a rotating wheel. Beads 
were then washed five times in 1 ml lysis buffer and boiled in 4X sample buffer  
 
4.2.3.2 Western blot analysis 
Cells were lysed in 1% SDS, followed by addition of 1% Triton-X-100, 25 mM NaF, 
1 mM Na3VO4 and 10 mg/ml aprotinin, then incubated on ice for 10 min. Lysates 
were clarified by centrifugation at 14000 g for 30 min. Cleared lysates were boiled 
for 5 min in 4X sample buffer and separated on a 4-12% Bis-Tris polyacrylamide gel 
at 150 V in NuPAGE MES running buffer (Invitrogen). Proteins were then 
transferred to a nitrocellulose membrane (GE Healthcare, Chalfont St Giles, UK) for 
immunblotting. Transfer was carried out for 90 min at 100 V in transfer buffer (25 
mM Tris HCl pH 8.3, 192 mM glycine, 20% methanol). Membranes were then 
blocked in blocking buffer (5% nonfat dried milk in TBS (25 mM Tris HCl 7.6, 50 
mM NaCl, 2.5 mM KCl)) for 1 hour at room temperature and incubated with 1:1000  
dilutions of the following antibodies: c-myc (sc-789, Santa Cruz), GFP (FL, Santa 
Cruz), RhoU (Wrch-1 ab80315, Cambridge, UK) and GAPDH (Millipore, Watford, 
UK)) primary antibody either for 1 hour at room temperature or overnight at 4°C. 
Membranes were washed three times in TBS, containing 0.1% Tween-20, and 





3 washes, immunodetection was performed using an ECL detection kit (GE 
Healthcare) according to manufacture’s instructions and signal detected by exposure 
































4.3.1 RhoV expression in T-ALL cell lines and siRNA transfection in Jurkat 
cells 
The function of the atypical Rho GTPase RhoV is far from being fully understood. 
The RhoV gene is not expressed in primary-T-lymphoblasts but expressed in a 
subset of T-ALL patients samples (Figure 3.1). This raises questions concerning  its 
possible role in the pathogenesis of T-ALL.  
First, the expression of RhoV was analysed in different T-ALL cell lines and 
primary-T-lymphoblasts. As already mentioned, primary-T-lymphoblasts do not 
express RhoV and they were included as a negative control. RNA was purified from 
Jurkat, CCRF-CEM, PEER and SUPT1 T-ALL cell lines and primary T-lymphoblast 
cells. The expression of RhoV was then determined by quantitative PCR. Among the 
T-ALL cell lines Jurkat and Supt1 expressed the highest level of RhoV.  
Interestingly these cell lines also expressed the highest level of RhoU, as described 
in chapter 3 (see Figure 3.3.). CCRF-CEM and PEER cell lines had lower levels of 
RhoV and primary T-lymphoblasts had no detectable RhoV (Figure 4.4A). Jurkat 
cells were then selected for further studies of RhoV as this cell line was already well 
characterized and used for previous studies in the laboratory.  
In order to study whether RhoV affected adhesion and migration, Jurkat cells were 
transfected with four different siRNAs targeting RhoV and an siRNA control. Cells 
were also nucleofected with nucleofection reagent only (Mock control). In the 
absence of a reliable antibody to detect endogenous RhoV protein, the efficiency of 
RhoV mRNA depletion was determined by qPCR. Two siRNAs siRhoV-1 and 




















Figure 4.4 RhoV expression in T-ALL cell lines and RhoV siRNA knockdown. 
Total RNA was isolated from Jurkat, CCRF-CEM, PEER, SUPT1 and primary-T-
lymphoblast cells (A and B) or Jurkat cells transfected with control siRNA or four (C 
and D) or two (E) different oligos for RhoV. mRNA was converted into cDNA and 
the amount of RhoV cDNA was determined by qPCR. Ct value of RhoV (A) is 
shown relative to Ct value for GAPDH (B and C). All values in D and E are 
represented as percentage of siControl. C and D represent data from one single 
experiment. Data shown in A, B and E are the mean of 3 independent experiments ± 





4.3.2 RhoU and RhoV depletion reduces adhesion of Jurkat cells to fibronectin 
and endothelial cells 
T-ALL progression is characterized by T-ALL cell accumulation in lymph nodes, 
spleen and CNS (Kebriaei et al., 2002). Molecules involved in migration, adhesion 
and chemotaxis of T-ALL cells are likely to be important in the infiltration process. 
β1 integrin is widely expressed in mammalian cell types and is expressed in T-
lymphocytes (Bauer et al., 2009; Zhang and Wang, 2012). Integrins are important for 
both rolling and adhesion of T cells on endothelial cells. It has been demonstrated 
that β1 integrin-deficient T cells are unable to infiltrate the CNS (Bauer et al., 2009). 
Fibronectin is a ligand for β1 integrin (Hauzenberger et al., 1994).  In chapter 3 (see 
section 3.4.6) RhoU depletion, was shown to reduce adhesion of CCRF-CEM, Jurkat 
and Peer and Jurkat cells to fibronectin. It was therefore further investigated whether 
RhoU and RhoV could affect adhesion of Jurkat cells to fibronectin. A reduction of 
50% in the binding of Jurkat cells to fibronectin was observed after depletion of 
RhoU and RhoV compared to Mock and siRNA control (Figure 4.5). This indicates 
that both proteins are important for adhesion of Jurkat cells to fibronectin. The 
physiological ligand of β1 integrin on endothelial cells is the VCAM-1 on 
endothelial cells. Upregulation of VCAM-1 is observed after stimulation of 
endothelial cells with TNF-α (Cernuda-Morollon and Ridley, 2006). To investigate 
the effect of RhoU and RhoV depletion on T cell adhesion to endothelial cells, 
HUVECs were used. Two different types of adhesion assay were carried out. The 
first assay was performed in order to visualize the effect of RhoU and RhoV 
knockdown on adhesion. In this assay HUVECs were grown on coverslips and 
adherent Jurkat cells were counted manually. Knockdown of both RhoU and RhoV 
with 2 single oligos significantly decreased the adhesion of Jurkat cells to HUVECs 
(Figure 4.6A and B). The second assay, similar to the adhesion assay on fibronectin 
described in chapter 2 and 3, was used to obtain an automated quantification of 
adhered cells. In these experiments, knockdown of RhoU and RhoV also reduced 
adhesion of Jurkat cells to the endothelial monolayer (Figure 4.6 C).  
Taking together these results indicated that RhoU and RhoV regulate Jurkat cell 



























Figure 4.5 RhoU and RhoV depletion affect adhesion of Jurkat cells to 
fibronectin. Jurkat cells were transfected with transfection reagent alone (MOCK), 
control siRNA or two different siRNAs targeting RhoU or RhoV. After 72 h cells 
were labelled with Cell Tracker CMFDA and added to wells coated with FN. 
Adhesion was determined after 30 min. Data shown are the mean of 3 independent 






























































Figure 4. 6 RhoU and RhoV depletion affect adhesion of Jurkat cells to 
HUVECs. Jurkat cells were transfected with MOCK, control siRNAs or two 
different siRNA targeting RhoU or RhoV. After 72 h cells were labelled with Cell 
Tracker CMFDA and then added to a confluent HUVEC monolayer on coverslips (A 
and B) or to a confluent HUVEC monolayer on a 96 well plate. After 15 min 





fixed and stained for F-actin. Images were acquired by confocal microscopy. Five 
random fields for each condition were acquired and the total number of cells per 
field was counted. (A) Images are representative of 3 independent experiments. 
Scale bar, 50 µm. (B) Graph shows adhered cells as percentage of siControl. (C) 
Adhered cells were measured by detection of fluorescence on a plate reader. Data 




4.3.3 RhoU and RhoV depletion reduces transendothelial migration 
RhoU or RhoV knockdown decreases the adhesion of Jurkat cells to endothelial 
cells. Adhesion of leukaemia cells to the endothelium is an important step for 
transendothelial migration. T-ALL cells often migrate to and infiltrate lymph nodes 
and bone marrow where they proliferate.  The bone marrow has been suggested as a 
site that allows neoplastic cells to evade chemotherapy and several adhesion 
molecules are involved in this process and affect patient outcome (Feng et al., 2010). 
In order to investigate whether RhoU and RhoV knockdown could affect 
transendothelial migration of Jurkat cells, HUVECs were allowed to grow on 0.5 µm 
transwell filters and stimulated with TNF-α. Jurkat cells were then seeded onto the 
HUVECs and the chemokine CXCL12 was added as a chemoattractant to the bottom 
(Figure 4.7). Both RhoU and RhoV depletion significantly impaired the 














































Figure 4.7 RhoU and RhoV down-regulation reduces TEM. Jurkat cells were 
transfected with siRNAs targeting RhoU, RhoV or siRNA controls and then added to 
confluent HUVECs on transwell filters. CXCL12 (30 ng/ml) was added to the 
bottom well. After 3 h, cells that had transmigrated through the HUVECs into the 
lower chamber were counted with a Casy counter.  





4.3.4 RhoU and RhoV induce morphological changes in Jurkat and SUPT1 
cells. 
To determine the effect of RhoU and RhoV overexpression on T-ALL cell lines, 
pRK5 empty vector (as a control), or vectors encoding Myc-RhoU and Myc-RhoV 
were transfected into Jurkat cells. After 24 h, cells were allowed to adhere to 
fibronectin. Cells were treated with CXCL12 to stimulate migration. RhoU and 
RhoV localized mainly on the plasma membrane and in punctate structures in the 
cytoplasm (Figure 4.8). 
Expression of RhoU and RhoV increased the number of cells with filopodium-like 
protrusions compared to the control samples (Figure 4.8A and B). This has been 





Filopodia protrusions were also observed by timelapse confocal microscopy (see 
supplementary movies 12 and 13). 
Expression of RhoU and RhoV induced an increase in cell spreading (Figure 4.8). 
Interestingly, in chapter 3 RhoU-depleted CCRF-CEM cells were shown to have a 
round, less spread phenotype and reduction in tail formation (see section 3.4.6). 
Similarly, RhoU and RhoV overexpression increased filopodium formation in 

































Figure 4.8 RhoU and RhoV overexpression induce cell spreading and 
filopodium formation. Jurkat (A) or SUPT1 (C) cells were transfected with pRK5 
empty vector, pRK5-myc-RhoU and pRK5-myc-RhoV. After 24 h, cells were plated 
onto fibronectin-coated wells and stimulated with 1 ng/ml CXCL12 for 30 min. 
Samples were then fixed and stained for F-actin and myc-epitope and imaged by 
confocal microscopy. Arrows indicate punctate structures. Images show maximum 
intensity projection of 20 Z-stacks. Scale bar, 20 µm (A) or 10 µm (C). The 
percentage of Jurkat cells with filopodia formation and cell spreading was quantified 
by counting 100 myc-epitope positive cells in each of the pRK5-myc-RhoU and 
pRK5-myc-RhoV samples or 100 random cells in the pRK5 transfected cells in each 









4.3.5 Dynamic analysis of RhoU and RhoV distribution  
The distribution of RhoU and RhoV was followed by timelapse microscopy.                                    
GFP-RhoU or RhoV were expressed in Jurkat cells. RhoU strongly localized in 
vesicle-like structures and at the plasma membrane. These structures accumulated in 
the perinuclear area. Vesicles were often observed to traffic toward the 
lamellipodium and retract from the uropod during cell movement (Figure 49A, B and 
C). Vesicles were highly dynamic and trafficked to and from the plasma membrane 
(Figure 4.9D).  GFP-RhoU showed a similar distribution during cell movement  in 
CCRF-CEM cells (Figure 4.9F). Similar to GFP-RhoU, GFP-RhoV localized in 
vesicles in the perinuclear area (Figure 4.10). GFP was expressed as a control in both 
Jurkat and CCRF-CEM showing a uniform distribution in the entire cell (Figure 4.9E 
and G). To determine the speed of the vesicles 1 sec per frame movies were 
acquired. This acquisition allowed better visualization of the trafficking of the 
vesicles toward and from the plasma membrane (Figure 4.11).  
It was really interesting to observe that RhoU and RhoV showed a similar dynamic 
distribution on vesicles and accumulation on membranes, suggesting they might co-
localize. Indeed mCherryRhoU and GFP-RhoV co-localized strongly on vesicles and 
on the plasma membrane (Figure 4.12). An increase in the speed of the cells was 
observed when RhoU and RhoV were co-expressed although this has not been 
quantified so far (Supplementary Movies 22 and 23). It was not possible to perform 
1 sec per frame movies of cells co-expressing mCherry-RhoU and GFP-RhoV due to 
photobleaching and phototoxicity problems. These are mainly induced by excited 
fluorophores, which produce ROS leading to loss of fluorescence signal and cell 























Figure 4.9 RhoU distribution in T-ALL cells. Jurkat or CCRF-CEM cells were 





on fibronectin-coated glass wells and stimulated for 30 min with 1 ng/ml CXCL12. 
Cells were imaged by confocal microscopy acquiring images every 10 sec for 9 min. 
(A, B, C and D) Images show 3 frames of pEGFP-RhoU expressing Jurkat cells. (A) 
Arrows indicates RhoU accumulation at the uropod and vesicle formation during tail 
retraction. (B) Arrows indicate vesicle trafficking from the perinuclear area toward 
the plasma membrane. (C) Arrows indicate RhoU accumulation at the 
lamellipodium. (D) Image shows merging of 10 time frames. Each frame is 
represented with a different colour. (F) Image shows a frame of pEGFP-RhoU 
expressing CCRF-CEM cell. The red arrow indicates RhoU vesicles migration from 
the uropod. The yellow arrow indicates vesicles migrating toward the lamellipodium. 
The white arrow indicates RhoU accumulation at the lamellipodium. (E and G) 
Images show Jurkat (E) and CCRF-CEM (G) cell transfected with pEGFP-C1. Scale 

























































































Figure 4.10. RhoV distribution in Jurkat cells. Jurkat cells were transfected with 
pEGFP-RhoV (A, B, C and D) and pEGFP-C1 (E) plasmid. After 24 h cells were 





CXCL12. Cells were imaged by confocal microscopy acquiring images every 10 sec 
for 9 min. (A) Arrows indicate vesicle trafficking toward the plasma membrane. (B) 
Arrows indicate RhoV accumulation at the plasma membrane. (C) Arrows indicate 
vesicle trafficking from the plasma membrane. (D) Image shows merging of 10 time 
frames. Each frame is represented with a different colour. (E) Image shows Jurkat 
cell expressing GFP. Scale bar, 10 µm. Images are representative of three cells of 




















































Figure 4.11 RhoU and RhoV distribution in Jurkat cells. Jurkat cells were 
transfected with pmCherry-RhoU (A, B and D) or pEGFP-RhoV (C and D) plasmid. 
After 24 h cells were seeded on fibronectin coated glass wells and stimulated for 30 
min with 1 ng/ml CXCL12. Cells were imaged by confocal microscopes acquiring 
images every sec for 1 min. Images show Jurkat cell expressing pmCherry-RhoU (A) 
of pEGFP-RhoV (B). Zoom of pmCherry-RhoU (B) or pEGF-RhoV (D) showing 
migration of a vesicle toward (yellow arrows) or from the plasma membrane (orange 





determined by tracking 10 vesicles per condition of three independent experiments.  
Scale bar, 10 µm. 
 
 
Figure 4.12 RhoU and RhoV co-localize. Jurkat cells were co-transfected with 
pEGFP-RhoV and pmCherry-RhoU or GFP and mCherry empty vector. After 24 h, 
cells were seeded onto FN-coated glass wells and stimulated for 30 min with 1 ng/ml 
CXCL12. Cells were imaged by confocal microscopy acquiring images every 10 sec 
for 10 min. (A) Images show 12 sequential frames of a Jurkat cell expressing GFP-
RhoV and mCherry-RhoU. The white arrow indicates RhoU-RhoV co-localization in 
vesicles and the orange arrow accumulation in the front of the cell. (B) Images show 
Jurkat cell co-transfected with GFP and mCherry empty vector. Scale bars, 10 µm. 





co-localization of pEGFP-RhoV and pmCherry-RhoU using Zeiss Software. Mean of 
three frames of each cells of three independent experiments.  
 
4.3.6 RhoU and RhoV localize in part on endosomes 
RhoU and RhoV-containing vesicles accumulated in the perinuclear area around the 
MTOC as indicated by α-tubulin staining of myc-RhoU and myc-RhoV transfected 
cells (Figure 4.13). This distribution suggested an endosomal localization (Palfy et 
al., 2012). This was investigated using an antibody to an early-endosomal protein 
(EEA1). EEA1 interacts with early endosomes via binding to the membrane lipid 
phosphatidylinositol 3- phosphate and the active form of the small GTPase Rab5 
(Callaghan et al., 1999). Unfortunately antibodies against RhoU and RhoV suitable 
for immunofluorescence experiments with endogenous RhoU and RhoV are not 
available. Therefore, immunofluorescence analysis was carried out on cells 
expressing exogenous RhoU and RhoV as described below. 
mCherry-RhoU or GFP-RhoV showed a partial co-localization with EEA1 in Jurkat 
cells (Figure 4.14). The co-localization was also observed in cells co-expressing 
RhoU and RhoV (Figure 4.15). Cdc42 was reported to localize to the Golgi (Hehnly 
et al., 2010). It was therefore interesting to investigate if RhoU and RhoV localize to 
the Golgi. Jurkat cells expressing Myc-RhoU or Myc-RhoV were stained with 
GM130 antibody. This antibody is used as Golgi marker as it recognizes GM130 
protein. This is a peripheral cytoplasmic protein part of the cis-Golgi matrix,  and has 
a role in maintaining cis-Golgi structure (Nakamura et al., 1995). Myc-RhoU and 
Myc-RhoV did not co-localize with GM130 (Figure 4.16). 
In summary, these results demonstrate that RhoU and RhoV partially co-localize on 






















Figure 4.13 RhoU and RhoV-containing vesicles localize around the MTOC. 
Jurkat cells were transfected with pRK5, pRK5-myc-RhoU and pRK5-myc-RhoV. 
After 24 h cells were plated onto fibronectin-coated wells and stimulated with 1 
ng/ml CXCL12. Samples were then fixed and stained for α-tubulin and myc-epitope, 
and imaged by confocal microscopy. Arrows indicate the MTOC. Scale bar, 10 µm. 















Figure 4.14 RhoU and RhoV localize on endosomes. Jurkat cells were transfected 
with pmCherry-C1, pmCherry-RhoU (A and B), pEGFP-C1 and pEGFP-RhoV (C 
and D). After 24 h cells were plated onto FN-coated wells and stimulated with 1 
ng/ml CXCL12. Samples were then fixed and stained for EEA1 and imaged by 
confocal microscopy. Scale bars, 10 µm. Images (B and D) show ortho projections. 
















































Figure 4.15 RhoU and RhoV co-localize on endosomes. Jurkat cells were co-
transfected with plasmid encoding pEGFP-C1 and pmCherry-C1 (top panel), and 
vectors encoding pmCherry-RhoU and pEGFP-RhoV (bottom panel). After 24 h 
cells were plated onto fibronectin-coated wells and stimulated with 1 ng/ml 
CXCL12. Samples were then fixed and stained for EEA1 and imaged by confocal 
microscopy. Scale bar, 10 µm. Images (B) show ortho projections. Images are 







Figure 4.16 RhoU and RhoV do not localize to the Golgi. Jurkat cells were 
transfected with control pRK5, pRK5-myc-RhoU and pRK5-myc-RhoV. After 24 h 
cells were plated onto fibronectin-coated coverslips and stimulated with 1 ng/ml 
CXCL12. Samples were then fixed and stained for GM130 Golgi marker and myc 
and imaged by confocal microscopy. Scale bars, 10 µm. The bottom panels show 










4.3.7 RhoU interacts with RhoV  
Immunofluorescence analysis and live imaging movies of Jurkat cells showed a 
partially colocalization of RhoU and RhoV on endosomes and at the plasma 
membrane. To determine if an interaction occurs between RhoU and RhoV, Cos7 
cells were cotransfected with plasmids encoding GFP-RhoV and Myc-RhoU. (Figure 
































Figure 4. 17. Coimmunoprecipitation of RhoU and RhoV. Cos7 cells were 
transfected with pRK5-myc-RhoU and pEGFP-RhoV or empty vectors. After 24 h 
cells were lysed and cell lysates incubated with anti-myc-epitope agarose beads. GFP 
and GFP-RhoV proteins interacting with RhoU were detected by immunoblotting 
with antibody to GFP. GAPDH was used as a loading control. Image is 






4.3.8 The N-terminus of RhoV is not required for RhoU binding 
Unlike other Rho GTPases, RhoU has a prolin rich domain (Saras et al., 2004) that is 
likely to interact with SH3 domain containing proteins (see section 1.3.4.1 and 
1.3.4.2). As the SH3 domain could act as an adaptor between two proteins, it was 
hypothesized that the interaction between RhoU and RhoV could occurred via the N-
terminus of these proteins. To investigate the requirement of this domain, Cos7 cells 
were cotransfected with plasmid encoding GFP-RhoV lacking the N-terminal 
domain (ΔN-RhoV) or full length RhoV with Myc-RhoU plasmid (Figure 4.18). 
Wild type and ΔN-RhoV were both able to coprecipitate with RhoU suggesting that 




















































Figure 4.19 Coimmunoprecipitation of RhoU and ΔNRhoV. Cos7 cells were 
transfected with pRK5-mycRhoU and full length pEGFP-RhoV, CB6-GFP-ΔNRhoV 
or empty vectors. After 24 h, cells were lysed and incubated with anti-myc-epitope 
agarose beads. GFP and GFP-RhoV proteins interacting with RhoU were detected by 
immunoblotting with antibody to GFP. GAPDH was used as a loading control. 

















4.3.9 FLIM analysis of Jurkat cells expressing cherry-RhoU and GFP-RhoV or 
GFP-ΔNRhoV 
Immunofluorescence analysis and coimmunprecipitation experiments showed that 
RhoU and RhoV interact. This interaction was further analyzed. A widely used 
method to study protein-protein interactions in single cells (live or fixed) is Förster 
resonance energy transfer (FRET). FRET is a dipole-dipole coupling process where 
two proteins of interest are attached to two fluorophores (donor and acceptor) (Peter 
et al., 2005). Fluorophores have characteristic excitation and emission spectra. If 
these two molecules are close in proximity, the excitation of the donor fluorophores 
leads to a transfer of the energy to the acceptor, resulting in higher acceptor emission 
and quenching of the donor (Wouters et al., 2001). The absorption spectrum of the 
acceptor must overlap the spectrum of the fluorescence emission of the donor in 
order for the energy transfer to occur. Different pairs of fluorophores with 
overlapping emission can be used, including CFP/YFP, BFP/EGFP or GFP/mCherry 
(Morton and Parsons, 2011).  The energy transfer can occur between fluorophores 
which are up to 11 nm apart (Sekar and Periasamy, 2003). In FLIM instead of 
fluorescence intensity, the fluorescence lifetime is measured. Fluorophores are not 
just characterized by an excitation and emission spectra but also by their lifetimes. 
The lifetime of a fluorophore refers to the average time it stays in its excitation state 
before emitting a photon. The fluorescence lifetime of a fluorophore is affected by 
FRET and in the presence of a suitable acceptor, the lifetime of the donor will 
decrease. This decrease in lifetime is measured by FLIM (Morton and Parsons, 
2011).  
In the experiments analysed by Dr Maddy Parsons, FLIM was used to measure 
fluorescence lifetime of GFP. The GFP lifetime of cells expressing “GFP-alone” was 
important to compare the difference in the GFP lifetime and the GFP lifetime in the 
presence of the acceptor (Morton and Parsons, 2011). FLIM analysis of Jurkat cells 
co-expressing RhoU and RhoV showed these proteins interact at the plasma 
membrane and partially in the cytoplasm. These results suggest that RhoU and RhoV 
are able to form heterodimers (Figure 4.20A and C).  
To investigate whether RhoU and ΔNRhoV interact in T-ALL cells. Jurkat cells co-
expressing mCherry-RhoU and GFP-ΔNRhoV were used. This was analysed by Dr 





FLIM analysis of Jurkat showed that ΔNRhoV was still able to interact at the plasma 
membrane and in the cytoplasm with RhoU (Figure 4.20B and C).  
Taking together these results demonstrate that RhoU interacts with RhoV and that 
this interaction occurs at the plasma membrane and in vesicles. RhoV lacking the N-
terminus of proline-rich domain is still able to bind RhoU suggesting this domain is 
not required for their binding. It will be important to generate new mutants in order 
























































































Figure 4.20 FLIM analysis of RhoU and RhoV interaction. Jurkat cells were 
transfected with plasmids encoding pEGFP-RhoV or co-transfected with pmCherry-
RhoU and pEGFP-RhoV (A) or CB6-GFP-ΔNRhoV (B). After 8 h, cells were 
seeded on FN-coated glass bottom coverslips and stimulated with 1 ng/ml CXCL12. 
After 30 min cells were fixed and subjected to FRET analysis by FLIM. FRET is 
depicted using a pseudocolour scale (blue, normal lifetime, red FRET). Graph (C) 





4.3.10 RhoU and RhoV form homodimers 
Since RhoU and RhoV heterodimerize, the possibility that they homodimerize was 
investigated. Cos7 cells were co-transfected with plasmids encoding GFP-RhoU and 
myc-RhoU, or cotransfected with GFP-RhoV and myc-RhoV. Immunoprecipitation 
analysis showed that myc-RhoU associates with GFP-RhoU and myc-RhoV with 
GFP-RhoV (Figure 4.21). 
These results suggest that both RhoU and RhoV are able to form homodimers, 

























Figure 4.21 RhoU and RhoV homodimerize. Cos7 cells were cotransfected with 
pRK5-myc-RhoU and pEGFP-RhoU or pRK5-myc-RhoV and pEGFP-RhoV or 
empty vectors. After 24 h cells were lysed and incubated with myc-epitope agarose 
beads. GFP proteins interacting with RhoU or RhoV were detected by 




4.3.11 RhoU interacts with Rac1, Rac2 and RhoV but not RhoA or Cdc42. 
In the previous chapter, RhoU depletion was shown to affect the morphology and 





Rac1 or Rac2, which are well-characterized for their roles in migration and 
cytoskeleton rearrangement (Rougerie and Delon, 2012). A possible interaction of 
RhoU with these GTPases has not been investigated before. Interestingly RhoU co-
immunoprecipitated not only with RhoV but also with Rac1 and Rac2. However it 
did not co-immunoprecipitate with RhoA and Cdc42, demonstrating the specificity 











Figure 4.22 RhoU co-immunoprecipitates with Rac1, Rac2 and RhoV. Cos7 cells 
were transfected with pRK5-mycRhoU and CB6-GFP-RhoA, CB6-GFP-Cdc42, 
CB6-GFP-Rac1, pEGFP-Rac2 or pEGFP-RhoV or empty vectors. After 24 h cells 
were lysed and incubated with myc-epitope agarose beads. GFP proteins interacting 
with RhoU were detected by immunoblotting with antibody against GFP. Image is 





4.3.12 RhoU but not Rac1 and RhoV interact with NCK1 
NCK1 and NCK2 are adaptor proteins containing three SH3 domains and one SH2 
domain. NCK1 protein has been shown to interact with a proline-rich region of R-
Ras (Wang et al., 2000) and to interact with proteins involved in cytoskeleton 
regulation. It was demonstrated that RhoU binds NCK2 and that the N-terminus of 
RhoU mediates this interaction (Saras et al., 2004). Moreover Rac1 associates with 
the adapter protein Crk via a proline-rich region in its C-terminus (van Hennik et al., 
2003). It was therefore hypothesized that a bridge between RhoU and Rac could be 
mediated by NCK1. This was investigated by coimmunoprecipitation analysis. Cos7 
cells were cotransfected with GFP plasmids encoding for RhoU, RhoV or Rac1, and 
Myc-NCK1 (kind gift of Matthias Krause) and cell lysate incubated with Myc-beads. 
Preliminary western blot results confirmed that RhoU interacted with NCK1, but not 
Rac1 and RhoV (Figure 4.23). As NCK1 appears not to be an adaptor protein for 























Figure 4.23 NCK1 co-immunoprecipitates with RhoU but not Rac1 or RhoV. 
Cos7 cells were cotransfected with pEBB-myc-NCK1 and pEGFP-RhoU, pEGFP-
RhoV or CB6-GFP-Rac1. After 24 h cells were lysate and incubated with myc-
epitope agarose beads. GFP proteins interacting with RhoU were detected by 





4.3.13 RhoV regulates RhoU levels 
siRNA depletion of RhoV induces a similar functional effect to RhoU depletion 
cells. RhoU and RhoV are both important for adhesion to fibronectin and endothelial 
cells. Moreover a reduction in transendothelial migration has been observed when 
these proteins are knocked down. It was therefore tested whether RhoV was able to 
affect RhoU expression levels. Western blotting analysis of RhoV-depleted cells 
with two single oligos showed a decrease in the protein expression of RhoU 
compared to Mock or siControl (Figure 4.24A and B). It was not possible to 
investigate if RhoU knockdown affects RhoV level due to a lack of a specific 
antibody. To determine whether RhoV was directly able to induce RhoU expression, 
GFP-RhoV was expressed in COS7 cells. RhoV expression leads to an increase in 
RhoU protein level (Figure 4.24C and D). Taking together, these results showed that 

















Figure 4.24 RhoV regulates RhoU expression. (A and B) Jurkat cells were 
transfected with transfection reagent alone (MOCK), control siRNA or two different 
siRNAs targeting RhoU and RhoV. Cells were lysed after 72 h and analysed by 
immunoblotting using the indicated antibodies. (B) Relative RhoU levels were 
quantified using ImageJ. (C and D) Cos7 cells were transfected with vectors 
encoding for GFP  or GFP-RhoV. After 24 h cells were lysed and analysed by 
immunoblotting using the indicated antibodies. (D) Relative RhoU levels were 
quantified using ImageJ. Data shown are the mean of 3 independent experiments ± 













The aim of the research described in this chapter was to investigate the role of RhoU 
and RhoV in T-ALL cell adhesion and migration. It was demonstrated that both 
RhoU and RhoV depletion reduced Jurkat cell adhesion to fibronectin and 
endothelial cells and decreased transendothelial migration. RhoU and RhoV 
localized on endosomes and the plasma membrane. RhoU and RhoV were found to 
interact and to form hetero- and homodimers. Intriguingly, RhoV was demonstrated 
to modulate RhoU protein expression.  
RhoU and RhoV were in vesicular structures and on the plasma membrane. 
Timelapse movies revealed that these vesicles traffic to and from the plasma 
membrane. RhoU and RhoV could be involved in vesicular trafficking of proteins to 
the plasma membrane, or they might play a role at the plasma membrane and be 
transported there by vesicles. RhoU and RhoV were also found to co-localize on 
these vesicles, suggesting they might cooperate to regulate membrane trafficking. 
The vesicles were found to be endosomes, a well-characterized cell compartment 
that provides a spatio-temporal regulation of cell signalling. Several Rho GTPases 
are involved in membrane trafficking (Segev, 2011). Rac1 and RhoA are involved in 
the uptake of extracellular material through pinocytosis and phagocytosis (Castellano 
et al., 2000; Leung et al., 1999). Cdc42 was demonstrated to control antigen 
internalization in dendritic cells (DC). Immature DCs actively internalize antigen, 
while in mature DCs endocytocis is strongly reduced as these cells mainly present 
the antigen to T cells. The reduction in endocytosis was demonstrated to reflect  
dowregulation of Cdc42 activaty (Garrett et al., 2000).  
Generally, endocytosed molecules, including receptors, are first delivered to early 
endosomes which  therefore provide spatial regulation of signalling (Vignjevic et al., 
2006). Different mechanisms of internalization have been identified. The best 
characterized is clathrin-dependent endocytosis, which involves the assembly of 
different proteins including clathrin to form a clathrin-coated pit (CCP) on the 
cytplasmic face of the plasma membrane. The CCP facilitates the accumulation of 
the molecules that needed to be internalized. CCP then invaginate and form vesicles 
inside the cell (Yamashiro et al., 1998).  The Rho GTPases RhoA and Rac1 were 
reported to inhibit CCP-dependent internalization of the transferrin receptors (Ellis 





internalization. These endocytic pathways are driven by actin polymerization and 
include phagocytosis, caveolar-mediated uptake and pinocytosis.  
Ative Rac1 has been observed in early endosomes. These compartments were 
suggested to be important in regulating Rac1 distribution towards specific area of the 
cells in order to promote membrane ruffling (Miaczynska and Bar-Sagi, 2010).  Rac1 
co-localize at the plasma membrane and on endosomes with ADP-ribosylation factor 
6 (ARF6). Rac1 recycling from endosomes to the cell surface appears to be 
facilitated by ARF6 (D'Souza-Schorey and Chavrier, 2006; Radhakrishna et al., 
1999). Inhibition of ARF6-dependent membrane trafficking alters also the trafficking 
of Cdc42-positive vesicles and consequently cell polarity (Osmani et al., 2010).  
Interestingly, RhoJ and RhoQ, which belong to the Cdc42 subfamily, were reported 
to control membrane trafficking. Like RhoU and RhoV, RhoJ was shown to localize 
on the plasma membrane and endosomes. Depletion of RhoJ disrupted 
internalization of transferrin receptor and was shown to be necessary for transport of 
endocytosed receptors to the early endosome (de Toledo et al., 2003). In adipocytes 
RhoQ was reported to regulate the insulin-dependent transfer of the glucose 
transporter GLUT4 from storage compartment to the plasma membrane (Chiang et 
al., 2001). This involved actin cytosketon rearrangements induced by RhoQ 
activation through N-WASP (Jiang et al., 2002). RhoB localizes to endocytic 
vesicles and regulates trafficking of EGF receptor by retarding the progress of the 
receptor to lysosomes for degradation (Ellis and Mellor, 2000; Kress et al., 2007). 
EGF receptor was also demonstrated to colocalize with RhoU on endosomes in a 
Grb2-dependent manner contributing to cell migration (Zhang et al., 2011). This 
supports the hypothesis that RhoU is involved in intracellular and receptor 
trafficking. It would be interesting to test whether RhoV is involved in transferring 
receptor or EGF receptor internalization.  
In the previous chapter (see Figure 3.6) it was shown that downregulation of RhoU 
by siRNA reduced CCRF-CEM, Jurkat and PEER cell adhesion to fibronectin. In 
this chapter, it was demonstrated that both RhoU and RhoV knockdown strongly 
inhibit adhesion of Jurkat cells to fibronectin and endothelial cells. Interestingly, 
RhoU and RhoV reduced adhesion of prostate cancer cells (PC3) to the endothelium 
(Dr Nicolas Reymond, personal communication). In agreement with these results, 
cranial neural crest cells were shown to adhere poorly to fibronectin when depleted 





role of RhoU in adhesion is not just restricted to T-ALL cells. In the previous chapter 
(see Figure 3.7), RhoU-depleted cells had a rounded morphology and a defect in 
uropod/tail formation. Loss of the tail is consistent with a defect in adhesion. The 
mechanism by which RhoU and RhoV inhibit adhesion still remains to be clarified. 
RhoU has been shown to regulate focal adhesion dynamics in HeLa cells (Chuang et 
al., 2007). It is possible that RhoU and/or RhoV control integrins. Jurkat cells 
preferentially bind to fibronectin, a ligand of β1 integrin. No significant changes 
were observed in total β1 integrin expression levels in RhoU and RhoV-depleted 
cells (data not shown). Since RhoU and RhoV were found to traffic between the 
plasma membrane and cytoplasm it is possible they control the localization and 
clustering of β1 integrin. Integrins are trafficked by the endosomal pathway, and this 
trafficking is important for the polarized distribution of integrins (Caswell et al., 
2009). Endosomes have been found to mediate the redistribution of integrins during 
cytokinesis (Pellinen et al., 2008). Moreover, it has been hypothesized that a 
polarized endocytic cycle is required to return integrins from the rear of a migrating 
cell toward its front (Bretscher, 1996), although there is no yet evidence for this. To 
investigate a possible role of RhoU and RhoV in β1 integrin localization 
immunofluorescence analysis would need to be performed.  
RhoU and RhoV are targeted to the membrane by palmtoylation, and this protein 
modification allows proteins to move to and from membranes (Navarro-Lerida et al., 
2012). It was interesting to observe that RhoU and RhoV vesicles traffic to and from 
the plasma membrane as this suggests a recycling mechanism. It would be therefore 
important to test if they traffic to perinuclear recycling compartments before 
returning to the plasma membrane through a mechanism requiring Rab11 or ARF6. 
Rab11 and ARF6 proteins controll traffic through the recycling endosome (Caswell 
et al., 2009). As RhoU and RhoV vesicles were observed to migrate from the rear of 
the cells during cell migration, one possible scenario could be that RhoU and/or 
RhoV control recycling of integrins from the tail of the cell.  
A decrease in cell spread area upon RhoU siRNA knockdown has also been 
observed in HeLaS3 cells (Chuang et al., 2007). Here, overexpression of RhoU or 
RhoV increased cell spreading and filopodium formation. Filopodia are finger-like 
protrusion of the plasma membrane. They are formed of 10 or more parallel bundles 





the entire length of filopodia and fascin1 depletion leads to a reduction in the number 
of filopodia and migration (Vignjevic et al., 2006; Vignjevic et al., 2007; Yamashiro 
et al., 1998). The main function of filopodia is to sense the extracellular 
environment, and they are linked to enhancement of directed migration as the key 
components of filopodia promote cell motility. They contribute to angiogenesis, 
chemotaxis and adhesion (Eilken and Adams, 2010; Zhang et al., 2004) and an 
increase in filopodia is considered a characteristic of invasive cancer cells (Arjonen 
et al., 2011; Mattila and Lappalainen, 2008; Schafer et al., 2009). During cell 
spreading, integrins accumulate in filopodia in an active state, creating sticky fingers 
at the front of the cell, promoting cell adhesion and migration (Galbraith et al., 
2007). Therefore filopodium formation and cell spreading induced by RhoU and 
RhoV could contribute to their roles in adhesion and migration. It would be 
interesting to investigate the localization of active β1 integrins on RhoU and RhoV 
expressing cells to analyze whether they accumulate in the filopodia induced by 
RhoU and RhoV.  
Given the effect of RhoU and RhoV on adhesion to extracellular matrix and 
endothelial cells, it was important to investigate if these proteins were affecting 
transendothelial migration. Interestingly, RhoU and RhoV depletion inhibited Jurkat 
cells transmigration. siRNA depletion of RhoU was also shown to reduce 
transendothelial migration of CCRF-CEM cells (Heasman et al., 2010). The effect on 
transendothelial migration might be due to the role of RhoU and RhoV adhesion of 
Jurkat cells to the endothelium.  
It is well established in the literature that Rho GTPases cooperate or antagonize each 
other to control many biological processes. One example of cross-talk between Rho 
GTPases is between the Rnd proteins and RhoA where Rnd1 and 3 inhibit RhoA 
activity and consequently cell contractility (Chardin, 2006; Guilluy et al., 2011). 
Hence, Rho GTPase interaction is important for cellular functions, but a direct 
interaction between two Rho GTPases has never been observed before.  
It was surprising to observe that RhoU and RhoV interact, and this interaction occur 
at the plasma membrane and in vesicles. These observations suggest these two Rho 
GTPases can act together to regulate membrane trafficking and their cooperation 
could be therefore fundamental for their functions.  Dimerization is an important 





can enhance protein specificity, can facilitate the orientation and proximity of two 
molecules, or increase their surface of interaction with other proteins or DNA 
(Klemm et al., 1998). In yeast the Rsr1 GTPase has been shown to form homodimers 
and heterodimers with Cdc42 in a spatio-temporal controlled manner important for 
cell polarity. The C-terminal polybasic region of Rsr1 mediates the dimerization 
(Kang et al., 2010). In this chapter, it was demonstrated that both RhoU and RhoV 
are able to form homodimers. It would be interesting to determine which domain of 
these proteins is important for their inteaction with itself. This could be mediated as 
for Rsr1 and Cdc42 by their polybasic region at the C-terminus.  
Homodimerization of some proteins facilitates or promotes their interaction with 
other proteins. For example it has been demonstrated that the homodimerization of 
ROCK-1 is required for Rnd3/RhoE binding (Garg et al., 2008).  
It is possible that part of the phenotypic effects observed upon RhoV knockdown are 
due to its effect on RhoU protein levels. It was already proposed that RhoU could 
have a similar function to RhoV, controlling in a similar manner cell adhesion and 
migration of cranial neural crest cells. Moreover, it was demonstrated that RhoV 
depletion affects the induction of neural crest markers. This phenotype was rescued 
by RhoU expression (Guemar et al., 2007). The mechanism by which RhoV 
regulates RhoU expression still remains to be clarified. It would be critical to test 
whether RhoU depletion is also able to affect RhoV protein level. This was not 
analysed here due to the lack of a suitable antibody to detect endogenous RhoV. 
Moreover, it is interesting to observe that the expression pattern of RhoV in the T-
ALL cells analysed (see Figure 4.4A) is similar to that of RhoU (see Figure 3.3). 
SUPT1 and Jurkat cells, express the highest levels of RhoU and RhoV. This might 
be explained by the modulation of RhoU expression mediated by RhoV.  
Given that RhoV depletion induces a decrease in RhoU protein, it possible that the 
binding of these two proteins protects RhoU from proteosomal degradation. 
Proteosome inhibitors could be used upon RhoV siRNA knockdown to test whether 
they could prevent the reduction in RhoU levels.  
Interestingly, RhoU was found to interact with Rac1 by co-immunoprecipitation. The 
main characterized function of Rac1 is to induce formation of lamellipodia. 
Depletion of RhoU in cranial neural crest cells inhibited lamellipodia formation (Fort 
et al., 2011) and Rac1 and RhoU interaction could mediate this effect. In NIH3T3 





downstream of this defect as stimulation with PDGFP-BB an activator of Rac was 
able to rescue the lack in lamellipodia (Saras et al., 2004). A lack of lamellipodia 
upon RhoU overexpression was never observed in T-ALL cells, and thus this effect 
is restricted to fibroblasts. This does not rule out the possibility that the interaction 
between Rac1 and RhoU also occurs in fibroblast. Rac1 endocytosis is important for 
its activation and recycling to the plasma membrane, where Rac1 induces 
lamellipodia (Palamidessi et al., 2008).  
Since RhoU localizes to endosomes, it could control Rac1 traffic to the plasma 
membrane. The control of Rac1 trafficking toward the plasma membrane would be 
therefore important for Rac1 function. Rac1 depletion reduced transendothelial 
migration of T-ALL cells (Heasman et al., 2010). The regulation of Rac1 trafficking 
by RhoU could contribute to a correct localization of Rac1 to the lamellipodium 
where it drives migration and transendothelial migration.  
NCK1 is an SH2/SH3 domain-containing adapter protein and is implicated in actin 
cytoskeleton rearrangement and cell migration (Buday et al., 2002). The proline-rich 
domain at the N-terminus of RhoU interacts with the middle and C-terminal SH3 
domains of NCK2 (Saras et al., 2004). Although Rac1 also has a proline-rich domain 
at the C-terminus (van Hennik et al., 2003), NCK1 did not interact with Rac1 and 
thus is unlikely to link Rac1 to RhoU (or RhoV). 
RhoU and RhoV were shown to interact with PAK1 (Saras et al., 2004; Weisz 
Hubsman et al., 2007).  It is well established that PAKs are activated by Rac and 
Cdc42 and that they are important regulators of cell migration and invasion. PAKs 
are overexpressed and/or hyperactivated in several human tumours and PAK-
targeted therapeutics are being developed (Dummler et al., 2009).  It can be 
speculated that RhoU and RhoV control migration through activation of PAK1 
(Saras et al., 2004; Weisz Hubsman et al., 2007). In this case, it could be possible 
that RhoU and/or RhoV dimerization is required for their binding to PAK1. It was 
demonstrated that the N-terminus of RhoV is not required for the binding with RhoU 
by co-immunoprecipitation experiments and FRET/FLIM. Their interaction could be 
mediated by their polybasic regions at their C-terminus. In that case, 
homodimerization could act as a negative regulator of RhoU and RhoV interaction, 
as they might compete for the same domain. 
As the effects of RhoU and RhoV co-expression on migration have not been 





each other. They could compete for their binding to Rac1. It is also possible that 
RhoU, RhoV and Rac1 form a proteins complex that regulates migration through 
PAK1. RhoV was also demonstrated to interact with Rac1 (data not shown) and to 
interact with RhoU. One possible scenario is that RhoU and RhoV 
hetero/homodimerization mediates the binding of Rac1 to PAK1. It is also possible 
that RhoU and RhoV dimerization controls PAK1 activity. There is no evidence that 
PAK1 localizes on endosomes but it was found on pinocytic vesicles in SWISS-3T3 
cells, similar to Rac1 (Dharmawardhane et al., 1997).  
Here, RhoU was also shown to interact with Rac2. Rac1 and Rac2 share 92% of 
identity and most of their effectors (Heasman and Ridley, 2008) (Figure 4.25). 
 
 
Figure 4.25. Sequence alignment between Rac1 and Rac2. Rac1 and Rac2 share 




Rac1 and Rac2 are both important for the production of superoxidase in 
phagocytic cells. The high similarity suggests redundancy between these two Racs. It 
has been proposed that the main difference between Rac1 and Rac2 lies in their 
pattern of expression. Rac2 is highly expressed in haematopoietic tissues (Shirsat et 
al., 1990) and in human neutrophils Rac is the main isoform. The redundant function 
might be the reason why they both interact with RhoU. Interesting, in macrophages 
was showed that Rac1 and Rac2 have distinct roles. Macrophages lacking Rac2 had 
reduction in podosomes while lack of Rac1 altered cell shape and reduced membrane 
ruffling (Zhang et al., 2012). It is therefore possible that Rac1 and Rac2 have distinct 





A main characteristic of T-ALL is the extent of tumour cell dissemination between 
the bone marrow and peripheral blood. In T-ALL patients, the T lymphoblasts 
comprise more than 25% of the bone marrow cells. Patients have also a high number 
of circulating T-lymphoblasts (Feng et al., 2010) (Goldberg et al., 2003). Poor T-
ALL prognosis is related to the infiltration of different tissues, in particular CNS. In 
order to infiltrate tissues leukaemic cells need to extravasate from the blood stream 
through the endothelium. Here, RhoU and RhoV depletion inhibited Jurkat cells 
adhesion to the endothelium and transendothelial migration. These proteins were 
also found to be up-regulated in T-ALL (Chapter 2). It is therefore possible that the 






















5   
Concluding remarks 
In T-ALL, leukaemia cells can migrate and infiltrate multiple tissues, including the 
central nervous system, and this correlates with poor prognosis. Therefore the 
identification of genes involved in the migration of leukaemic cells is fundamental to 
understand this process and ultimately to design therapies for T-ALL patients. Ras 
superfamily proteins are already known to contribute to cancer formation and 
progression. Ras mutations have been found in 30% of all human tumours (Bos, 
1989) while GTPases activity is increased in several tumours (Vega and Ridley, 
2008). Most GTPases are post-translationally prenylated by farnesyl or 
geranylgeranyl isoprenoids which facilitates their anchorage in membranes and is 
important for Rap/Rho GTPase signalling. 
 
In the first results chapter of this thesis, the effect of statin and GGTI on T-ALL cell 
adhesion and migration was described. Statins prevent prenylation of GTPases. 
These cholesterol lowering drugs were previously reported to have anticancer 
properties since they were shown to induce apoptosis in acute myeloid leukaemic 
and neuroblastoma cells (Dimitroulakos et al., 1999). These properties were 
attributed to the suppression of GTPase prenylation leading to a reduction in 
downstream signals essential for cell cycle progression (Gauthaman et al., 2009). 
Randomized controlled trials for preventing cardiovascular disease indicated that 
statins had benefits for reducing colorectal cancer and melanoma (Demierre et al., 
2005). Atorvastatin was shown to decrease the metastatic potential in melanoma 
cells causing disruption of stress fibres a process mediated by Rho inhibition. 
Similarly, as a result of Rho inhibition statins were shown to reduce the invasive 
potential of breast carcinoma cells (Gauthaman et al., 2009).  
Statins exhibit potent antileukaemic properties in vitro. For example, atorvastatin and 
fluvastatin were found to be inducers of cell differentiation and apoptosis of the NB4 
acute promyelocytic leukemia cell line. These effects were correlated with 
engagement of the c-Jun kinase pathway (Sassano et al., 2007).  
Results presented in this thesis demonstrated that treatment of T-ALL cells with 1 





needed to inhibit adhesion of primary T-lymphoblasts. Moreover siRNA depletion of 
Rap1b phenocopied statin effects. Rap1 levels are higher in primary T cells than T-
ALL cells which could explain their reduced sensitivity to statins (Figure 5.1). This 
suggests that statin, GGTI and inhibitors of Rap1b could be used to prevent T-ALL 







Figure 5.1 Schematic mechanism of action of statins in primary-T-lymphoblast 
and in T-ALL cell adhesion. Treatment of primary-T-lymphoblasts with 1 µM 
statin does not affect prenylation of Rap1b. This GTPase can still localize properly 
on the plasma membrane where it promotes β2-integrin activation. Active β2-
integrin can bind to ICAM-1 expressed on the endothelium surface, leading to firm 
adhesion between T cell and the endothelium. Treatment of T-ALL cells with 1 µM 
statin inhibits Rap1b prenylation and consequently its localization on membranes. 
The mislocalization of Rap1b causes a decrease in the activation of β2-integrin 
affecting adhesion of T-ALL cells to the endothelium. 
 
 
Given these promising in vitro results, it would be interesting to study the effect of 
statins, GGTI and Rap1b inhibitors in T-ALL using an in vivo model. The studies of 





models. In the colorectal cancer mouse model, it was consistently found that statins 
reduced tumour incidence by 30–67% (Demierre et al., 2005). Lovastatin reduced 
tumour formation and metastatic dissemination to the lung from established 
mammary tumours of a mouse model (Alonso et al., 1998).  
The LMO2 T-ALL mice express LMO2 selectively in T cells leading to the 
development of T-ALL. These mice would be a good model to study the effect of 
statins on T-ALL cells in vivo (McCormack et al., 2010). The LMO2 T-ALL mice 
could be also crossed with Rap1b knockout mice to study the role of Rap1b on T-
ALL cells in vivo (Chrzanowska-Wodnicka et al., 2005). 
 
In the LMO2 T-ALL mouse model the Notch1 oncogene is spontaneously mutated in 
approximately 50% of mice with T-ALL. In the second results chapter of this thesis, 
RhoU was described as a target gene of Notch1 in T-ALL. RhoU was demonstrated 
to be important for T-ALL cell adhesion to fibronectin and also for chemotaxis and 
migration possibly through its role in adhesion. It was also shown that Notch1 
siRNA depletion induced a decrease in the adhesion and migration of T-ALL cell 
lines, suggesting that Notch1 could affect migration of T-ALL cells through RhoU. 
The LMO2 T-ALL mouse model could therefore be used to investigate whether the 
expression of RhoU is related to aberrant Notch1 signaling in vivo. The model could 
be also used to perform functional analysis on cell adhesion and migration in order to 
understand whether Notch1 signaling could affect T-ALL cell adhesion and 
migration through RhoU in vivo.  
 
In the last results chapter of this thesis, it was demonstrated that expression of RhoU 
and its closest relative RhoV in T-ALL cell lines induces cell spreading and 
filopodium formation. RhoU and RhoV siRNA depletion were found to inhibit 
Jurkat cell adhesion on fibronectin and endothelial cells and to reduce TEM. It would 
be important to perform adhesion assays on endothelial cells and TEM assays using 
another T-ALL cell line as these experiments were performed only in Jurkat cells. 
Unexpected, RhoU and RhoV were found to form homo- and heterodimers. 
However, in yeast the Rsr1/Bud1GTPase was shown to interact with itself, and 
Cdc42 and Ras molecules were found to exist as oligomers (Kang et al., 2010; 





Intriguingly, RhoV was shown to modulate RhoU protein expression. In the absence 
of a reliable antibody to detect endogenous RhoV, it was not possible to investigate 
whether RhoU is able to modulate RhoV protein expression. Therefore this 
possibility cannot be excluded. 
As mentioned in the results chapter, it would be critical to perform rescue 
experiments to determine whether RhoU could rescue the effect of RhoV depletion 
and vivecersa. RhoU could be overexpressed in a RhoV knockdown background to 
analyse whether adhesion and TEM could be rescued in a T-ALL cell line such as 
Jurkat cells.  
RhoU and RhoV were demonstrated to co-localize on endosomes and on the plasma 
membrane suggesting they could be involved in membrane trafficking. How RhoU 
and RhoV regulate T-ALL cell adhesion still remains to be clarified. It would be 
important to analyse whether RhoU and RhoV could modulate the trafficking or 
activation of integrins.  
It can be also speculated that RhoU and RhoV could modulate adhesion through 
Rap1b. Rap1 proteins are well known regulators of integrins activation, and in the 
second chapter of this thesis, Rap1b was demonstrated to be important for adhesion 
of T-ALL cells to both fibronectin and ICAM-1, whereas Rap1a was shown to 
mainly mediate adhesion to fibronectin. Rap1 proteins localize on endosomes and 
the plasma membrane (Hattori and Minato, 2003). Given the possible role of RhoU 
and RhoV in membrane trafficking it is possible that RhoU and RhoV control the 
trafficking of Rap1b. A possible interaction between Rap1b and RhoU/RhoV could 
be investigated by co-immunoprecipitation analysis. It could be therefore 
informative to analyze the localization of Rap1b in the context of RhoU/RhoV 
depleted cells, to understand whether this could cause a mislocalization of Rap1b 
protein. 
RhoU was shown to interact with Rac1 and Rac2 by co-immunoprecipitation 
experiments. The best characterized function of Rac1 is to promote lamellipodium 
formation (Rougerie and Delon, 2012). Rac1 and Rac2 depletion were shown to 
inhibit TEM of CCRF-CEM cells (Heasman et al., 2010). It would be interesting to 
perform FLIM/FRET experiments to further characterize the interaction of RhoU, 
and possibly RhoV, with Rac1 and Rac2. It is possible that RhoU regulates the 
trafficking of Rac1 and Rac2 to the plasma membrane where they drive migration 





analysis (data not shown). It would therefore be useful to analyze the localization of 
endogenous Rac1 and Rac2 in RhoU/RhoV depleted cells to determine whether they 
regulate the localization or Rac1 and Rac2. RhoU and RhoV share PAK1 as a 
downstream effector with Rac1 (Heasman and Ridley, 2008; Saras et al., 2004; 
Weisz Hubsman et al., 2007). The PAK proteins play important roles in cytoskeletal 
organisation, cellular morphogenesis and survival, and several PAKs have been 
implicated in cancer (Crawford et al., 2012). Expression of RhoU and RhoV 
activates PAK1 (Aronheim et al., 1998; Rougerie and Delon, 2012; Saras et al., 
2004) and PAK1 could mediate the effect of RhoU and RhoV on T-ALL cell 
migration. It would therefore be interesting to perform migration assays in which 
siRNA depletion of RhoU and/or RhoV are used in the context of cells 
overexpressing a constitutively active form of PAK1, to investigate whether this 
could rescue the effect of RhoU and RhoV in migration. PAK inhibitors are still 
quite rare, and few exhibit 'drug-like' properties, however it is expected that other 
PAK inhibitors will be developed in the future (Crawford et al., 2012). These 
inhibitors could be used to analyse their effect on T-ALL cell migration in vitro. 
Finally, the LMO2 T-ALL mouse model described above could be used as a tool to 
develop and test new therapies to target the signalling pathway of RhoU and RhoV 
GTPases. In fact the implication of these proteins in leukaemia raises the question of 
whether inhibitors can be designed to target RhoU and RhoV. For example, 
inhibitors of RhoU/RhoV could be designed to prevent the interaction with 
Rac1/Rac2 and/or PAK1, which could be tested for effects on cell migration.  
 
In conclusion the three chapters of this thesis indicate for the first time that Rap1b, 
RhoU and RhoV are crucial players in the adhesion and migration properties of T-
ALL cells. The understanding of the intricate signalling pathways regulated by 
Rap1b, RhoU and RhoV will be important to design therapeutic drugs.   
The following figure represents a hypothetical model of Rap1b, RhoU and RhoV 














Figure 5.2 Hypothetical model for the control of adhesion and migration by 
Rap1b, RhoU and RhoV in T-ALL. Aberrant Notch1 signalling in T-ALL induces 
an increase in the transcription of its target gene RhoU. In the cytoplasm RhoU can 
form heterodimers with RhoV. These two proteins interact in vesicles that traffic 
toward the plasma membrane. In vesicles, RhoU and RhoV could form a complex 
with Rap1b promoting its localization on the plasma membrane. The localization on 
the plasma membrane of Rap1b leads to the activation of β1 and/or β2 integrin, 





process that could be mediated by the RhoU/RhoV complex. RhoU and RhoV 
heterodimers could also interact on vesicle with Rac1 promoting its localization on 
the plasma membrane, where it induces actin polymerization and lamellipodium 
formation important for cell migration. Dimerization could prevent these proteins 
from proteosomal degradation. RhoU and RhoV dimerization could enhance their 
binding to their downstream effector PAK1. The binding could promote the 
transition of PAK1 to an active conformation that exposes key residues to undergo 
autophosphorylation. Rac1 also binds and activate PAK1. Activation of PAK1 or 
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